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The oncoprotein MDM2 has an integral role in cancer development via multiple 
signalling pathways. Two proteomic mass spectrometry screens, label-free with spectral 
counting quantitation and 8-plex iTRAQ were used to identify proteins up or 
downregulated over time by the MDM2 targeting drug Nutlin. A subset of previously 
identified MDM2 binding partners were identified as altered after Nutlin treatment, 
along with proteins which have not as yet been linked to MDM2 or p53. Proteins altered 
two hours after Nutlin treatment were screened for sequence similarity to an MDM2 
binding consensus motif based on the BOX-I region of p53. Peptides corresponding to 
this motif were validated for MDM2 binding, and the mode of binding investigated 
using competition ELISA and thermal denaturation assays. Known MDM2 ligands such 
as Nutlin were shown to have a range of effects on the binding of these newly identified 
MDM2 peptides, which may be attributed to allosteric regulation of MDM2. The effects 
of Nutlin on two full length proteins identified by the MS screens, CypB and NPM, were 
confirmed in vivo. In vitro binding of MDM2 to CypB and PK, which contain BOX-I 
like motifs, was also demonstrated validating proteomic mass spectrometry screens as a 
method to identify new protein-protein interactions. To further investigate the potential 
of linear motifs to modulate protein-protein interactions, a peptide aptamer targeting the 
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1.1 Overview of the molecular basis of cancer 
1.1.1 Carcinogenesis and the cancer phenotype 
Cancer is a disease arising from a combination of factors which have their basis in 
genetic mutations, and around 13% of worldwide deaths are attributable to cancer1. 
Cancer cells are unable to arrest or die, which leads to uncontrollable cell proliferation 
eventually resulting in a tumour. There is huge diversity between different types of 
cancer, and each tumour has a unique molecular signature. The mechanisms by which a 
healthy cell transforms into a cancer cell, carcinogenesis, include a range of pathways 
and events which accumulate to finally result in a malignant tumour. A combination of 
immunity to growth signals, cell immortality, increased proliferation, ability to invade 
surrounding tissues, resistance to the immune system and altered metabolism may 
contribute to carcinogenesis2. The micro-environment of a tumour can include non-
cancerous cells, altered extracellular matrix and cancer stem cells which cooperate with 
the cancer cells, further complicating the phenotype of a tumour3. Genetic mutations 
giving rise to altered expression of proteins, expression of mutant proteins and deletion 
of regulatory proteins are factors which can give rise to a cancerous phenotype4. 
Constitutively active or inactive fusion proteins also contribute to carcinogenesis 
through the activation of cancer promoting pathways5. Some of these cancer promoting 
mutations are in the genes controlling cell cycle progression, and pathways which 
control checkpoints to prevent cells with DNA damage from dividing and proliferating, 

















Figure 1.1- Summary of factors contributing to carcinogenesis, tumour 
microenvironment and tumour progression 
 
function in proteins can also disrupt other intracellular signalling pathways, and 
deregulation of a combination of pathways regulating the other processes described 
above can contribute to the transformation of a cell into a cancerous cell (Fig. 1.1). 
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Genetic instability therefore leads to misregulation at the protein level, which is where 
the changes which cause a cell to become cancerous are effected. Pathways misregulated 
in cancer also include growth factor response, metabolic pathways, transcription and 
translation machinery, protein degradation and apoptosis2, 6. In summary, many normal 
cellular processes are misregulated and aberrant in cancer cells, and the genetic 
instability of cancer cells translates to proteome level alterations which manifest as the 
altered behaviour observed in cancer. 
1.1.2 Current cancer therapeutic strategies 
There is diversity in mutations causing misregulation of cancer pathways and cancer 
survival mechanisms which raises a problem for designing new cancer therapeutics. 
Cancer treatments can include surgery and radiotherapy, however these methods of 
treatment may leave cancer cells behind which can continue proliferating. Cancer drugs 
targeting the proteins which cause transformation and cell survival are a more directed 
type of therapy7. With a wide range of proteins and pathways involved in the survival of 
a cancer cell, there can be difficulty in choosing targets for drug development. The drug 
must preferably target only cancer cells, and cause the arrest or death of cancer cells to 
such an extent that no cancerous cells remain to continue proliferating. Pathways and 
proteins which are central to carcinogenesis can provide rich sources of targets for 
cancer therapeutics due to their vital role in the continued survival of a cancer cell. Cell 
signaling pathways regulating proliferation, cell cycle checkpoints and apoptosis are 
obvious targets for cancer therapeutics. Additionally, the environment of a cancer cell 
may have unnatural metabolic conditions due to increased hypoxia, reliance on 
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glycolysis rather than oxidative phosphorylation8 and over or underexpression of 
proteins required to maintain the correct balance of protein synthesis and degradation, 
also known as proteostasis9.  
 
Cell surface receptors and kinases which regulate cell signaling pathways are attractive 
targets, due to the availability of a substrate binding interface or pocket which allows 
rational design of drugs to fit the binding site10. Targeting receptors and kinases has the 
potential to knock-out or activate a whole pathway by targeting a single protein. 
Successes in cancer therapy have included drugs which target general features of 
cancerous cells which are also required for the survival of healthy cells. Examples are 
paclitaxel, or taxol which targets microtubule dissassembly11 and cisplatin which targets 
DNA transcription12, both of these therapeutics are based on the principle that cancer 
cells are more rapidly dividing and therefore will be more negatively affected by these 
drugs than slower dividing healthy cells. A recently developed drug which fits this 
profile is bortezomib also known as Velcade™, which targets the proteasome, the theory 
behind this being that cancer cells produce more misfolded proteins than healthy cells 
which places a higher burden on the proteasome13. Drawbacks with these drugs which 
broadly affect cellular processes are that they can also affect healthy cells, and are not 
targeted directly to cancerous cells, which results in the side effects of these treatments. 
More specific drugs have been developed which are targeted to particular proteins, such 
as kinases, ATP binding proteins or cell surface receptors. Successes in this area include 
the bcr-abl tyrosine kinase inhibitor, Gleevec™, which targets the oncoprotein fusion of 
Bcr and abl often found in chronic myeloid leukaemia (CML) and is constitutively 
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activated14. Antibody therapeutics such as anti-Her2/neu, known as Herceptin™, which 
specifically binds the Her2 receptor are another example of precisely targeted 
therapeutics15. These drugs are effective for specific types of cancer, however they will 
only work for cancer cells with a specific mutation or characteristic and therefore are 
limited to the treatment of particular types of cancer. Discovery of new targets alongside 
tried and tested treatments is required to broaden our arsenal of available cancer 
treatments and find drugs to treat cancers which do not respond to the current repertoire 
of anti-cancer therapeutics.  
 
1.1.3 Hub proteins and interactomes as drug targets 
Proteins which are at the junction of multiple pathways can promote cancer cell survival 
and transformation. These proteins are attractive targets for therapeutics, because 
targeting them could have effects against a wide range of cancer cells without a negative 
effect on healthy cells. They also have potential as targets for combination therapies to 
enhance the effect of precisely targeted drugs. The chaperone HSP90 is an example of a 
hub protein, it is widely involved in cancer related protein folding pathways for example 
p53 pathways, BRAF and Akt pathways16. Targeting HSP90, for example with the 
inhibitor geldanamycin and the geldanamycin derivative 17-AAG17, has been shown to 
be very effective as a potential anti-tumour therapeutic. Another advantage of targeting 
heat shock proteins is that cancer cells exhibit altered proteostasis, due to the 
requirement of a higher rate of production of proteins to support the accelerated 
proliferation and division of cells18. Proteostatic pathways encompass translation and 
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degradation machinery, and finding out the molecular details of these pathways will be 
useful for cancer research. The p53 tumour suppressor is another important example of a 
hub protein, mediating transcription and regulating cell cycle checkpoints and apoptosis, 
and participating in multiple pathways including TGF-beta, ubiquitin proteasome 
pathway and cell cycle regulation19 (Fig. 1.2). It is often quoted that p53 is mutated or 










Figure 1.2 – Summary of pathways which contain proteins in the p53 regulatory 
network generated using PANTHER database, segments represent the number of 







based on their p53 status which may eventually be regularly tested for as an indicator as 
to which drugs will be effective22. To verify this statistic, it would be necessary to carry 
out widespread proteomic studies on tumours as well as genetic studies, due to 
regulation on the protein level often being a cause of p53 misregulation. Targeting p53 
for reactivation is an extremely attractive cancer target, as this can result in the 
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activation of cell cycle arrest and apoptosis pathways, and many cancer research efforts 
have focused on this.  
 
It is becoming widely acknowledged that cellular proteins are regulated by an 
‘interactome’ rather than by individual binary protein-protein interactions. A protein 
interactome can be defined as all of the proteins which bind to or are regulated by the 
protein of interest23. Proteins are part of complexes, which are dynamic and regulated by  
multiple factors, and their interactome is variable and responsive to the cellular 
environment. It is possible to investigate the interactome of a protein by using protein-
protein interaction identification techniques such as yeast two-hybrid, phage peptide 
display and affinity purification as well as mass spectrometry24. The proteome could be 
described as a collection of overlapping interactomes, since proteins share common 
transcription, translation and degradation machinery all cellular proteins will be linked 
via their interactomes in a vast cellular network. The environment inside cells means 
that most proteins are tightly packed with other proteins, and are surrounded from 
translation to degradation, thus the linkages between proteins in pathways or cellular 
functions are highly regulated and highly complex25.  
 
1.2 p53 structure and functions in cancer  
1.2.1 p53 role in cancer 
The tumour suppressor p53 has been the subject of a vast amount of cancer research 
since being discovered in 1982 by Levine et al26. Activation of p53 can cause cell cycle 
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arrest or apoptosis in cancer cells as part of the DNA damage response pathway, and is 
central to the cells defense against cancer. p53 is therefore an important target for cancer 
therapeutics, and a critial protein to study to enhance our understanding of the 
mechanisms involved in carcinogenesis and cancer cell survival. 
 
1.2.2 The structure of p53 













Figure 1.3 – A) Domain structure of p53 with domains highlighted and location of three 
most common p53 mutations in cancer TAD – transactivation domain (contains two 
TAD motifs
27
), PRD – proline rich domain, CORE – Core domain, TET – 
tetramerisation domain, CTD – C-Terminal domain B) Location of conserved BOX 




















Figure 1.4 – A) Representation of p53 core domain structure residues.
28
 B) p53 core 
domain with disordered N-terminal region of core highlighted in red. PDB: 2WXR C) 
Disopred
29
 prediction of stuctural disorder in full length p53, TAD – transactivation 
domain, Core – core domain, TET – tetramerisation domain 
 
however the molecular weight of p53 is actually 43.7 kDa. p53 has a high degree of 
disorder and has been shown to form both dimers and tetramers30, 31. The protein is 393 
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amino acids long, and contains several distinct domains, and conserved regions of p53 
have also been designated BOX-I, II, III, IV and V (Fig. 1.3)19. The domains of p53 are  
the N-terminal transactivation domain, a proline rich domain, the core DNA binding 
domain, the tetramerisation domain and the C-terminal regulatory domain. The core 
domain (Fig. 1.4a,b) and the tetramerisation domain structures of p53 have been solved 
by X-ray crystallography and small angle X-ray scattering (SAXS), both for wild type 
p53 and several p53 core domain mutants28, 32-34. Although the core DNA binding 
domain is an ordered region of p53 there are still many disordered loops in the core 
structure, and SAXS has revealed the high degree of disorder in the p53 structure32. The 
tetramerisation domain is an alpha helical domain which forms a helix-helix interface 
with other p53 monomers35. Overall p53 is a highly unstructured protein, with large 
predicted regions of disorder29 (Fig. 1.4c). Full-length p53 readily unfolds at elevated 
temperatures, this inherent flexibility may facilitate degradation, and be linked to the 
necessity to quickly degrade p53 in order to allow cell cycle progression36. Some p53 







Figure 1.5 – Disordered C-terminal domain of p53 bound to A) S100b  as an alpha helix 





degradation and deactivation of the p53 response in cancer cells34. The core domain in 
isolation has a higher degree of stability than the full-length protein, this may be due to 
this domain mediating DNA binding and requiring a more ordered structure. However 
many of the p53 protein interaction interfaces are located in other domains. In particular 
the N-terminal and C-terminal domains of p53 are highly disordered, and both of these 
regions have been proposed to have a role in binding the negative regulator of p53, 
MDM238, 39. Interestingly, it has recently been shown that the disordered region of p53 
between the proline rich domain and the core domain confers stability to the core 
through binding to it as a linear motif28 (Fig. 1.4b), highlighting the important functional 
role of disordered regions of p53. The C-terminal domain of p53 has also been shown to 
adopt multiple conformations in the presence of different protein ligands, an example of 
binding induced folding and a mechanism by which p53 can bind multiple proteins (Fig. 
1.5)40. The high degree of disorder in p53 structure, and observed changes in p53 
structural rearrangement on binding in crystal structures, suggests p53 interactions may 
be extensively regulated by mechanisms involving ‘folding on binding’ which is a 
concept central to disordered protein binding mechanisms41. 
 
1.2.3 Functions of p53 in tumour suppression 
p53 is a transcription factor which promotes cell cycle arrest proteins such as p21, and 
apoptotic effectors such as BAX. Increased levels of p53 therefore correlate with a 
higher incidence of apoptosis and cell cycle arrest42. p53 is central to the DNA repair 
pathway, stimulus such as UV and X-ray which cause DNA damage activate p53 as a 
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transcription factor and stabilise cellular levels of p53. It is interesting to note that p53 
has been reported to have greater than 300 interactions43 (Fig. 1.2), and participates in 
many multi-protein complexes. Roles for p53 have been proposed in aging44, 
metabolism45 and development46 as well as functioning as a tumour suppressor. This is 
an intriguing example of one cancer related protein participating in a diverse 
interactome, and mediating the cross-talk between multiple cellular pathways. A large 
amount of research has been focused on p53, and it is a possibility that other less well 
known proteins may have equally large interactomes. 
 
1.2.4 Misregulation of p53 in cancer and therapeutic targeting 
The inactivation of p53 can occur by deletion or downregulation, as well as through the 
production of mutant p53 with aberrant functions. p53 mutants are common in cancer, 
and there are mutation hotspots in the p53 sequence, particularly focused in the core 
DNA binding domain19. It is often the case that p53 mutant proteins are dominant over 
the wild type form of the protein where both are expressed, and in these cases mutant 
p53 acts as an oncoprotein43. Therefore there are two ways to target the p53 pathway in 
cancer: reactivation of wild type p53 or inhibition of mutant p53. Other mechanisms by 
which p53 can be misregulated in cancer include an increase in negative regulators of 
p53 such as MDM2 and other E3 ubiquitin ligases47, 48, the cytoplasmic relocalisation of 
p53 which downregulates p53 functions and misregulation of downstream targets of 
p5349. Drugs which have been developed with the aim of reactivation of p53 related 
processes include molecules which bind and inactivate or rescue mutant p53. The drug 
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CP-31398 for example binds to mutant p53 and abrogates the oncogenic effects of this 
protein by stabilizing the protein50. Mutant p53, such as Y220C, has a binding pocket 
which can be targeted by rational drug design, and studies have shown that this may be a 
viable route for reactivating p5351. The anti-cancer compound PRIMA covalently 
modifies reactive cysteines, which affects p53 due to the dependence of p53 on reactive 

























Figure 1.6 – Mechanism of ubiquitination mediated by E1, E2 and E3 ligases. RING E3 
ligases conjugate ubiquitin directly to substrate lysine residues, HECT E3 ligases 
transfer ubiquitin to substrate via an intermediate step where ubiquitin is conjugated to 
the E3 via a thiol linkage. S – substrate, Ub – ubiquitin. 
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is due to it attacking a broad range of reactive cysteines and is not necessarily p53 
specific. Many p53 targeting strategies focus on MDM2 which is an E3 ligase for p5347. 
E3 ligases function as enzymes which catalyse the ubiquitination of a substrate which 
targets the substrate for proteasomal degradation. E3 ligases work as part of an 
ubiquitination pathway, which includes the transfer of ubiquitin from an E1 and E2 
enzyme. The E3 which makes contact with the substrates, can ubiquitinate proteins via 
two known mechanisms, RING E3 ligases directly transfer ubiquitin from the E2 to the 
substrate and HECT E3 ligases form a thiol bond with the ubiquitin prior to transfer to 
the substrate53 (Fig. 1.6). NEDD8 and SUMO are ubiquitin-like proteins, and can be 
conjugated to substrates, including p53 and MDM2, although this is not linked to 
proteasomal degradation in the same way as ubiquitination54. MDM2 is not the only p53 
E3 ligase, others include Pirh55, CHIP56 and COP157, as such these proteins may also 
represent targets for reactivation of p53. The MDM2 p53 binding interfaces are well-
characterised and it has also been shown in many studies that MDM2 regulates p53 
transactivation, cellular localization and mRNA translation58, 59. Although targeting 
MDM2 has primarily been investigated as a means of reactivating p53, MDM2 also has 
a complex interactome and participates in many cellular pathways which are not 
necessarily p53 dependent. These pathways are not yet characterized to the extent of p53 
pathways. Discovering more about MDM2 related pathways would be instructive, as 
these two proteins are major ‘hubs’ in cancer. 
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1.3 The role of MDM2 in cancer 
1.3.1 Functional roles of MDM2 
MDM2 is a multi-functional, multi-domain protein primarily characterized as an E3 
ubiquitin ligase targeting the tumour suppressor p5347, 60. As well as an E3 ligase 
targeting p53, MDM2 has been shown to be involved in ribosomal pathways, 
translation59, nuclear localisation and chaperone functions61. Over 150 proteins have 








Figure 1.7 – Overlapping p53 and MDM2 interactomes 
 
overlap with the p53 interactome (Fig. 1.7) MDM2 also has many binding proteins not 
known to be associated with p53 and therefore the inhibition of MDM2 in cancer could 
have wider ranging effects than an increase in p53 levels. Similarly p53 has many non-
MDM2 related binding partners, suggesting that targeting MDM2 may not re-activate all 
of the functions associated with p53. 
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1.3.2 Structure of MDM2 



















Figure 1.8 – A) Domain structure of MDM2 and binding site of a selection of known 
ligands NT – N-terminal domain, AD – Acidic domain, ZF – zinc finger, RING – RING 
domain B) Sequence of lid domain and position in NMR structure, lid highlighted in 
blue, Ser17 highlighted in red PDB: 1Z1M C) Sequence of tail domain and position in 
RING dimer structure, tail highlighted in red, zinc highlighted in pink PDB: 2HDP D) 
Disopred
29
 disorder prediction of MDM2 structure and position of major domains 
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which can also promote carcinogenesis62. The overall domain structure of MDM2 is 
illustrated in Figure 1.8a, MDM2 has a structured N-terminal domain with a 
hydrophobic pocket, a disordered central acidic domain containing a nuclear localization 
signal, a zinc finger, and a C-terminal really interesting new gene (RING) domain which 
has similarity to other members of the RING E3 ligase family63. The RING domain 
contains an ATP binding site with sequence similarity to the P-walker ATP binding loop 
and a zinc coordination site64. There are also two mini-domains at the N and C-terminus 
of MDM2, the disordered N-terminal lid and the C-terminal tail which mediate MDM2 
ligand binding and possibly RING oligomerisation respectively (Fig 1.8b, c)65, 66. 
Overall the full-length MDM2 protein is predicted to have a high level of disorder, 
particularly in the acidic domain (Fig. 1.8d), which may contribute to the difficulties 
encountered in determining the structure of full-length MDM2.  
1.3.3 MDM2 N-terminal structure 
The structure of the N-terminal domain of MDM2 has been solved by x-ray 
crystallography and NMR, in an apo form and in complex with drugs and peptide 
ligands derived from p5367, 68. There are interesting differences between the X-ray 
structure and the NMR structure which hint at a degree of flexibility in this domain (Fig. 
1.9a,b). The N-terminal domain contains a hydrophobic pocket, and there is an 
electrostatic patch around the ligand binding pocket, with a region of negative charge 
including the residue glutamate 25 (1.9a,b,c). Although the N-terminal domain overall is 
relatively structured, the N-terminal lid is flexible and unstructured and can act as a  












Figure 1.9 – N-terminal structures of MDM2. A) X-ray structure of N-terminal domain 
showing hydrophobic pocket, PDB: 1YCR B) NMR structure of N-terminal domain 
PDB: 1Z1M C) p53 N-terminal BOX-I sequence binding MDM2 with Glu25 highlighted  
 
particularly the hydrophobic pocket and the RING domain, of MDM2 is partially 
conserved in organisms as diverse as Trichoplax adhaerens, Danio rerio and Mytilus 
trossulus.(Fig. 1.10)69, 70 which supports the idea that there is a vital role of the p53-
MDM2 axes in non-cancerous pathways. The lid and tail regions are also well 
conserved, indicating a functional role for these disordered regions.  
1.3.4 RING domain structure 
RING E3 ubiquitin ligases, which contain a zinc finger motif, interact with an E2 
conjugating enzyme to transfer ubiquitin to the substrate. This is in contrast to HECT 
ligases which are covalently modified with ubiquitin by a thiol linkage before 






















Figure 1.10 – A) Alignment of human, mouse, zebrafish, Trichoplax and Mytilus MDM2 
homologs with main domains highlighted maroon – lid, red – N-terminal domain, 
orange – acidic domain, yellow – RING domain, green - tail
72
 B) Structure of human 
MDM2 with conserved residues in Trichoplax highlighted in purple 
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been obtained, both as a homodimer by NMR and as a dimer with the MDM4 RING 
domain by x-ray crystallography73 (Fig. 1.11), and has similarity to other members of 
the RING E3 ligase family63. Mutation of residues in the RING domain which 
coordinate the zinc results in loss of ubiquitin ligase activity of MDM2, and ability to 
ubiquitinate p5360. The RING domain in isolation has been shown to function as an E3  
ligase74, with no requirement for the other MDM2 domains which may therefore confer 






Figure 1.11 – A) RING domain dimer of MDM2 PDB: 2HDP, zinc atoms highlighted in 
pink B) RING dimer of MDM2 and MDMX RING domains, zinc atoms highlighted in 
pink PDB: 2VJE 
 
1.3.5 The MDM2 acidic domain 
The central domain of MDM2, known as the acidic domain is highly unstructured. 
However it has been shown to form higher order structures with the unstructured domain 
of ARF which may be an indication of a folding on binding mechanism, as ARF is a 
known MDM2 ligand75. The structure of full-length MDM2 has not been obtained, and 
is unlikely to be viable for crystalisation due to the disorder and flexibility of the acidic 
domain and other regions of the full-length protein. There are two putative beta sheets 
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located in the acidic domain, however overall this region appears to be highly plastic76, 
77. 
1.3.6 Known MDM2 ligands and cofactors 
As the structure of MDM2 suggests, it is a complex protein with the capacity to bind 
multiple ligands which facilitate cross-talk between MDM2 domains. MDM2 binds zinc, 
both at the zinc finger in the acidic domain and in the RING domain and it has been 
demonstrated that zinc may enhance some anti-MDM2 therapeutics78. RNA is bound by 
the RING domain79, and there is also an ATP binding site in the RING domain. These 
co-factors can mediate the function of MDM2, for example zinc and RNA inhibit the 
MDM2 interaction with a p53 derived peptide known as BOX-I, and also with the 
chaperone HSP9080. RNA may stimulate ubiqutination by MDM2, and has been shown 
to potentiate the interaction between MDM2 and the interferon regulatory protein 
IRF281. MDM2 has been shown to bind p53 mRNA in particular, and mediate the 
translation of p53 which is another interesting aspect of MDM2 functional regulation of 
p5359. This may link to the MDM2 role in binding ribosomal proteins, and it is 
interesting to speculate whether MDM2 can bind multiple mRNAs, possibly via a 
consensus sequence, and thus act as both a mediator of translation and protein 
degradation.  
 
1.3.7 Post-translational modification of MDM2 
MDM2 has multiple phosphorylation sites, and is phosphorylated in response to DNA 
damage, growth factor mediated signaling and also dephosphorylated in some sites after 
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DNA damage. Serine 17 has been shown to be particularly important in regulation of the 
N-terminal lid which can regulate availability of the N-terminal domain of MDM2 to 
ligand binding and is phosphorylated by DNA-PK82. Other phosphoylation sites in 
MDM2 include multiple ATM sites near the RING domain, which when phosphorylated 
prevents p53 from exporting p53 to the cytoplasm83. The degradation of MDM2 has 
been demonstrated to be controlled by the phosphorylation of sites in the acidic domain 
by CK1 which mediates SCF βTRCP degradation pathways84. As an E3 ligase, MDM2 
is also ubiquitinated, and can auto-ubiquitinate as well as neddylating substrates such as 
p5385 and the ribosomal protein L11 with the ubiquitin like modifier NEDD886. Sumo 
specific protease can modulate MDM2 regulation of p53, indicating MDM2 may be 
sumoylated and this regulates MDM2 function87.  
 
1.4 MDM2 regulation of p53  
1.4.1 p53 and MDM2 feedback loop 
p53 and MDM2 are in a feedback loop, which regulates the level of p53 and therefore 
downstream functions of p53 activity, and vice versa. As well as MDM2 catalysing the 
ubiquitination of p53 which targets it for proteasomal degradation MDM2 also prevents 
the p53 transactivation domain binding to transcriptional coactivator proteins, halting the 
transcription of genes which effect the activation of p53 regulated pathways. p53 
promotes the transcription of MDM2 as a downstream target, and this linked with the 
MDM2 mediated degradation of p53 forms a negative feedback loop (Fig. 1.12a)19. It is 



























regulation mechanisms may be more complex than this simple feedback loop (Fig. 
1.12b). ARF and ribosomal proteins can cause relocalisation of MDM2 which prevents 
ubiquitination of p5379, 88. It has also been proposed that p21 acts as a positive regulator 
of p53, due to the cyclical behaviour observed for both p53 and p21 levels in cells which 
are not stimulated by DNA damage to activate p5389. As previously mentioned, MDM2 
also regulates the translation of p53 mRNA, linked to MDM2 regulation by ribosomal 
proteins. MDM2 can stimulate internal ribosomal entry site (IRES) translation of p53 
mRNA, which is an alternative method of translation initiation. MDM2 is therefore also 
a positive regulator of p53 levels, particularly when ER stress mechanisms are 
activated90. There are doubtless many other factors influencing these feedback 
mechanisms, and the balance between these opposing functions of MDM2 determines 
the level of p53 in the cell. 
 
1.4.2 Dual site MDM2 ubiqutination mechanism 
The mechanism by which MDM2 ubiquitinates p53 has been extensively studied, and 
has been shown to be mediated by multiple binding interfaces between p53 and MDM2, 
particularly the conserved BOX-I and BOX-V regions. The current model proposes that 
the BOX-I region of p53 binds the N-terminal domain of MDM2 with high affinity 
which allosterically activates the acid domain and stimulates the p53 BOX-V domain to 
bind MDM291 (Fig. 1.13). This BOX-V binding site is sometimes referred to as the 
‘ubiquitination signal’ and subsequent to p53 binding this domain the RING domain 
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catalyses mono and poly ubiquitination of p53. The allostery between these two domains 



















Figure 1.13 – Dual site mechanism of MDM2 ubiquitination of p53
91
 and conserved 
MDM2 binding motifs BOX-I and BOX-V. N – N-terminal domain, AD – Acidic domain, 
R – RING domain.  
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domain, however inhibitors of binding at the N-terminus such as the drug Nutlin can 
actually enhance p53 ubiquitination although overall the protein is stabilized91. It has 
also been shown that acid domain ligands strongly inhibit ubiquitination and also weakly 
inhibit binding at the N-terminus of MDM2, which suggests this allostery can function  
in both directions81, 91. The dual site mechanism is further complicated by the role of the 
tail for MDM2 dimerisation66, and the lid domain regulation of the hydrophobic 
pocket65. It is unclear what effect dimerisation or indeed the formation of higher order 
oligomers would have on MDM2 function. MDM2 runs at a range of molecular weights 
on an SDS-PAGE gel, which can be a characteristic of disordered proteins, and elutes at 
multiple peaks by size exclusion chromatography92. These data suggest that there are a 
range of conformations or oligomers possible for full length MDM2, and MDM2 
allostery may depend on conversion between these conformers. The RING domain has 
also been shown to exert an allosteric effect on MDM2 binding p53, with RING mutants 
affecting the zinc coordination site or exhibiting different binding and ubiquitination of 
p53 compared to the wild type protein60, 64. Cofactors also play a role in the allosteric 
regulation of MDM2, as described previously, the presence or absence of zinc and RNA 
regulates the binding of MDM2 to BOX-I peptide and also HSP90 derived peptides80, 92. 
Phage peptide display results show that different consensus sequences are obtained when 
MDM2 is pre-incubated with different cofactors, highlighting the importance of 
structural rearrangements of MDM2 in response to binding ligands80. It has been 
demonstrated that both the N-terminal domain of MDM2 and the RING domain are 
involved in ubiquitinating p53. Perhaps it is the combination of these domains in one 
allosteric protein which facilitates the multiple mechanisms of p53 regulation by 
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MDM2, with the acidic domain functioning as a regulatory module and a signal 
transducer between the various domains.  
1.4.3 Proteins regulating the MDM2-p53 feedback loop 
Other MDM2 binding proteins can regulate the p53-MDM2 feedback loop. The tumour 
suppressor RB1 has a binding site in the acidic domain of MDM2, and can prevent p53 
binding at this site91. ARF also interacts with MDM2 in this domain, and regulates 
MDM2 activity. Various kinases, such as DNA-PK, interact with MDM2 to post-
translationally modify the protein which has also been shown to affect p53 binding82, 93, 
and MDM4 has widely been suggested to participate in a regulatory network with 
MDM2 and p53, although the exact details of this mode of regulation are not yet fully 
understood. There is a recently discovered phosphorylation site in the BOX-V region of 
p53, with an unknown kinase which may regulate MDM2 binding and p53 
ubiquitination94. Ribosomal proteins which bind MDM2 have been shown to have an  
effect on the regulation of p53 as they occupy the p53 binding sites of the acidic domain 
of MDM2 and move it into a different subcellular localization and pathway88. 
 
1.5 The MDM2 interactome 
1.5.1 Non-p53 related MDM2 mechanisms 
Amongst the functions for MDM2 that have been characterized are as an E3 ligase, a 
ribosomal regulator, a chaperone and a signaling molecule. MDM2 has been described 
as a ‘partially disordered hub protein’ and as it is situated at the intersection of multiple 
signaling pathways it is an attractive target for anti-cancer therapeutics95. Although 
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MDM2 is important for regulation of p53, it is becoming clear that the non-E3 ligase 
functions of MDM2 are also important in cancer cells. 
1.5.2 MDM2 as an E3 ligase 
As well as ubiqutinating p53, MDM2 has been shown to ubiquitinate the ribosomal 
protein S796, IRF281 and the endonuclease APE197 amongst other targets. It is not known 
whether the MDM2 ubiquitination mechanism is identical for each of these proteins, the 
S7 binding site has been mapped to the acidic domain96, whereas IRF2 appears to have 
MDM2 binding sites in both the N-terminus and acidic domain81. Further research is 
required to determine whether or not the MDM2 ubiquitination mechanism must always 
have multiple domain contacts, as is the case with p53. Proteomics methods have 
previously been used to attempt to determine the substrates of E3 ligases98, however in 
practice this is a difficult problem due to the abundance of ubiquitinated proteins in a 
cell and the potential for substrates to be ubiquitinated by multiple E3 ligases. In the 
case of MDM2, many binding proteins have been shown to be ubiquitinated, however as 
the RING ubiquitinates in the absence of the other regulatory domains of MDM2 these 
results should be treated with caution. 
 
1.5.3 MDM2 and ribosomal proteins  
MDM2 has been extensively shown to interact with multiple ribosomal proteins, 
including RPL11, RPS7, RPL5, RPL26, RPL5 and RPL2388. These ribosomal proteins 
are part of the regulatory pathway of MDM2, and can mediate MDM2 localisation and 
function with regards to p53 regulation. The regulation of MDM2 by RPL11 is mediated 
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by MDM2 neddylation of RPL11 which results in it localizing to the nucleolus. In 
nucleolar stress situations RPL11 is relocated to the nucleoplasm and it is proposed that 
binding of MDM2 by RPL11 here overrides MDM2 binding to p53 and this inhibits the 
downregulation of p53 by MDM286, 99. S7 is another interesting ribosomal MDM2 
ligand, it has also been proposed to prevent MDM2 binding to p53100 and has been 
mapped to a binding interface in the MDM2 acid domain. S7 has also been shown to be 
ubiquitinated by MDM2 and this is linked to increased degradation of ribosomal protein 
S796.  The ribosomal mediation of MDM2 activity may be ARF independent, although 
ARF relocalises MDM2 to the nucleolus101. RPL26 has been shown to be 
polyubquitinated by MDM2 and RPL26 may promote the translation of p53, which is 
negatively regulated by MDM2102. MDM2 also binds nucleophosmin, which can shuttle 
it to and from the nucleolus, indicating the nucleolar localization of MDM2 is an 
important factor in the regulation of p53 and other MDM2 functions103. Overall, 
misregulation of the level of ribosomal proteins or rRNA synthesis can activate p53 via 
an MDM2 dependent pathway104. The balance of proteins present in the ribosome is an 
important mechanism for maintaining proteostasis, and further understanding of the role 
of in the regulation of these proteins will clarify what role this has in cancer cells and 
healthy cells. 
 
1.5.4 MDM2 stabilisation of E2F1 
In contrast to the regulation of p53 by MDM2, the transcription factor E2F1 is stabilized 
by MDM2 and inhibition of MDM2 binding to E2F1 with the drug Nutlin results in the 
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degradation of E2F1105. This protection of E2F1 from degradation by MDM2 is due to 
the fact that MDM2 sequesters E2F1 to protect it from other ubiquitin ligases. As E2F1 
binds the N-terminus of MDM2, disrupting this domain with Nutlin results in the release 
and subsequent degradation of E2F1105, 106. The kinase CK1α, which increases in 
response to cellular stresses linked with cancer such as X-ray irradiation and virus 
infection also participates in stabilization of E2F1 in a complex with MDM2107. MDM2 
mediated regulation of the stabilization of E2F1 illustrates the ability of MDM2 to 
function as a stabilizing binding partner, unlike as destabilizing binder mediating p53 
ubiquitination. 
 
1.5.5 MDM4 influence on MDM2 
MDM4, also known as MDMX, has a high degree of homology to MDM2 and has been 
shown to form a RING domain dimer with MDM2 (Fig. 1.11b)73. MDM4 can bind p53, 
although it has not been shown to have E3 ligase activity. MDM4 has an overall 
similarity to the domain structure of MDM2, although structural studies have shown 
extensive differences in the p53 N-terminal binding domain108. Studies show that 
MDM4 can inhibit the transactivation of p53, facilitate the MDM2 ubiquitination of p53, 
and affect the localization of the p53-MDM2 complex. Although links have been found 
between MDM4 and MDM2 with regards to p53 regulation, there are also instances 
where these proteins are independently amplified in cancer, indicating they have 
independent roles109. MDM4 is undoubtedly part of the MDM2 interactome, however it 
is unclear how many of MDM2 functions are dependent upon MDM4 activity. 
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1.6 Linear motifs, disorder and the MDM2 interactome 
1.6.1 Linear motifs as mediators of protein-protein interactions 
Linear motifs are sequence features which mediate protein-protein interactions, usually 
located in disordered regions of proteins110, 111. It has been thought of as particularly 
difficult to target protein-protein interactions due to larger surface areas involved in the 
interaction compared with a substrate binding pocket. In fact, many protein interactions 
are mediated by these short peptide motifs and have critical residues which make contact 









Figure 1.14 – A) Lock and key mechanism of enzyme substrate interaction. B) Schematic 
of linear motif interaction, yellow - motif 
 
thought for many enzyme substrate reactions, this is not based on the classic ‘lock and 
key’ mechanism proposed by Emil Fischer112, 113, but an induced fit or ‘folding on 
binding’ mechanism (Fig. 1.14)114.  Examples of these peptide motifs can occur in loops 
between structural features like alpha helices and beta strands, which are hotspots for 
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protein-protein interactions. The word ‘linear’ is slightly misleading, as these motifs are 
flexible and adopt structure on binding115. A linear motif may correspond to a consensus 
sequence based on residues which are necessary for binding to a target protein, examples 
of this are: the HSP90 binding motif, 14-3-3 protein binding motif, kinase binding 
motifs which can be as simple as two amino acids, and numerous targeting or signal 
sequences such as KDEL in endoplasmic reticulum targeting110. A linear motif is a short 
amino acid sequence, which can act as the binding site for another protein similarly to a 
ligand. Linear motifs can also adapt to bind different target proteins, their plasticity 
means they can adapt to fit a given target. The C-terminal region of p53 is a good 
example of this kind of plasticity (Fig. 1.5). Linear motifs are frequently associated with 
disordered regions of proteins, and programs for locating linear motifs such as 
DILIMOT110 and SLiMFinder116 incorporate this into the criteria for identifying a linear 
motif. An interesting example of protein-protein interaction mediation by linear motifs 
and how they can mediate to the mechanism of disordered proteins is the highly 
disordered yeast E3 ligase San1. San1 binds disordered substrates in a ‘quality control’ 
mechanism, to degrade misfolded proteins which are also chaperoned by San1. This 
involves the recognition of linear motifs by the disordered region of San1 coming into 
contact with these motifs which induces folding on binding117. Linear motifs are also 
interesting for the paradigm of allosteric proteins, due to a concept known as ‘fuzziness’, 
which describes the phenomenon where a bound ligand can continue to move or alter the 
conformation of a binding partner118. A known linear motif is attractive as a starting 
point to develop protein-protein interaction inhibitors which mimic these motifs, 
peptidomimetics and drugs which match the pharmacophore of interaction peptides can 
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be developed based on a known peptide. The drug Nutlin, discussed in section 1.6.6 is 
an example of how this can be put into practice. 
 
1.6.2 Discovery of linear motifs and protein-protein interaction inhibitors 
It is possible to target protein-protein interactions (PPI), although this is not yet as 
amenable to chemical and computation screening as substrate binding pockets. Phage 
peptide display is a developing method by which is it possible to find high affinity 
peptide ligands. Proteins, and peptides obtained by phage display can both be used to 
search databases for proteins which contain similar sequences, and as the starting point 
for developing peptidomimetic drugs119, 120. Other methods of finding protein-protein 
interaction motifs are to search for similarity in known binding partners of a protein, or 
search yeast two hybrid assay results. If there is a known peptide binder of the protein of 
interest, it is also possible to map the residues required for a binding interface using 
peptide arrays. Miniaturised SPOT based arrays can be employed to substitute every 
residue to every other residue and find optimized and high affinity binding peptides for 
purified proteins121. Protein-protein interactions are a relatively new target for drug 
development, peptides themselves are not yet considered optimal for use as drugs due to 
poor cell permeability and may be quickly degraded in the cell. This can be improved by 
adding cell penetrating sequences, such as penetratin, or creating versions of the peptide 
with peptoids, hydrocarbon stapling of the peptide backbone or retro-inverso peptides 
with D-amino acids in reverse sequence which are not targeted for proteolysis. Chemical 
optimization can improve upon the basis of a known structure to create peptidomimetics 
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which are drug-like and inhibit protein-protein interactions122. Although this is a difficult 
route for drug discovery the number of proteins targeted for drug development has 
leveled off in recent years, and the number of proteins which are extensively studied 
only includes a small percentage of the proteome. Disordered proteins, which have a 
propensity to interact via linear peptide motifs could be targeted by protein-protein 
interaction inhibitors. They make up approximately 50% of the proteome95, and 
represent a neglected category of proteins for research into drug discovery. This is 
perhaps due to the reliance of current methods on crystal and NMR structures, and the 
success of drug design using these methods.  
 
1.6.3 Discovery of a potential linear motif representing peptide by phage display 
Phage peptide display is a method of acquiring high affinity peptide ligands to a protein 
target, these peptides can then be used as tools or to investigate consensus binding 
sequences for a protein. Antibody epitope mapping is one example of how phage display 
can find consensus sequences, and this was carried out previously for p53123. A study to 
expand the interactome of a protein and develop peptide ligands for a protein using 
phage display was carried out on the protein AGR2124.  
 
The protein AGR2 was discovered as an overexpressed protein in Barrett’s oesophagus, 
which is a metaplastic tissue associated with progression to oesophageal cancer. AGR2 
has been implicated in the negative regulation of p53, and as a biomarker for various 
types of cancer125-127. Peptide phage display and sequence optimization revealed the 
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AGR2 binding peptide PTTIYY, which was subsequently shown to bind AGR2 and 
affect the subcellular localization of both AGR2 and p53, and possibly re-activate the 
p53 pathway124, 128. Although AGR2 has few known binding partners, this peptide 
represents a potential AGR2 binding motif and is a starting point to search for proteins 
containing this sequence which may then be validated as AGR2 binding partners. This 
illustrates the potential of linear motifs as a starting point to find new protein-protein 
interactions, which is the reverse of using protein-protein interaction interfaces to design 
drugs based on linear motifs. Phage peptides may also represent a starting point for the 
design of drugs, so it is possible to find new therapeutic leads both from optimized 
peptide ligands, and from mimickry of naturally occurring linear motif interfaces. 
 
1.6.4 Representative MDM2 binding motifs in p53, BOX-I and BOX-V 
The dual site mechanism of MDM2 binding to p53 is mediated by BOX-I and BOX-V 
regions of p53, in particular two linear motifs which are bound by the N-terminal 
domain and acidic domain respectively91. The BOX-I motif binds the MDM2 N- 
terminus at the hydrophobic pocket region (Fig 1.15a). It has been shown that mutation 
of the BOX-I motif at three critical residues (Fig. 1.15a, b) abrogates MDM2 binding to 
p53. These residues intercalate into the MDM2 hydrophobic pocket creating a strong 
binding interface, electrostatic attraction of the residues surrounding this hydrophobic 
core also contribute to the BOX-I-MDM2 interaction39, 129. Other residues such as the 






















Figure 1.15 A) N-terminal domain of MDM2 in complex (coloured according to b-
factor) with BOX-I peptide (green), key binding residues highlighted in pink PDB:1YCR 
B) BOX-I sequence, MDM2 binding residues highlighted in red C) Full p53 sequence 
with BOX-I highlighted in orange and BOX-V highlighted in green D) BOX-V (yellow) 
position in core domain of p53 PDB: 1UOL 
 
 58 
contribute positively to the BOX-I-MDM2 interaction. The BOX-V motif, located in the 
DNA binding domain of p53 (Fig. 1.15c) in a region known to contain a mutation 
hotspot, binds the acidic domain with a lower affinity than the N-terminal interface, and 
this region of MDM2 also binds peptide motifs derived from the RB1 tumour suppressor 
and is a docking site for multiple ribosomal proteins and the ARF tumour suppressor77, 
88, 91. It is interesting to note that the BOX-V domain is slightly buried on the p53 
structure, which may account for the lower affinity of this motif for MDM2 and require 
structural rearrangement to bind MDM2 (Fig. 1.15d). Phage display against MDM2 
yielded consensus binding peptide sequences corresponding to these p53 motifs80, 92. 
This suggests that these motifs are dominant MDM2 binding sequences. Other motifs 
were also discovered which do not correspond to sequences in p53 but do have 
similarity to the protein SAFA, subsequently shown to bind MDM2. The chaperone 
HSP90 also contains sequence similarity to peptides which bind MDM2 obtained by 
phage display80, and has also similarly been validated as an MDM2 binding protein. The 
motifs discovered by phage display were varied based on the presence of different 
MDM2 cofactors, indicating structural changes in MDM2 mediate which motifs the 
protein can bind to. 
 
1.6.5 Peptide ligands of MDM2 obtained by p53 optimisation 
The BOX-I motif was optimised to develop high affinity ligands for MDM2, some of 
which have the ability to also bind the less well defined hydrophobic pocket of 
MDM4130. This is interesting because it has been suggested that the dual inhibition of 
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MDM2 and MDM4 would result in a greater effect than inhibiting MDM2 alone. The 
PMI peptide was the result of optimization of the BOX-I motif, and differs in sequence 
to BOX-I (Fig. 1.16a), although the residues necessary to contact the hydrophobic 
pocket are conserved130. The Kd for PMI binding to the N-terminus of MDM2 is 3.2 nM 









Figure 1.16 A) BOX-I and PMI peptides, important binding residues highlighted in red 
B) Residues in each peptide and contribution to MDM2 interaction (positive: +, neutral 
or deleterious: -) 
 
PMI peptides reveals which residues are neutral, contribute to binding or are deleterious 
in each peptide (Fig. 1.16b)131. This study is instructive for understanding linear motifs, 
because it reveals that the consensus sequence found in a linear motif which gives rise to 
high affinity interactions is important, but there is also considerable room for non-
essential residues to vary without affecting binding activity. It is interesting to note that 
the proline residue in BOX-I and the glutamine residue in PMI contribute negatively to 
BOX-I affinity, these residues might be important for docking, resulting in a higher 
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dissociation constant. The concept that variable sequences are tolerated in linear motifs 
is illustrated by numerous ‘non-canonical’ motifs found in proteins which are still bound 
by a protein which recognizes a consensus. The peptides investigated in these studies 
have high affinity for MDM2, however lower affinity binding peptides may also be 
biologically relevant as transient interactions in the cellular environment can be 
significant. The BOX-V and RB1 interactions with MDM2 for example are weak 
compared to BOX-I, however this interface actually forms the ubiquitination signal for 
p53 and both of these peptides can affect, albeit mildly, binding at the N-terminal 
domain of MDM291. Transient motif binding is likely to be highly dependent on other 
proteins participating in a complex and the environment of the protein interaction, which 
are predicted to increase by orders of magnitude the affinities and activities observed in 
vitro due to proximity of ligand and binding partner. It has been shown by ion mobility 
mass spectrometry that small heat shock protein has up to 300 oligomerisation states and 
conformers132. Due to the observed allostery of MDM2 and internal disorder it is 
possible that it is also converting between conformers in order to bind different peptide 
ligands. 
 
1.6.6 Nutlin as an MDM2-p53 protein-protein interaction inhibitor 
MDM2 has many of the characteristics of a promising target for cancer therapeutics. It is 
at the hub of multiple signaling pathways, is the binding partner of the important tumour 
suppressor p53, is aberrantly regulated in many cancers and has a drug binding pocket in 
the form of the hydrophobic cleft. A small molecule screen for MDM2 inhibitors 
 61 
identified cis-imidazolines know as ‘Nutlins’ named for ‘Nutley inhibitor’ as a high 
affinity MDM2 binding molecule133. The Nutlins are cis-imidazolines which are 
synthesized as two enantiomers, one of which is 150 times more effective than the other. 
Nutlin-1, 2 and 3 (Fig. 1.17a) are all effective MDM2 binders, with Nutlin-3 having the 















Figure 1.17 A) Chemical structure of Nutlin-1, 2 and 3 B) Structure of Nutlin-2 bound to 




it binds the MDM2 hydrophobic pocket in the same region as the BOX-I peptide from 
p53, mimicking the residues which intercalate into the hydrophobic pocket (Fig. 
1.17b,c). The p53 residues which are mimicked are F19, W23 and L26 which have been 
shown to contribute to the high affinity of BOX-I for MDM2. Interestingly, the original 
x-ray structure of MDM2 with Nutlin shows more than one molecule of Nutlin bound to 
the N-terminus, although it is clear that the Nutlin in the hydrophobic pocket is a 
molecular mimic of the corresponding BOX-I residues which have previously been 
shown to be vital for BOX-I MDM2 binding. The affinity of Nutlin-3, is 90 nM 
compared to the BOX-I Kd of 440 nM and it effectively competes both BOX-I and full-
length p53 tetramer from the N-terminal domain of MDM265, 91. It has also been shown 
that Nutlin can bind the hydrophobic pocket of Bcl-xl, which has some similarity to the 
MDM2 pocket, and is a protein involved in apoptosis134. Nutlin does not have a high 
affinity for MDM4, which is appealing as a specific inhibitor of MDM2, although some 
studies suggest dual inhibition of MDM2 and MDM4 is desirable108, 135. 
 
1.6.7 Computational studies of MDM2 N-terminal binding 
There are different components to the MDM2-BOX-I interaction, the core hydrophobic 
packing contributes to a decrease in the entropy of the BOX-I peptide, and around the 
hydrophobic pocket electrostatic interactions with residues around the hydrophobic core 
also stabilise the peptide binding to MDM2108. Nutlin takes advantage of disrupting the 
entropic component of this interaction, which for the BOX-I peptide is the dominant 
force maintaining contact between the linear motif and MDM2. Each residue in the 
BOX-I motif contributes to the interaction to a slightly different extent, shown by 
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molecular dynamics modeling of the residues involved108 as well as substitution analysis 
in vitro which optimized the BOX-I peptide to the PMI inhibitor131. These computational 
studies reveal that other residues than those which intercalate BOX-I or Nutlin also 
mediate peptide binding by forming interactions around the hydrophobic cleft. The 
Tyr100 residue has been referred to as a ‘gatekeeper’ of the pocket, and can flip between 
‘open’ and ‘closed’ positions to ostensibly block the hydrophobic pocket136. Charged 
residues, particularly glutamate 25 also potentiate BOX-I binding by attracting the 
positively charged C-terminus of the peptide before it packs into the hydrophobic 
pocket108. It is not inconceivable that these electrostatic interactions are required to dock 
this peptide before it ‘snugly’ binds into the hydrophobic pocket. Given that at this 
position in MDM4 this residue is represented by a glutamine, this would result in the 
loss of the electrostatic effect and would account partially for the lower affinity of 
MDM4 for BOX-I. As previously described, p53 regulation by MDM2 depends on an 
allosteric mechanism in MDM291. This allostery is regulated by the transduction of 
signals binding at the N-terminal domain to the disordered acidic domain. N-terminal 
MDM2 regulation is actually even more complicated, with recent studies showing that 
phosphorylation of the lid domain at serine 17 in the lid of the N-terminus of the protein 
can mediate ‘opening’ and ‘closing’ of the hydrophobic pocket65, 137. This has been 
shown by Worrall et al. although NMR studies suggested the lid did not bind at the N-
terminus137, 138. Molecular dynamics based computational studies have indicated that 
there are minor differences in the structure of the phosphorylated residue and the 
phospho-mimic, which lead to slightly different conformations of the lid over the 
hydrophobic pocket, and it is possible for the lid to occlude peptide but allow the 
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binding of Nutlin into the pocket139. This indicates that although Nutlin is an effective 
inhibitor of the BOX-I MDM2 interaction, it may be possible for other MDM2 N-
terminal interactions to be affected differently by Nutlin due to slight differences in the 
binding site. 
 
1.6.8 Therapeutic significance of Nutlin 
As a potent inhibitor of the interaction between the N-terminal interface of p53 and 
MDM2, Nutlin has been investigated as a drug with therapeutic potential. There have 
been studies showing nutlin may be effective in retinoblastoma140 and melanoma in cells 
with wild type p53. However there are some drawbacks to using Nutlin as a drug. Some 
studies show Nutlin has a wide range of affects in non-cancerous cells, and the MDM2-
p53 axis although aberrant in cancer cells cannot be totally abolished as this would cause 
widespread cell death. Nutlin has been shown to be effective in combination with the 
proteasome inhibitor bortemozib141 which is promising for the use of nutlin as part of 
combination treatments which target multiple aspects of cancer cells in one course of 
treatment. Although there are conflicting results about how effective Nutlin would be in 
the clinic, it remains a useful tool for investigating MDM2 and p53 pathways. It is also 
the case that Nutlin may be a scaffold for the development of more advanced 





1.7 Proteomics methods 
1.7.1 Overview of proteomics methods 
Although the human genome project catalogued the complement of genes present in the 
human genome, this base of knowledge is perhaps immeasurably complicated when 
translated to the protein level. The term proteomics was coined by Marc Wilkins at 
Macquarie University in 1994, to mean the protein complement of the genome142. 
Although many proteomics efforts are in progress, it is not yet possible to identify every 
protein in the human proteome. This is partly because of the increased complexity of the 
proteome compared to the genome, and partly because there is no one technology which 
can ‘read’ the proteome of a cell, such as DNA sequencing can ‘read’ the genome. The 
major differences between the proteome and genome are that the former is dynamic and 
constantly changing and adapting to stimulus over short timescales whereas the genetic 
code is stable to preserve information between generations and stable mutations arise 
over a longer period of time. When the proteome of a cell is discussed, this is different 
for every cell type, organism and environment of the cell, as it is primarily on the protein 
level that cells respond to stresses143. Post-translational modifications such as 
glycosylation, phosphorylation and proteolytic cleavage alter proteins on a proteomic 
level. Although these modifications are not directly coded for in the genome sequence 
they could be regulated epigenetically, by the silencing and activation of different genes 
or miRNAs due to DNA and histone modifications144, 145. Splicing events can alter 
mRNA prior to translation, sometimes resulting in multiple protein products from the 
same gene which further increases the complexity of the proteome146. Efforts to improve 
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knowledge of the proteome have focused on improving proteomic methods to absolutely 
validate the amount of protein in a cell, or relatively quantify protein levels in different 
states of the same cell type. This involves both improving technology used to measure 
the level of multiple proteins in a cell, and also optimizing the way proteomic data is 
analysed and validated. The aims of proteomic experiments can include finding out more 
about the interactome of a known protein, detection of new biomarkers for cancer and 
other diseases and to compare to microarray data for investigating whether genes are 
regulated on the transcriptional or translational level. Mass spectrometry (MS) is 
undoubtedly the key method which makes it possible to carry out large scale proteomics, 
due to the capability to sequence peptides without using chemical methods147. 
 
1.7.2 Quantitative proteomic methods – gel based 
Some of the earliest methods used for quantitative proteomics were based on 2D gel 
electrophoresis, and detection of differences between the intensity of spots representing 
proteins on a 2D gel. This was developed further into difference gel electrophoresis 
(DIGE) which runs two samples on the same gel labeled with two different fluorescent 
dyes to simultaneously compare the expression of two proteins and eliminate errors 
introduced due to reproducibility of electrophoresis148. Gel based methods can suffer 
from inadequate separation, as many proteins cluster at similar isoelectric points or 
molecular weights and a single spot can represent multiple proteins. The benefit of this 
method however, is that it is quick and simple to carry out without the need for specialist 
equipment.  
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1.7.3 Shotgun proteomics 
A commonly used non-gel based method for proteomic analysis of many proteins from a 
cell lysate is shotgun proteomics149. This technique involves the enzymatic digestion of a 
cell lysate proteolytically to yield peptide fragments from the cellular proteins, typically 
by trypsin. This is followed by sequencing detectable peptides by tandem mass 
spectrometry, also referred to as MS/MS, to identify which proteins are present in a 
mixture based on the presence of unique peptides (Fig. 1.18a,b)150. Tryptic peptides are 
detected in a primary MS scan, and selected peptides are subsequently sequenced by 
MS/MS147, 151. The primary peptide is referred to as the precursor or parent ion and the 
fragmented peptide known as product or daughter ions. The precursor ions are usually 
fragmented by collision induced dissociation (CID), and product ions are detected after 
separation by a second MS scan147. The difference in mass/charge (m/z) of the product 
ions can be used to determine the sequence of the peptide. If sufficient fragments are 
generated and detected in the MS/MS scan it is possible to calculate the mass of each 
individual amino acid present in the peptide from the difference in m/z between peaks, 
i.e. a loss representing 75.07 Da would represent loss of a glycine residue. There are 
different species of fragmented peptide ions which can be formed, which can depend on 
the fragmentation method and mass spectrometer. The reliability of the sequenced 
peptide is increased if there is good coverage over an ion series, for example the b and y 
series (Fig 1.18c). The sequences of the fragment ions can be used to determine the 
peptide sequence if enough fragment ions are obtained to calculate the loss of single 
amino acids. Files containing MS data which lists all of the peptides detected and 






















Figure 1.18 Overview of MS based shotgun proteomics A) Sample digestion and pre-
fractionation B) MS based stages in protein identification C) Fragmentation at the 




databases such as MASCOT (Matrix Science), which return a list of the proteins present 
in a sample151, 152. This method is fairly straightforward for identification of single 
proteins, or relatively abundant proteins which have been pre-separated for example by 
electrophoresis, however for complex samples such as whole cell lysates there are 
several obstacles. Some drawbacks with this method are that it relies on a wide dynamic 
range of the mass spectrometer to detect low abundance as well as high abundance 
peptides, and because the tryptic digests are complex also requires high resolution153. 
Shotgun MS is closely related to the power of liquid chromatography methods to 
initially separate peptide mixtures, and reproducibility in LC increases the confidence in 
proteomics results due to the ability to obtain reliable replicates. It is also possible to use 
other fractionation methods prior to shotgun MS to obtain a number of fractions with 
reduced complexity to aid detection of lower abundance peptides. These fractionation 
methods include subcellular fractionation, strong cation exchange or other 
chromatography methods and gas phase fractionation154. UltraHPLC and nanospray can 
also increase the power of shotgun MS due to the constant flow rate they create into the 
mass spectrometer155. Using high resolution mass spectrometers, such as those which 
contain Orbitraps (Thermo) and linear ion traps allows the complexity of a high number 
of precursor peptides to be resolved and this increases the number of proteins detectable 
in one mass spectrometry experiment. New methods have been developed to avoid some 
of the data analysis problems associated with shotgun proteomics. One of these methods 
is data-independent acquisition, such as the precursor acquisition independent from ion 
count (PAcIFIC) method156. Typically the ions selected for fragmentation are chosen 
because they are more intense than the other ions in a data-dependent method of mass 
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spectrometry, and product ions are assigned to mass of the precursor ion to determine 
the peptide sequence. Alternatively, data-independent acquisition fragments every 
peptide in a small mass/charge window, and assigns them to a m/z in the centre of the 










Figure 1.19 A) Data-dependent selection of ions for sequencing vs. PAcIFIC data-
independent acquisition. DD – data dependent, DI – data independent 
 
mass of peptides within the window is not significant. This results in a larger number of 
peptides being sequenced and a larger coverage of the proteome. Data-dependent 
acquisition can miss detection of lower abundance peptides which may nonetheless 
represent interesting proteins, p53 for example is an low abundance protein. 
1.7.4 Proteomic quantitation methods  
Many of the problems in proteomic experiments arise from quantitation of the detected 





















Figure 1.20 A) iTRAQ labels (Applied Bioscience) Reporter ion – blue, balance group – 
black, peptide reactive group - red B) iTRAQ workflow 
 
with at least three biological and technical replicates. The aim of this is to minimize the 
impact of sample variation, LC conditions and variation in detection of peptides between 
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LC runs, as a single run may contain false negatives or positives. There are several well 
investigated methods of proteomic quantitation. As mentioned in the previous section, in 
2D electrophoresis and DIGE quantify protein levels by measuring the intensity of a spot 
in a gel or a fluorescently labeled protein can be compared using specialized software, 
such as Progenesis (Nonlinear Dynamics).  
 
In LC based shotgun proteomics, there are a wider variety of quantitation methods 
available. Techniques which chemically label the tryptic peptides have been shown to be 
effective, particularly isobaric tags for relative and absolute quantification (iTRAQ) 
which labels up to 8 samples with isobaric tags which are released when a peptide is 
fragmented in the MS, the piperazine region of the tags have different combinations of 
heavy and light carbon isotopes resulting in a range of masses157 (Fig. 1.20a). The tags 
are initially isobaric to avoid any differences in peptide ionization or retention time for 
different iTRAQ labels. The ratio between these tags can then be used as a quantitation 
measure to detect the difference between the levels of proteins in different samples (Fig. 
1.20b). Care has to be taken however to use several unique peptides for iTRAQ 
quantitation, as variation between the ionization efficiencies of peptides can result in 
anomalous results, as can difference between the labeling reaction in two samples which 
may not have occurred to an identical extent in all samples158. iTRAQ can also suffer 
from the ‘compression effect’, which is the quenching of iTRAQ ratios in complex 
samples due to detection of a less intense change in ratio between protein levels than is 
detected by other methods159. Another labeling method is stable isotope labeling of cells 
in culture (SILAC)160, which involves cells in culture being grown in a heavy medium to 
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incorporate amino acids containing isoforms of amino acids with heavy elements into 
one sample to compare to a sample which has not been grown in heavy media160 (Fig. 
1.21). This method results in mass differences between otherwise identical precursor 


















N labeled arginine 
and lysine can be combined for multiplex quantitation 
 
quantitation, and this method can be multiplexed by using different heavy amino acid 
combinations for different samples. This route has proven effective, however cells have 
to be propagated in heavy medium for several passages before they can be used for 
SILAC, which can result in difficulties if a phenomenon is dependent on passage 
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number. This is also an approach which is not suitable, for example, to analyse 
biomarkers in clinical samples, due to the impossibility of heavy labeling a patient; 
although SILAC has been demonstrated on Drosophila161, mice162 and C. elegans163.  
 
18O labeling is a method which takes advantage of the trypsin digestion step, by using 
heavy water in the trypsin digest step which results in the incorporation of one or two 
heavy oxygen atoms into the tryptic peptide164. Where one sample is digested in heavy 
water,  and a second sample digested in light water the peptides obtained by digestion 
will have a mass difference, and this allows relative quantitation of the peptide by 
comparing intensities164. Although SILAC and 18O labeling do create peptides which 
have a different m/z, they do not contain a chemical labeling reaction step which is an 
advantage over methods like iTRAQ. Label free methods can avoid the problems in 
labeling peptides which can occur because of chemical reaction differences165. Label 
free quantitation methods include spectral counting, which simply counts the number of 
times a peptide appears in the initial MS spectrum and this can be compared to other 
samples166. This method requires algorithms which normalize the quantitation results 
based on the length of the protein a peptide is derived from, because longer proteins 
have more chance of the detection of multiple peptides167. This method also requires 
very reproducible LC conditions, as this can affect the number of times a peptide is 
detected. An alternative to spectral counting is to quantify peptides by measuring the 
area under the peak, which is the method usually used for multiple reaction monitoring 
(MRM) quantitation165.  
 
 75 
All of the methods above are relative methods of quantification, i.e. they compare two or 
more samples to each other. Absolute quantification is also possible with mass 
spectrometry based proteomics. Absolute quantification (AQUA) is a method which has 
been used to quantitate particular proteins by spiking lysates with a heavy peptide of a 
known protein, and using the known concentration of the spiked peptide to determine 
how much protein is present in a sample168. Variations on this technique include 
transfection of proteins which are concatomers of AQUA peptides which can be freed by 
tryptic digestion to quantify multiple proteins at once using this absolute quantitation 
method169. Drawbacks with these methods are that you have to know which proteins you 















Table 1.1 Summary of quantitation methods for proteomics 
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for measuring known biomarkers but not discovering new biomarkers. Shotgun 
proteomics experiments which rely on relative quantitation takes a snapshot of the whole 
proteome, and results may include new hits which have not been discovered by 
traditional cell biology and genetics methods. Proteomic MS quantitation methods are 
summarized in Table 1.1. 
 
1.7.5 Validation of proteomic data 
If an appropriate number of replicates have been carried out, proteomic data can be very 
reliable, and it is often possible to find internal validation in a proteomic dataset of 
known proteins linked to the phenomenon being studied. For reasons of large data 
volume, a proteomics dataset can be difficult to interpret. In a quantitative proteomics 
experiment it is necessary to choose cut offs to represent up or downregulation of a 
protein, and assign significance values to the quantitations obtained. In the absence of 
rigorous statistical validation of proteomic datasets, traditional biochemical and cell 
biology methods can be used to validate individual hits, however it is unlikely that it 
would be possible to do this for every interesting hit generated in a proteomic mass 
spectrometry experiment. Various bioinformatics efforts are aiming to deal with this 
problem, for example using meta-data associated with identified proteins such as 
subcellular localization and known functions to classify proteomics results170. Creation 
of machine learning models has also been used to carry out unbiased filtering of 
proteomic data171, and other bioinformatics based methods are very promising for 
continuing to make sense of the proteome and the dynamic nature of interactomes. 
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1.8 The aim of this project 
MDM2 has diverse functions, a complicated molecular mechanism and a large 
interactome. By finding out more about the wider MDM2 interactome, new cancer 
targets as well as means to re-activate cell arrest and apoptotic pathways may be found. 
This in turn will improve our understanding of the way proteins have multiple binding 
partners and regulate multiple pathways. It is becoming clear that the cellular 
environment is complex and dynamic, and one method of measuring this dynamic 
environment is by using quantitative proteomics. The aim of this work was to perturb the 
MDM2 interactome using the drug Nutlin, and to use quantitative proteomic screens to 
detect proteins which have altered levels after Nutlin treatment (Chapter Three). Results 
were filtered using a model based on linear motifs binding of MDM2, and MDM2 
binding peptides derived from proteins affected by Nutlin validated using biochemical 
methods such as ELISA and biophysical assays, in particular thermal denaturation 
(Chapter Four). Full-length proteins were then validated for MDM2 interaction and 
Nutlin response (Chapter Five). By targeting our efforts on a protein that is already 
relatively well characterised, MDM2, it can be evaluated whether this is a valuable 
method for interactomics and how successful the strategy of filtering of proteomic 
results by linear motifs is. Additionally, the concept of linear motif mediated interactions 
was investigated using the BOX-I and BOX-V motifs (Chapter Four). An AGR2 binding 





2 Experimental Methods 
2.1 Cell culture 
2.1.1 Mammalian Cell Culture 
MCF7 human breast adenocarcinoma cells were seeded on 6-well, 10 cm or 20 cm 
plates with 2 ml, 10 ml or 20 ml respectively DMEM growth medium (Invitrogen) 
supplemented with 10% foetal calf serum (FCS, Biosera) and 1% penicillin and 
streptomycin (PenStrep) (Invitrogen). Cells were incubated at 37°C with humidity, with 
a CO2 level of 5 or 10%. To maintain cultures, cells were grown until 90-100% 
confluent, washed twice with sterile phosphate buffered saline pH 7.4 (PBS) then 
incubated with 3 ml trypsin-ETDA (Invitrogen) at 37°C for 5-10 mins to detach from the 
plate. Trypsinised cells were then diluted 1:1 with fresh DMEM 10% FCS, 1% penicillin 
and streptomycin and seeded onto new plates at the desired density. A375 human 
melanoma cells were also cultured in the same way using DMEM, and H1299 human 
lung carcinoma cells were cultured in RPMI medium supplemented with 10% FCS and 
1% PenStrep (Invitrogen) with all other methods the same as for MCF7 cells. 
 
2.1.2 Freeze down of cell cultures 
For long term storage cells were stored in liquid nitrogen. Confluent cells were 
trypsinised as before with 3 ml trypsin-EDTA then diluted to 10 ml with growth 
medium. Cells were centrifuged at 1000 rpm for 5 mins and supernatant discarded. 
Pellets were resuspended in 5 ml freezing medium (FCS with 10% DMSO), aliquoted 
into cryovials and incubated at -80°C in an isopropanol chamber overnight before 
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transferring to liquid nitrogen. Cells were thawed by bringing an aliquot to 37°C and 
added to 5 ml growth medium supplemented with FCS and PenStrep to a 6 cm plate. 
Cells were washed with sterile PBS and fresh medium added the following day. 
 
2.1.3 Harvesting of cells 
Cells were harvested by washing twice with ice cold PBS, then scraping cells away from 
the plate into a small volume of ice cold PBS and transferring to a microfuge tube. Cells 
were then centrifuged for 3 mins at 3000 rpm, and the supernatant removed by pipetting 
before either snap-freezing the cell pellet in liquid nitrogen or proceeding directly to 
lysis. 
2.2 Plasmids and transfection 
2.2.1 Plasmids  
Plasmids for transfection were purified by mini or maxi-prep (Qiagen) and concentration 
determined by measuring A260 on a NanoDrop UV/Vis spectrometer (Thermo). Plasmids 










Invitrogen Empty 5'-TAATACGACTCACTATAGGG-3' 
        p53   
        MDM2   







4.7 Ampicillin  Origene RPS7 5'-GGACTTTCCAAAATGTCG-3'   
        ERp60   
Table 2.1 – Plasmids for transfection 
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2.2.2 Transfection protocol 
Transfection mixture (for a 10 cm plate): 
0-10 µg plasmid DNA 
15 µl Attractene (Qiagen)  
Made up to a final volume of 300µl with serum free growth medium (SFM) 
 
Cells were allowed to grow to 90-100% confluence, washed twice with sterile PBS, and 
10 ml growth medium supplemented with FCS and PenStrep. Transfection mixture was 
added to cells dropwise and they were incubated overnight at 37°C and 5% CO2. After 
incubation cells were harvested as described.  
 
2.2.3 siRNA Treatment of Cells 
siRNA Transfection Solution 1: 
190 µl SFM 
10 µl siRNA (final concentration 1 µM) 
 
siRNA Transfection Solution 2: 
196 µl SFM 
4 µl Dharmafect (Dharmacon) 
 
siRNA stocks were prepared in ddH2O to 20 µM in 1x siRNA buffer (Dharmacon). 
Cells were grown on 6-well plates to approximately 60% confluence, washed twice with 
sterile PBS and 1.6 ml fresh medium containing FCS was added per well. The two 
transfection solutions were prepared and incubated for 5 mins before solutions 1 and 2 
were combined and incubated at room temperature for 20 mins. 400 µl per well of this 
solution was added to each well dropwise. Cells were harvested after 24 or 48 hrs as 
previously described.  
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2.3 Drug treatment of cells  
2.3.1 Nutlin treatment of cells 
A stock solution of 43 mM Nutlin-3 (Alexa Biochemicals) was prepared in 100% 
DMSO. Nutlin was added to medium to a final concentration of 0-40 µM and then added 
to cells after washing them twice with sterile PBS. Cells were harvested at the desired 
time point (Between 0-48hrs). Control cells were treated with DMSO only. 
 
2.3.2 MG-132 treatment of cells 
A stock solution of 10 mM MG-132 (VWR) was prepared in 100% DMSO. MG-132 
was added to medium at a final concentration of 10 µM and then added to cells after 
washing them twice with sterile PBS. Cells were harvested after 4-5 hrs. Control cells 
were treated with DMSO only. 
 
2.3.3 Cycloheximide treatment of cells 
A stock solution of 10 mg/ml cycloheximide was prepared in 100% ethanol. 
Cycloheximide was added to fresh medium to a final concentration of 10 µg/ml and 
added to cells after washing twice with sterile PBS. Cells were harvested at time points 
between 0 and 2 hrs. Control cells were treated with ethanol only. 
 
2.3.4 Peptide aptamer treatment of cells 
Penetratin (RRMKWKK) tagged peptide aptamers (Clonestar) were dissolved to a stock 
concentration of 2.5 mM in ddH2O and neutralized to pH 7.0 with 5 M NaOH. Peptide 
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aptamers were diluted in growth medium to the desired final concentration between 0 
and 50 µM and cells were washed twice with sterile PBS before adding peptide 
containing medium to plates. Cells were harvested 6-72 hrs after aptamer treatment, 
lysed and analysed by SDS-PAGE. 
 
2.4 Cell lysis and subcellular fractionations 
NP40 Lysis Buffer:   SDS Lysis Buffer 
150 mM NaCl   0.15% SDS 
1% NP40    20 mM HEPES pH 8.0 
50 mM Tris.HCl pH 8.0  10 mM NaF 
50 mM NaF   150 mM NaCl 
5 µM EDTA   1 mM EDTA 
    1 mM EGTA 
 
Urea Lysis Buffer    
50 mM Tris.HCl pH 8.0   
150 mM NaCL    
6 M Urea pH 8.0    
50 mM NaF    
5 µM EDTA    
 
Cell pellets were lysed in NP40 lysis buffer, SDS lysis buffer or urea lysis buffer. Cell 
pellets were incubated with 100-400 µl lysis buffer for 30 mins on ice, then centrifuged 
for 30 mins at 13 000 rpm to obtain lysate and an insoluble pellet. The insoluble pellet 
was either discarded or lysed with urea lysis buffer. Concentrations of lysates were 
obtained by Bradford assay172. For subcellular fractionation, cell pellets were lysed as 
per manufacturers instructions with a subcellular proteome extraction kit (calbiochem) 







200 µl aliquots of Bradford reagent were incubated for 5 minutes with 1-2 µl bovine 
serum albumin (BSA) standards between 0-2 mg/ml. The same volume of each sample 
of unknown concentration was also added to a 200 µl aliquot of Bradford reagent. 50 µl 
of each standard and unknown sample were pipetted into a clear 96-well plate in 
triplicate and absorbance at 595 nm read using a VICTOR3 1420 multi-label plate reader 
(PerkinElmer). Standards graph was constructed using absorbances from the BSA 
samples, fit with a straight line equation and concentration of unknown samples 
calculated from standard fit. 
 
2.5.2 Peptide enzyme-linked immunosorbent assay (ELISA) 
ECL I:    ECL II: 
2.5 mM luminol    0.02% v/v H2O2 
100 mM Tris.HCl pH 8.5  100 mM Tris.HCl pH 8.5 
0.4 mM p-coumaric acid    
 
White 96-well plates (Costar) were incubated with 50 µl per well 16 µg/µl streptavidin 
(AnaSpec) overnight at 37°C to coat plate with streptavidin. Plates were washed 6 times 
with 200 µl PBS 0.05% Tween-20 (PBS-T) and then incubated with 1-5 µg biotinylated 
peptide (Mimotopes) per well for 1 hr with shaking on a rotating table. Plates were 
washed as before, prior to blocking with 200 µl 3% bovine serum albumin (BSA) PBS-T 
per well for 1 hr at room temperature. Blocking solution was removed and peptide 
coated wells were then incubated with 50 µl protein diluted in 3% BSA PBS-T. To show 
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peptide-protein binding titrations of protein serial dilutions were prepared with a non-
binding peptide or protein as a negative control. If the assay was to measure competition 
the protein was incubated with competitor for 30-60 mins prior to addition to plate. 
Wells were washed as before, then incubated for 1 hr at room temperature with 50 µl per 
well primary antibody diluted in 3% BSA PBS-T (Antibodies – 2.3.3) and gentle 
shaking. Wells were washed again as before and incubated for 1 hr at room temperature 
with 50 µl per well secondary antibody diluted in 3% BSA PBS-T. After washing as 
before, ECL1 and ECL2 were combined in equal volumes directly before adding 50 µl 
of ECL mixture to each well. Plates were exposed to X-ray film which was developed as 
described in immunohistochemistry section, and also luminometry measurements were 
taken using a Labsystems Fluoroskan Ascent FL plate reader and the Labsystems 
Picogreen program to interpret data. 
 
2.5.3 Protein-protein ELISA 
White 96-well plates were coated with 10-50 µg protein diluted in 50 µl 0.1 M NaCHO3 
pH 8.0 per well overnight at 4°C, then washed as in the peptide ELISA and blocked with 
200 µl 3% BSA-PBST. Plates were then incubated with protein and antibodies and 
developed as described for the peptide ELISA. 
 
2.5.4 In vivo His-Ubiquitin assay 
H1299 cells were transfected with pcDNA His-Ubiquitin, candidate protein (p53, CypB, 
S7) with or without cotransfection of pcDNA-MDM2 (Table 1.1). After 24 hrs 
transfected cells were treated for 4-5 hrs with the proteasome inhibitor MG-132 
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(Calbiochem) at a concentration of 10 µM prior to harvesting and snap freezing in liquid 
nitrogen.  
Buffer A (100 ml)     Buffer B 
6 M Guanidinium    (100 ml): 
47.35 ml 0.2 M Na2HPO4   8 M Urea 
2.65 ml 0.2 M NaH2PO4   23.7 ml 0.2 M Na2HPO4 
10 mM Tris.HCl pH 8.0   1.33 ml 0.2 M NaH2PO4 
70 µl 14.3 M β –mercaptoethanol  10 mM Tris.HCl pH 8.0 
Adjust to final pH of 8.0   35 µl 14.3 M β -mercaptoethanol 
     Adjust to final pH of 8.0 
      
Buffer C (50 ml):    Buffer D   
8 M Urea    Buffer C + 0.2% Triton X-100 
11.25 ml 0.2 M Na2HPO4    
38.75 ml 0.2 M NaH2PO4   Buffer E  
10 mM Tris.HCl pH 8.0   Buffer C + 0.2% Triton X-100 
70 µl 14.3 M β-mercaptoethanol   
      
Ub Lysis Buffer:    Elution Buffer (1 ml) 
100 ml Buffer A    200 mM imidazole 
5 mM imidazole    5% SDS 
     150 mM Tris-HCl pH 6.7 
     10% Glycerol 
     50 µl 14.3 M β -mercaptoethanol 
 
Cells were lysed in 1 ml lysis buffer, pipetting through an 8 µ syringe several times to 
enhance lysis. 800 µl of lysate was transferred to a 15 ml falcon tube containing 4 ml of 
lysis buffer. The remaining 200 µl of lysate was retained for loading controls. 75 µl of 
Ni-NTA agarose beads (Qiagen) were added to the falcon tube and samples were 
incubated on a rotary shaker at 4°C overnight. Beads were then collected by centrifuging 
at 2000 rpm for 3 mins and the supernatant discarded. Beads were resuspended in 750 µl 
Buffer A, transferred to a microfuge tube and incubated at room temperature with 
 86 
rotation for 15 mins. Mixtures were then centrifuged as before, supernatant discarded 
and beads washed with buffers B, C, D and E by resuspending in 750 µl of buffer then 
centrifuging as before and discarding supernatant. To elute His-ubiquitin tagged proteins 
beads were incubated with 75 µl elution buffer for 30 mins at room temperature, then 
centrifuged at 14 000 rpm for 5 mins at 4°C. Supernatant was collected and analysed by 
SDS-PAGE using Novex 4-12% pre-cast gels (Invitrogen). 
 
2.5.5 In vitro His-Ubiquitin assay 
Reaction mix for 16 reactions: 
 
25 mM HEPES pH 8 (4°C) 
6 mM MgCl2 
0.05% v/v Triton X-100 
0.5 mM DTT 
1 mM Benzamidine 
80 µg/ml ubiquitin 
3 mM ATP 
Make up to a final volume of 400 µl with 
ddH2O 
 
Fresh in vitro ubiqutination mixture was prepared on ice and mixed gently by inversion. 
4 µl 1 M creatine phosphate and 2 µl 10 mg/ml creatine kinase were added and again 
mixed gently by inversion. 0.78 µl E1 UBE1 and 0.48 µl E2 UbcH5 (Boston 
Biochemicals) were added to the mixture along with substrate (p53 or CypB) and a 
titration of MDM2. Tubes were incubated at 30°C for 15 mins, then transferred back to 
ice, mixed with sample loading buffer and incubated at 95°C for 2 mins before analysis 





 peptide arrays 
Slides functionalized with candidate peptides (Intavis) were blocked for 4 hours at room 
temperature in Tris buffered saline (TBS), 0.05% Tween (TBST) containing 5% BSA. 
Slides were then rinsed in TBST and incubated with 10 µg MDM2 or N-terminal 
domain MDM2 diluted in TBST 0.5% BSA overnight at 4°C. 3 x 10 min washes with 
TBST were carried out on slides, before incubation with primary antibody diluted in 
TBST 1% BSA for 1 hr at room temperature. Slides were washed as before, and 
incubated with LiCor IRDye 800CW donkey anti-mouse secondary antibody for 1 hr at 
room temperature. Slides were read on a LiCor Odyssey plate reader, and analysed using 
the LiCor software. 
 
2.5.7 Co-immunoprecipitations 
Cells were lysed in NP40 lysis buffer. 100 ml protein G sepharose beads (Sigma Aldrich 
or Expedeon) were washed with 1 ml cold lysis buffer three times by resuspending and 
centrifuging at 5000 rpm for 1 min, discarding the supernatant. Lysates were then pre-
cleared of proteins which bind to protein G or sepharose beads by incubating lysate with 
100 µl protein G beads for 40 mins on a rotary shaker at 4°C. This mixture was 
centrifuged at 13 000 rpm for 2 mins and supernatant transferred to a fresh eppendorf. 2 
µg of anti-MDM2 (2A10) was added to the lysate and incubated overnight at 4°C with 
rotation. 15 µl protein G beads which had been washed as before were added to the 
lysate-antibody mixture and incubated for 1 hr at 4°C with rotation. Beads were washed 
by centrifuging at 5000 rpm for 2 min at 4°C, discarding supernatant and resuspending 
 88 
in fresh lysis buffer for each wash. Antibody-protein complexes were eluted by boiling 
for 3-5 min with SDS sample loading buffer, then centrifuging at 5000 rpm for 5 min to 
obtain supernatant. Supernatant, load and wash fractions were then analysed by SDS-
PAGE and western blot. 
 
2.6 SDS-PAGE and western blotting 
2.6.1 SDS-PAGE 
5x Sample Loading Buffer:  10x Running Buffer: 
250 mM Tris.HCl pH 6.8  250 mM Tris.HCl 
50% v/v glycerol   2 mM Glycine 
5% w/v SDS   1% w/v SDS 
0.5% w/v bromophenol blue   
250 mM DTT   10x Transfer Buffer 
    
250 mM Tris.HCl 



















30% acrylamide mix (diluted to required 
percentage) 
5% v/v acrylamide mix 
(Protogel) 
375 mM Tris.HCl pH 8.8  125 mM Tris.HCl pH 6.8 
0.1% w/v SDS    0.1% w/v SDS 
0.1% w/v APS    0.1% w/v APS 
0.04% v/v TEMED   0.04% v/v TEMED 
 
Whole cell lysate concentration was measured by Bradford assay and then normalized 
using water or lysis buffer. Sample loading buffer was diluted 1 in 5 into samples and 5-
10 µg of total protein was analysed in each gel lane. Gels were either Novex pre-cast 
with a 4-12% gradient (Invitrogen), or running buffer and stacking buffer were prepared 
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as above at the desired percentage of acrylamide (10, 12 or 15% v/v). Gels were run at 
180-200 V with the appropriate running buffer (MOPS for pre-cast (Invitrogen) or SDS 
for freshly prepared gels), using Bio-Rad gel apparatus and power pack until markers 
and protein standards (Fermentas) reached the bottom of the gel. Gels were either 
stained with coomassie stain or RapidBlue (Expedeon) and destained in 10% methanol, 
7% acetic acid, transferred to water or used for western blotting. 
 
2.3.2 Western blots 
Transfer buffer was diluted to 1x with a final concentration of 20% v/v methanol. After 
SDS-PAGE gels were transferred to western blotting cassettes as follows from negative 
to positive electrode - sponge, two sheets of blotting paper, gel, membrane (Hybond, 
GE), two sheets of blotting paper, sponge, with all components soaked in transfer buffer. 
Cassettes were transferred to an electrophoresis tank with an ice pack, and transfer 
buffer was added to tank covering gel and membrane completely. Transfers were run at 
300 mA for 1 hr, and either rinsed in H2O before Ponceau staining to visualize bands or 
immediately blocked. Nitrocellulose membranes were blocked with 3% milk powder 
(Marvel) PBS-T for 1 hr at room temperature with gentle shaking. Membranes were then 
incubated with primary antibody diluted in 3% milk PBS-T at 4°C overnight. After 
incubation with primary antibody membranes were washed three times for 10 mins in 
PBS-T and incubated with secondary antibody diluted in 3% milk PBS-T at room 
temperature for 1 hr. Membranes were washed as before, then blotted dry and incubated 
on a glass sheet with ECL for 1 min after combining ECL1 and ECL2 directly before 
use. ECL was completely blotted off membrane before exposing x-ray film to 
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membranes in a dark room for variable exposure times. Films were developed with an 
Xograph developing machine. 
 
2.3.3 Antibodies 
2.3.3.1 p53 and MDM2 antibodies 
p53 and MDM2 antibodies were all obtained from Moravian Biotechnology 
p53 antibodies – DO1 (mouse monoclonal), DO12 (mouse monoclonal), CM1 (rabbit 
monoclonal) 
MDM2 antibodies – 2A10 (mouse monoclonal), 4B2 (mouse monoclonal), 3G5 (mouse 
monoclonal), polyclonal anti-MDM2 (rabbit polyclonal) 
 
2.3.3.2 Other antibodies 
 p21 (mouse monoclonal, Calbiochem), E2F1 (mouse monoclonal, Santa Cruz), β-actin 
(mouse monoclonal, Sigma Aldrich), Anti-AGR2 K47 (rabbit monoclonal, Moravian 
Biotechnology), RPS7 (mouse monoclonal, Abnova), CypB Poly (rabbit polyclonal, 
Abcam), CypB Mono (mouse monoclonal, Abnova), DNA-PK (goat monoclonal, Santa 
Cruz), NME1 (rabbit monoclonal, Cell Signalling), APEX1 (mouse monoclonal, 
Abcam), ERp60 (rabbit polyclonal, Abcam), NPM (rabbit polyclonal, Cell Signalling 
Technology), HMGB1 (mouse monoclonal, Abnova), Anti-His-tag (mouse monoclonal, 
Sigma Aldrich). 
 
2.3.3.3 Secondary antibodies  
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HRP conjugated rabbit anti-mouse (Dako), HRP conjugated swine anti-rabbit (Dako) 
and HRP conjugated donkey anti-goat (Santa Cruz). 
 
2.4 Mass spectrometry 
2.4.1 PAcIFIC sample preparation and mass spectrometry 
MCF7 cells grown on 20 cm culture plates and treated with 40 µM Nutlin-3 were 
harvested at 0, 2, 4, 8 and 12 hrs and lysed in NP40 lysis buffer. Lysates were analysed 
at the Proteomics Core Facility in University of Geneva by Precursor Acquisition 
Independent from Ion Count (PAcIFIC) LC-MS/MS on a linear ion trap Orbitrap 
(ThermoFisher) as described in156, (A. Scherl). Identifications were obtained using the 
Phenyx database (GeneBio, Switzerland), with a false positive identification rate of less 
than 5%. Peptides were quantified by spectral counting, discarding any quantitations 
which rely on less than three spectral counts, and normalized to the length of the 
identified protein.  
 
2.4.2 iTRAQ cell lysis and trypsin digestion 
MCF7 cells were grown to confluence on 20 cm plates and treated with 40 µM Nutlin-3 
were harvested at 0, 1, 2, 4, 8, and 12 hrs after nutlin treatment, lysed in 1 ml SDS lysis 
buffer per sample and briefly sonicated to fragment genomic DNA. The soluble fraction 
was obtained by centrifuging at 10 000 rpm and removing supernatant by pipetting into 
a clean microfuge tube. Total protein content was determined by Bradford assay. 80 µg 
of each lysate was incubated with 2 µl reducing agent (Applied Biosystems) for 1 hr at 
60°C, followed by incubation with 1 µl cysteine blocking reagent (Applied Biosystems) 
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for 10 mins at room temperature. After reduction and alkylation three volumes of 0.25 
M triethylammonium bicarbonate (TEAB) pH 7-9 were added to each sample. Trypsin 
(Promega Gold) was resuspended to a final concentration of 1 µg/µl in MilliQ purified 
H2O and added 1:20 protease:protein to samples which were then incubated overnight at 
37°C.  
 
2.4.3 iTRAQ labeling reactions 
Trypsin digested samples were lyophilized using a vacuum centrifuge for 1-3 hrs and 
pellets resuspended in 30 µl 0.5 M TEAB pH 7-9. 8 separate iTRAQ labels, which yield 
reporter ions at 113, 114, 115, 116, 117, 118, 119 and 121 m/z units (Applied 
Biosystems) were resuspended in 70 µl isopropanol. Trypsin digests were then labeled 
with one iTRAQ reagent per sample by incubation of digest with iTRAQ reagent for 2 
hr at room temperature. 2 µl of each labeled digest was mixed and desalted by zip-
tipping (Millipore). 
 
2.4.4 Desalting peptide mixtures and MALDI MS 
C18 zip-tips (Millipore) were activated by washing five times with 10 µl 90% 
acetonitrile, 0.1% TFA, then washed five times with 10 µl 0.1% TFA. 10 µl of sample 
was pipetted into the zip-tip, and re-pipetted ten times. Zip-tips were then washed three 
times with 0.1 % TFA and desalted sample eluted with 2-3 µl 4 mg/ml MALDI matrix 
resuspended in 70% acetonitrile, 0.06% TFA and spotted onto a 384 Opti-TOF MALDI 
target plate adjacent to MALDI peptide standards. Samples were analysed with an AB 
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SCIEX 4800Plus Proteomics Analyser automated MALDI-TOF/TOF to check for the 
presence of iTRAQ labels. 
 
2.4.5 iTRAQ analysis by LC-MS/MS 
All 8 iTRAQ labeled tryptic digests were combined in a microfuge tube and lyophilized 
in a vacuum centrifuge for 1-3 hrs. Samples were separated by strong cation exchange 
(SCX) and fractions containing peptides were resuspended in 100 µl 0.1% TFA, 2% 
acetonitrile, with several fractions with lower peptide content pooled to create a total of 
20 separate samples for MS analysis. Fractions were then analysed by nanoLC ESI 
MS/MS with a QStar XL mass spectrometer (Applied Biosystems, Australian Proteome 
Analysis Facility) using positive nanoflow electrospray analysis in a data dependent 
acquisition mode. Proteins were identified using ProteinPilot (Applied Biosystems, 
Version 2.01) to submit a query via the MASCOT (Matrix Science) search engine. 
Parameters for searching were: Database – SwissProt, Labelling - iTRAQ, Fixed 
modifications - cysteine alkylation, Variable modifications – methionine oxidation, 
Enzyme - trypsin, Instrument - Qstar, Species - Homo sapiens. Peptides were quantified 
through the Paragon algorithm in the ProteinPilot programme after background 
correction and bias correction by the software (Applied Biosciences). 
 
2.5 Protein Purification 
2.5.1 Plasmids and Constructs 
Full length MDM2 (FL-MDM2) and N-terminal domain MDM2 (NT-MDM2) were 
both expressed from pGEX-6p vectors, with an N-terminal GST tag cleavable at the 
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Precission protease™ (GE Healthcare) target site, LEVLFQGPL, which has a cleavage 
site between the glutamine and glycine residues. CypB is in the pDEST14 vector with an 




Competent BL21(DE3) E.coli were incubated with 1-2 µl plasmid DNA on ice for 1 hr 
then incubated at 42°C for 45 secs to heat shock. 1 ml LB medium was added to bacteria 
which were then incubated for 1 hr at 37°C with shaking. Cells were centrifuged at 6000 
rpm for 2-5 mins and 800 µl of the supernatant discarded. Pellet was resuspended in the 
remaining 200 µl LB medium, spread onto pre-warmed LB agar plates ampicillin at 100 
µg/ml and incubated overnight at 37°C. Plates were sealed with parafilm and stored at 
4°C until required. 
 
2.5.3 GST-MDM2 Purification 
Lysis Buffer: 
10% sucrose 
50 mM Tris.HCl pH 8.0 
150 mM NaCl 
0.5% NP40 
5 mM DTT 
1 mM Benzamidine 
1 protease inhibitor tablet (Roche Complete) per 10 ml of buffer 







Wash Buffer 1:    Wash Buffer 2: 
20 mM HEPES pH 7.5   20 mM HEPES pH 7.5 
150 mM NaCl     0.5 M NaCl 
1 mM DTT     1 mM DTT 
0.1% NP40     0.1% NP40 
 
Glutathione Elution Buffer:   Precission Elution Buffer: 
25 mM HEPES pH 7.5   25 mM HEPES pH 7.5 
1 mM DTT     1 mM DTT 
1 mM Benzamidine    10% Glycerol 
50 mM Glutathione    150 mM NaCl 
10% Glycerol     Protease Inhibitor (Roche Complete) 
150 mM NaCl 
 
Plasmids were transformed into E. coli BL21(DE3) and single colonies picked into 50 
ml LB supplemented with 100 µg/µl ampicillin. This starter culture was incubated 
overnight at 37°C with shaking. The starter culture was then diluted 1:100 into 500 ml 
LB supplemented with 100 µg/µl ampicillin in 2 L conical flasks and incubated at 37°C 
with shaking until an OD600 of 0.6 was reached. Flasks were then transferred to a room 
temperature shaker and induced with 1 mM isopropyl β-D-1-thiogalactopyranoside 
(IPTG) for 4-5 hrs. Cells were then centrifuged at 6000 rpm for 10-15 mins and pellets 
snap frozen in liquid nitrogen. Pellets were defrosted at room temperature then lysed in 
20 ml lysis buffer per 1 L of culture by resuspending the pellet in lysis buffer on ice and 
incubating for 30 mins. Lysates were sonicated for 10 secs three times (Soniprep 150 
plus), with 10 secs rest on ice between sonications. Lysates was then split into microfuge 
tubes and centrifuged for 10 mins at 10 000 rpm, to separate cell free extract 
(supernatant) from the insoluble fraction (pellet). 500 µl of glutathione sepharose beads 
slurry per 1 L of culture (GE healthcare) were washed three times with lysis buffer, and 
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then incubated with lysate for 1-2 hrs with the supernatant from the centrifuged lysate. 
Beads and lysate were transferred to a column jacket with a filter (VWR) and washed 
three times with wash buffer 1, a further three times with wash buffer 2 and then 0.5-1 
ml elution buffer was added to the beads and they were incubated for a further 1-4 hrs. 
Glutathione elution buffer was used to obtain GST tagged MDM2 and Precission buffer 
to obtain cleaved MDM2. After incubation with elution buffer, fractions of 
approximately 100 µl were collected in microfuge tubes and analysed by SDS-PAGE. 
Protein concentrations were determined by Nanodrop (ThermoFisher) Uv/Vis 
absorbance at 280 nM, Bradford assay or as compared to BSA standards on SDS-PAGE. 
 
2.5.4 Purification of His-AGR2 and His-CypB 
Lysis Buffer:     Wash Buffer 1: 
20 mM Tris.HCl pH 8.0   As lysis buffer with 40 mM  
150 mM NaCl     imidazole 
10 mM MgCl2 
0.1% NP40     Elution Buffer: 
10% Glycerol     As lysis buffer with 150 mM 
20 mM imidazole    imidazole 
 
E. coli BL21 (DE3) transformed with his-tagged protein vectors were picked from 
previously transformed plates and grown in 50ml LB medium containing 100µg/ml 
ampicillin overnight to make a starter culture. The starter culture was then diluted 1 in 
10 into 500ml LB 100µg/ml ampicillin and cells grown with shaking at 37°C to an 
OD600 of 0.6. Cells were then induced with 0.5 mM IPTG and grown for 3-4 hours at 
room temperature. Cells were harvested by centrifuging at 6000 rpm for 20 mins at 4°C 
and pellet snap-frozen in liquid nitrogen. For lysis cells were incubated on ice for 30 
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mins after being resuspended in lysis buffer. Lysate was sonicated three times for 15 
secs with a 15 secs break on ice between sonications, and centrifuged at 13 000 rpm for 
10 mins in microfuge tubes to obtain soluble fraction. 1 ml Ni-NTA agarose (Qiagen) 
was washed three times with lysis buffer, then supernatant from lysed cells was added to 
beads and incubated on a rotary shaker for 1 hr at 4°C. Mixture was transferred to a 6 ml 
column jacket and flow-through collected to analyse by SDS-PAGE. Beads were 
washed 2 times with 5 ml lysis buffer, then a further three times with 5 ml wash buffer 
1. Elution buffer was added to the column and 500 µl fractions collected and analysed 
by SDS-PAGE.  
 
2.5.5 Buffer exchange 
Zeba desalting columns (ThermoFisher) were washed 3-5 times with 300 µl desired 
buffer by adding to column and centrifuging for 1 min at 1 500g. 50-70 µl purified 
protein was then added to the column and eluted by centrifuging as before. 
 
2.6 Site directed mutagenesis 
2.6.1 Primers 
CypB W47A primers (mutated bases highlighted in bold) 
Forward – 5’-GAAAGTGACCGTGAAAGTGGCGTTTGATCTCGGATTGGTG-3’ 




PCR reactions were carried out with template DNA (CypB pDEST 14) and appropriate 
primers. 
 
PCR reactions for site directed mutagenesis were set up with: 
12.5 µl 2X Pfu MasterMix (Stratagene) 
2.5 µl Band Doctor (Stratagene) 
50 ng plasmid template 
0.13 µl forward primer (100µM stock) 
0.13 µl reverse primer (100µM stock) 
Nuclease free water to a final volume of 25 µl 
 
Thermal cycling conditions: 
95°C for 1 min 
95°C for 50 sec 
55°C for 1 min 
68°C for 12 mins (adjust for larger plasmids) 
repeat steps 2-4 for 15 cycles (or more) 
68°C for 30 min 
4°C forever. 
 
PCR reaction products were digested using 5 U DpnI (Invitrogen) at 37°C for 90 mins 
and reaction stopped by incubating at 65°C for 90 mins. 5 µl of digested or undigested 
plasmid were transformed into E. coli DH5 alpha and streaked on LB-Agar plates 
containing the appropriate antibiotic. Colonies from bacteria transformed with digested 
plasmid were picked and grown in LB with appropriate antibiotic overnight, plasmids 
extracted by mini-prep (Qiagen) and sequenced. 
 
2.6.3 DNA sequencing reactions 
Sequencing primers 
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T7 (for pGEX and pDEST vectors) – 5’- 3’ 
Internal CypB sequencing primers  
Forward - 5’-GGAAAGCACCAAAACCGATA-3’  
Reverse – 5’-CTTTCGGGGCTTTGTTAGCAG-3’ 
 
Sequencing reactions were carried out with the following recipe: 
1 µl Purified plasmid DNA (to be sequenced) 
1 µl sequencing primer 
1 µl BigDye (Applied Biosystems) 
2 µl BigDye 5x buffer (Applied Biosystems) 
5 µl nuclease free H2O 
 
Thermal cycling protocol: 
1. 96°C for 1 min 
2. 96°C for 10 sec 
3. 50°C for 5 sec 
4. 60°C for 4 min 
5. Go to step 2 for 24 cycles 
6. 4°C forever 
 
DNA was cleaned up by adding 2.5 µl 125 mM EDTA and transferring to a tube 
containing 30 µl ethanol, mixing and incubating for 15 min, then centrifuged at 13 000 
rpm for 20 min. Supernatant was discarded, residual removed after centrifuging again. 
30 µl 70% ethanol was added to the sample, then the sample was centrifuged as before 
for 5 mins. Supernatant was removed and discarded, then sample was re-centrifuged to 
remove residual. Pellet was air dried, then sent to Source Bioscience sequencing service. 
Results were analysed using Chromas and Expasy Translate. 
 
2.7 Thermal Denaturation 
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Protein was prepared by diluting in appropriate buffer to a range of concentrations and 
incubated with ligands or DMSO control for 30 mins. Sypro orange (Invitrogen) was 
added to 200 µl of protein/ligand to be analysed at a final concentration of 5x (stock is 
5000x). Protein-Sypro orange mixture was transferred to 96-well PCR plates (BioRad) 
in three identical replicates of 50 µl per well. PCR plates were sealed with film and 
centrifuged at 4000 rpm for 2 mins to ensure solution was at the bottom of the wells. 
Plates were analysed on a BioRad IQ5 ICycler using the BioRad ICycler software. 
Samples were heated in 1°C increments from 25°C to 95°C with a 30 second dwell time 
at each temperature and RFU of sypro orange measured at each degree. Melt-peaks were 
generated by plotting -dRFU/dt vs. temperature and determining the temperature at 
which the integrated peak minimum occured.  
 
2.8 Super Arrays 
cDNA was purified from cell lysates treated with aptamer as in section 2.3.4 and 
hybridized to arrays with genes representing p53 related pathways according to array 
manufacturers instructions (SABiosciences). Signal was detected using ECL and X-ray 
film and analysed using SABiosciences software, normalizing signal between arrays 
using the housekeeping genes GAPDH, Alpha-actin and CypB. 
 
2.9 Reagents 




3 - Proteomic investigation of Nutlin effects on MCF7 cells 
3.1 - Introduction 
Proteomic mass spectrometry can simultaneously identify many proteins which respond 
to a drug or stimulus, and thus detect previously unidentified proteins which are up or 
downregulated. The p53-MDM2 interaction inhibitor Nutlin has principally been 
characterized with regards to the effect it has on the p53 response. However since 
MDM2 is highly allosteric91, and off-target effects of Nutlin have not been widely 
characterized there are potentially also less well understood aspects to the Nutlin 
response. Two different MS based screens were carried out to investigate changes in 
global protein levels after Nutlin treatment. Results are considered in terms of whether 
any of these proteins are MDM2 or p53 binding or regulated proteins. Time points soon 
after Nutlin treatment were investigated with the aim of identifying proteins closely 
related to MDM2 before downstream responses to Nutlin treatment are activated. The 
two different MS methods chosen to analyse MCF7 cell lysates after a time course of 
Nutlin treatment, were 1) a label-free method, precursor acquisition independent from 
ion count MS/MS (PAcIFIC)156, with quantitation by spectral counting to measure 
protein levels, and 2) a screen where the peptides from a tryptic digest are labeled for 
quantitation, using isobaric tag for relative and absolute quantitation (iTRAQ)157 
(Chapter 1).  
 
3.2 Confirmation of early time point increase in level and activation of p53 by Nutlin 
treatment 
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The human breast cancer cell line MCF7 expresses wild type p53 and MDM248, and 
Nutlin treatment of these cells results in an increase in the level of p53 as early as 1 hour 
after treatment, which persists for up to 12 hours after treatment with a slight drop in the 
level 24 hours after treatment (Figure 3.1a, b). The p53 responsive protein p21 is 
observed to increase between 4 and 8 hours, following the increase in p53 which is an 
indication that the p53 which has increased in level is transcriptionally active174, and that 
this is dominant over the degradation promoting effect MDM2 has been observed to 
have on p21175. The observed effect of Nutlin on E2F1 levels over this time course is to 
destabilise E2F1 more gradually than p53, the level can be observed to have decreased 
very slightly at 2 hours and continues to drop up to an 8 hour time point (Figure 3.1c). 
The interaction between MDM2 and E2F1 has previously been described105, 107 and 
inhibition of the MDM2-E2F1 interaction destabilizes E2F1. Ubiquitination of p53 is 
also observed after Nutlin treatment when an SDS containing lysis buffer with reduced 
salt is used. This is likely due to increased levels of p53 and potentially the agonistic 
effect of Nutlin on p53 binding at the acidic domain91. MDM2 stabilisation is also 
observed after Nutlin treatment at 2 hours onwards (Figure 3.1c). This can be explained 
by a combination of p53 promoting MDM2 expression174 and the stabilizing effect of 
Nutlin binding to MDM2. These results confirm that very early time-points are also 
significant in the MDM2-p53 axis and potentially in the wider MDM2 interactome. 
 
3.3 Summary of label-free quantitative mass spectrometry screen results 
Samples from 0, 2, 4, 8 and 12 hours after Nutlin treatment were analysed by PAcIFIC 
mass spectrometry coupled with gas phase fractionation (GPP) prior to LC-MS 
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(Described in Chapter 2). This pilot screen was carried out with two technical replicates 
on different LC runs. The PAcIFIC screen identified 321 proteins in one replicate and 
362 in the second replicate distributed across all time points. Some proteins were 
detected at multiple time points, and some at a single time point. Identified proteins were 
categorized as being up or downregulated based on whether a two-fold change in the 
corresponding spectral count after Nutlin treatment relative to the spectral count in an 
untreated control sample was observed. The results are summarized in Figure 3.2 and 
fully listed in Appendix 1. Proteins which show a two-fold or greater change in both 
replicates are fully listed in Appendix 2. Detection in two replicates increases the 
likelihood that the changes observed are genuine, as detection of a two-fold change in 
only a single replicate may be due to poor or enhanced ionization of the peptides used 
for quantitation as well as other experimental errors. Overall, a greater amount of 
proteins were detected downregulated than upregulated (Figure 3.2b), and the number of 
proteins detected with altered levels at 4, 8 and 24 hours after treatment are slightly 
more than at the 2 hour time point. Of proteins identified as altered after Nutlin 
treatment many proteins were detected at two time points, whilst others were only 
detected at a single time point. For example the protein EIF4A1 is detected as 
upregulated two-fold or more in 2, 4 and 8 hour samples in replicate 2 relative to the 
level of detection in the 0 hour sample, but is undetected at 0 hours in replicate 1 and so 
exhibits an on/off style response at all other times for this replicate (Figure 3.3). It is 
possible to correct for this category of results by using a ratio based on log2 of each 
spectral count with 1 added to calculate fold change176. However as this screen did not 
include a robust number of replicates this kind of analysis may mask potential false 
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positives. Agreement between quantitations in both replicates increases the likelihood 
that the result is not simply due to missed detection of peptides from the protein of 
interest. A subset of proteins was detected as changed at multiple time points (Table 3.1, 
3.2), with each time point representing a separate lysis, digest and LC-MS run. A 
number of proteins identified in a single replicate are observed at multiple time points. 
These results are less reliable than those from two replicates however proteins detected 
in a single replicate can be tentatively used as leads for further validation or to compare 
to future MS results, particularly if they are detected at multiple time points (Figure 3.4). 
There are also a large number of proteins detected in either replicate with an altered 
level, but unchanged in the other replicate. To verify if Nutlin treatment has a 
reproducible effect on these proteins, as well as those identified in only a single replicate 
further MS repeats or further validation by another method would be necessary. The 
final class of proteins identified in this pilot screen are those which have conflicting 
quantitation results (Table 3.5). Many of these quantitations have missed detections at 
either time point, such as splicing factor U2AF, and this illustrates why it is important to 
do multiple biological and technical replicates in a quantitative mass spectrometry 
experiment. If this project was to completely depend on the label-free proteomic mass 
spectrometry results more replicates and statistical analysis would be necessary. 
 
3.4 Specific examples of protein level changes over time 
Proteins which are detected with altered levels at several times represent pathways 
which are affected by Nutlin over the whole time course, and proteins which are only 
 105 
altered at a single time point may be regulated by different mechanisms. The amount of 
the MDM2 binding protein HSP90177 detected for example, increases at two hours and 
remains high over the whole time course which is a similar pattern as observed for p53 
regulation by MDM2 (Figure 3.5a), whereas the amount detected of the previously 
identified MDM2 binding protein SAFA92 is decreased over time (Figure 3.5b). Other 
proteins exhibit different patterns of regulation, such as the cancer cell proliferation 
marker prohibitin-2178, which decreases at four hours then shows a recovery to near 
original levels (Figure 3.5c). Proteins which have not already been identified as part of 
the MDM2 interactome exhibiting similar patterns of regulation, for example CypB and 
stomatin like protein 2(Figure 3.5d, e) and are therefore potentially interesting leads for 
new MDM2 binding or regulated proteins. 
 
3.5 Comparison of identified proteins to MDM2 and p53 known interactomes 
Of hits which are up or downregulated in this screen, the presence of MDM2 or p53 
related proteins serves as an internal validation of the dataset. MDM2 and p53 binding 
proteins which have been validated have been catalogued43 and there are >150 and >300 
known interactions for each protein respectively. These interactomes were compared to 
the proteins which are detected as upregulated or downregulated in the PAcIFIC MS 
experiment to evaluate whether this pilot screen yielded results which have previously 
been validated biologically, and to investigate if the less confident results from single 
replicates are linked to the known biological data. Four proteins from the known MDM2 
interactome, HSP90177, DNA-PK82, PCNA179 and PSME3180 were modulated by Nutlin 
treatment in two replicates and eight proteins from the known p53 interactome were 
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detected, topoisomerase 1181, S100-A11182, TCP1 epsilon183 and PARP-1184, as well as 
DNA-PK, HSP90 PCNA and PSME3. Of the proteins detected only in a single replicate, 
no proteins were identified which are already known to participate in the known MDM2 
interactome. One protein from each replicate, TFAM185 and transcriptional activator 
BRG1186, were identified which participate in the p53 interactome. Other proteins 
identified in both replicates include proteins with functions related to cancer, and 
although these proteins have not to date been identified as directly binding to p53 or 
MDM2 they are associated with processes which have been attributed to MDM2 and 
p53 related pathways. Examples include stomatin-like protein two which is associated 
with metastasis and tumour progression187, eIF4G1 which binds mRNA in a pre-initation 
complex and is regulated by p53188, CypB which is an immunophilin linked to cancer 
mechanisms189 and XRCC5 (Ku) which plays a role in the DNA repair pathway along 
with DNA-PK190. A STRING database pathway map which links proteins based on 
known protein-protein interactions as well as well as predicted relationships191 shows 
that many of the proteins identified by this screen are linked in a wider network. There 
are well-validated sub-complexes amongst these results, such as the T-complex proteins, 
calnexin and protein disulphide isomerase complexes192, eIF proteins and ribosomal 
proteins193 and heterogenous nuclear ribonucleoproteins194 (Figure 3.6). 
 
3.6 Overview of iTRAQ mass spectrometry screen 
An 8-plex iTRAQ screen was carried out on the same MCF7 cell line treated with Nutlin 
and harvested at several time points. A one hour time point was included to investigate 
whether the response to Nutlin is more acute than shown by two hours in the PAcIFIC 
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screen and a 12 hour time point was also included. After this time cells can start to enter 
apoptosis or cell cycle arrest and widespread activation of downstream p53 related 
pathways107 may obscure effects which are directly attributable to modulation of MDM2 
interactions. As described in Chapter One, iTRAQ relies on a labeling step for 
quantitation, which adds an additional step in sample preparation before quantitation 
compared with PAcIFIC. Eight samples were combined and analysed simultaneously, 
and 1323 proteins detected in total (Table 3.5). 
 
3.7 Quantitation of Nutlin regulated proteins by iTRAQ 
Cut-off ratios of <0.77 or >1.33 were chosen to select proteins which are up or 
downregulated. For complex samples analysed by iTRAQ although the direction of the 
change in level, i.e. up or downregulated, is reliable, it has been reported that the 
numerical change may not be directly quantitative159 (Chapter One). Therefore for cell 
lysates analysed by iTRAQ a large change in protein expression may be accompanied by 
a small change in iTRAQ ratio, compared to methods which measure fold change such 
as spectral counting. The total number of up and downregulated proteins identified in the 
iTRAQ screen are summarized in Figure 3.7 and all proteins identified across the time 
course are listed in Table 6. 10 of the detected proteins occur over multiple time points, 
including DNA-PK, NONO, and the APEX1 protein which is closely linked to 
regulation of p53 DNA repair97. Interestingly, many more proteins were identified in one 
of the replicates at 12 hours than at the earlier times, with less shared identifications with 
the earlier time points (Figure 3.7). The majority of the proteins identified at 12 hours 
were detected in a single replicate, this may be due to differences in the efficiency of the 
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lysis for the two replicates, or differences in the efficiency of one labeling reaction 
compared with the other samples. This further illustrates the importance of carrying out 
multiple replicates of the same sample. The overall trend is an increase after Nutlin 
treatment over time of the amount of proteins detected at each time point, with a the 
largest amount of detections at the 12 hour time point (Figure 3.7). 
 
3.8 Comparision of iTRAQ hits with the known interactomes of MDM2 and p53  
Many ribosomal proteins were identified in the second replicate of the 12 hour time 
point (Table 3.6), which is interesting since MDM2 has been shown to be extensively 
involved in ribosomal pathways88. DNA-PK and nucleophosmin (NPM) were identified 
at multiple time points in the iTRAQ results and are known to interact with MDM2 at 
the N-terminal domain, where the Nutlin binding site is located82, 103. p53 interacting 
proteins identified include APEX197, SUB1195 and HMGB1196 suggesting the possibility 
that these are part of larger complexes or networks which participate in a response to 
Nutlin treatment either through direct interaction with MDM2 or further downstream. 
Other than known MDM2 binding proteins other notable proteins identified in this 
screen include VDAC proteins VDAC1 and VDAC2, which have been implicated in 
apoptotic pathways197 and these were detected here elevated at later time points. Another 
interesting identification is IQGAP1 which is regulated by S100 proteins and altered in 
hepatocellular cancer198. 
 
3.9 Comparison of label-free PAcIFIC and iTRAQ MS screens 
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There were fewer proteins with changes in detected levels after Nutlin treatment 
identified by iTRAQ than by the PAcIFIC screen, despite the higher number of 
identifications. This is likely due to the very high stringency conditions applied for 
iTRAQ quantitation. The iTRAQ MS screen identified 359 out of 417 unique proteins 
identified by PAcIFIC, and 1024 proteins which were not detected in either PAcIFIC 
replicate (Figure 3.8). Although the iTRAQ coverage is much greater there are still 
proteins which were only identified by PAcIFIC. This may be because PAcIFIC is 
optimized for detecting lower abundance proteins. The iTRAQ results however, contain 
all of the known p53 and MDM2 related proteins identified by the PAcIFIC screen. Four 
proteins were detected in the highest confidence set of results which were detected by 
both screens at any time point, NONO, ribosomal protein L6, DNA-PK and paraspeckle 
component 1. Of these proteins only DNA-PK has previously been characterized as 
important in the p53-MDM2 interactome82, however the others are new interesting new 
leads which may warrant further investigation. There are major differences in the 
quantitation between the two mass spectrometry screens. DNA-PK is the protein which 
occurs most frequently in both datasets over all time points, and is detected upregulated 
in the iTRAQ screen whereas it is seen as downregulated in the PAcIFIC screen. 
Paraspeckle component 1 and NONO also exhibit this contradiction, whereas ribosomal 
protein L6 is detected upregulated in both screens.  
 
3.10 Discussion 
A principal aim of the proteomics experiments carried out here was to find protein-
protein interaction leads from proteomics data. In turn these candidates validate further 
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and can be used to expand the MDM2 interactome, either with more comprehensive 
proteomics or coupled with biological validation (Chapter Four, Five). Label-free 
(PAcIFIC) proteomics revealed an extensive list of potential hits. However there were 
insufficient replicates in this experiment to rely on this as stand alone data. Comparison 
with the iTRAQ screen, which makes use of stricter quantitation and statistical analysis, 
revealed both features in agreement with the PAcIFIC screen and also some notable 
differences. Although some proteins were detected at multiple time points in both 
experiments, the two different MS methods resulted in different quantitation results. For 
example DNA-PK appears downregulated in the PAcIFIC screen but upregulated in the 
iTRAQ screen. A major factor in these discrepancies could be localization, as each 
method used a different lysis method. A relatively mild lysis buffer was used with the 
PAcIFIC samples and SDS containing lysis buffer and sonication was used to lyse the 
cells for iTRAQ. It is likely that this would result in the iTRAQ samples containing 
more nuclear and membrane proteins than the samples analysed by PAcIFIC. Although 
the quantitation results for some proteins obtained are contradictory between the two 
methods, these results are still informative because they indicate changes occur in the 
MDM2 interactome either by change in protein levels or localization. MDM2 
subcellular localization changes cell in response to different stimuli199 and a change in 
localization can result in significant alterations in the interactome of a protein. Indeed 
the protein nucleophosmin, frequently detected in the iTRAQ screen has previously been 
shown to regulate MDM2 localisation103. Other quantitation issues include the fact that 
the methods in these screens do not actually measure the level of intact protein, but 
peptides from tryptic digests. This is why it is important in the case of iTRAQ to use 
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more than one unique peptide for quantitation. The quantitations obtained here are also 
relative rather than absolute, with each time point being compared to a control sample 
which has not been treated with Nutlin. This means that any errors in the control sample 
due to detection issues or sample preparation are propagated in the values calculated at 
the other time points. Spectral counting, although it has been shown to correlate well 
with protein abundance176, requires normalization, very reproducible LC conditions and 
at least three replicates to be relied upon as a stand alone method. iTRAQ problems can 
include the compression effect159, which results in a reduction the magnitude of change 
in iTRAQ ratio in complex samples, and requires correction for the relative intensities of 
labeling reactions. In particular the 113 m/z label is often more intense than the other 
labels, and it is therefore inappropriate to use this label as a control159. Despite these 
drawbacks the data acquired from these experiments provides a wealth of information, 
and although the approach was applied to the MDM2 interactome it could also be used 
to investigate the interactomes of other proteins. 
 
Although only two technical replicates were examined for the PAcIFIC screen, and two 
biological replicates for the iTRAQ spectrometry screens, the time course format of this 
experiment allows greater confidence results which are detected at multiple time points. 
Each time point represents a separate lysis, digest and in the case of iTRAQ labeling 
step, and it is possible to observe trends over time. It is interesting that conflicting results 
were detected within the two replicates in the PAcIFIC screen, and some of these were 
observed over the whole time course in both replicates. One reason for this could be that 
if the protein is simply not detected in the control sample and it is detected at other time 
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points or vice versa it will appear to be up or downregulated. This problem may be 
solved by using more replicates for each individual time point.   
 
Proteins identified by both screens can be classified based on whether they are up or 
downregulated, and many exhibit a continued trend over time. An example of this is 
HSP90, however some proteins appear to stabilise to their original level after an initial 
change for example Prohibitin-2. This may be similar to the oscillation of a feedback 
loop, such as that exhibited by p5389, as observed by the slight decrease in level of p53 
at 24 hours in Figure 3.1a, or indicate entry into another pathway quickly after 
modulation of MDM2 activity by Nutlin. It is also interesting to note the difference 
between the early 1-4 hours modulated proteins in the iTRAQ screen, including APE1, 
NDKA and nucleophosmin which are already known to be closely related to MDM2, 
and increasing numbers of as yet unrelated proteins identified as up or downregulated at 
later times. This may be due to the early effects of targeting MDM2 with Nutlin causing 
a cascade of downstream effects from proteins in complex or regulated directly by 
MDM2. This highlights the utility of analyzing proteomic data over time courses, rather 
than choosing a fixed window to look at the effects of a drug, which gives us an insight 
into the complexity of the interactome of a protein over time. 
 
Although the label-free screen represents preliminary data, and more biological 
replicates are desirable for the iTRAQ screen, a number of interesting leads have been 
generated from these screens. Internal validation of the dataset is provided in both 
screens by the detected changes of known MDM2 binding and regulated proteins, such 
 113 
as PCNA, DNA-PK, NPM and HSP90. In the PAcIFIC screen more of these proteins 
were identified in two replicates than a single replicate, illustrating the fact that 
identifications from multiple replicates are more reliable than those from single 
replicates. The presence of these known MDM2 and p53 interacting proteins increases 
our confidence that some of the other proteins identified may represent new participants 
in these pathways and interactomes, and as such may warrant futher validation. These 
proteins would require biological validation, further mass spectrometry replicates or a 
combination of both. For example the presence of the NDKA protein at all time points in 
the iTRAQ screen, and splicing factor U2AF from 2 hours onwards suggests that these 
are important components of the Nutlin response. The presence of a dense network of 
chaperone proteins (Figure 3.6, Table 3.1, Appendix 2) also links to an MDM2 role in 
proteostasis9, which is recognised as a mechanism that cancer cells use to cope with the 
increased folding burden, and involves a balance between E3 ligases and degradation 
pathways with chaperones and ribosomal pathways. It has also recently been shown that 
the central proteome of a cell is centered around cell death, cell cycle, proteostasis and 
metabolism200, which is significant for MDM2 because it has been implicated in a 
number of these functions. Metabolic enzymes identified in these screens such as DLDH 
and citrate synthase warrant further investigation of these pathways in relation to 
MDM2. It is interesting to speculate how much a small change in the interactome of a 
protein, as with using Nutlin to target MDM2, can potentially have massive effects on 
the cellular interactome. An alternative hypothesis would be that feedback loops and 
proteostasis mechanisms compensate for these changes, however in this case the 
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induction of cell cycle arrest or apoptosis by Nutlin treatment do suggest cellular 
changes after Nutlin treatment are substantial. 
 
Absolute methods of quantitation such as those based on heavy peptide standards to 
obtain values corresponding to an absolute level of protein in the cell are being 
developed. One example of this quantifies ubiquitin bound proteins201, and these 
methods mainly focus on sample preparation to get maximum reproducibility. If the 
strict requirements for a reliable proteomic experiment, such as number of replicates, are 
not followed precisely, it is essential to do further experiments to validate any pilot data 
obtained by quantitative proteomics experiment. Two different kinds of proteomic 
experiment were carried out here, label-free (PAcIFIC) and peptide labeling (iTRAQ), 
and we found agreement in identifications between the two methods, but with significant 
differences in the quantitation results we obtained. As lead generating experiments these 
screens have succeeded, and there are multiple interesting proteins which respond to 
Nutlin treatment. However there are many more questions raised regarding how the 
novel proteins found in these screens are regulated by MDM2, and what the actual 
effects of Nutlin are on these proteins. This validation can take the form of either further, 
more comprehensive proteomic mass spectrometry experiments, or biological validation 
of some of the leads obtained in these screens. Further work detailed in Chapter 4 and 5 
describes biological validation methods used to further investigate the mass 































Figure 3.1 – MCF7 cells were treated with 40 uM Nutlin, lysed and proteins levels 
visualized by western blot (Antibodies described in section 2.3.3). β-actin levels were 
detected as a loading control.  A) p53 and p21 increased protein levels after 40 µM 
Nutlin treatment at different time points for cells lysed with NP40 containing buffer. B) 
Early increase in p53 and late increase in MDM2 levels 1-4 hours after Nutlin 
treatment. C) p53, MDM2 and E2F1 levels in cells lysed in SDS containing buffer at 
various points after Nutlin treatment, ubiquitination bands indicated by asterisk. 
















































Figure 3.2 – A) Overall identifications between two replicates analysed by PAcIFIC 
MS/MS B) Number of proteins identified in two replicates at each time point quantified 
as up or downregulated two-fold by spectral counting C) Number of proteins identified 





















Figure 3.3 - Spectral counts at each time point after Nutlin treatment from PAcIFIC 
mass spectrometry screen for the protein EIF4A1. Counts are normalized based on the 
length of the protein sequence. Fold changes for replicate 2 are indicated by numbers on 


































































Table 3.1 - Summary of upregulated proteins obtained at each time point 
after Nutlin treatment. Fold change (FC) of the spectral count of each protein for both 
replicates is shown, replicate indicated in brackets under time point. Where protein is 
not detected at either replicate at 0 Hr after Nutlin treatment proteins are categorised as 






































Table 3.2 - Summary of downregulated proteins obtained at each time point 
after Nutlin treatment. Fold change (FC) of the spectral count of each protein for both 
replicates is shown, replicate indicated in brackets under time point. Where protein is 
not detected at either replicate at 0 Hr after Nutlin treatment proteins are categorised as 

































Figure 3.4 – Overlapping identifications detected in single replicates at various time 
points. A) Replicate one; B) Replicate two. C) Spectral counts of proteins detected at 
multiple time points in replicate one excluding proteins which are only detected at one 
time point; D) proteins detected at multiple times in replicate two excluding proteins 

























































Table 3.3 – Conflicting quantitation results over the 24 hour time course, spectral 
counts are shown for both technical replicates where the direction of regulation after 





































Figure 3.5 – Examples of protein regulation trends over the Nutlin time course, for a 
selection of known and unverified MDM2 interacting proteins. Spectral counts over time 
for known MDM2 binding proteins; A) HSP90 B) SAFA and unverified MDM2 binding 














































Figure 3.6 – Search tool for the retrieval of interacting genes/proteins (STRING) 
interaction network for proteins identified at each time point. Complexes are highlighted 
as follows, Pink – HSP90, Green – eIF and ribosomal proteins, Red – T complex 
proteins, Blue – hnRNPs. Colour of nodes does not represent function, larger nodes 



















Table 3.4 – Labelling scheme for 8-plex iTRAQ experiment and summary of results. Cut-
off used highlighted in bold, >1.3 (95) represents the score assigned to each 















































Figure 3.7 – Overview of number of proteins identified in iTRAQ results across the 
Nutlin time course which are  up or downregulated and have a p-value <0.05 and a 
ratio of either >1.33 or < 0.77 relative to the control sample from cells which were not 
treated with Nutlin. Green – upregulated proteins, Red – downregulated proteins. (2) – 
































































Table 3.5 – All iTRAQ up and downregulated identifications with p-value < 0.05 
represented as ratio to control (untreated) sample. Values in brackets represent 
identifications from the second biological replicate. % Cov. – percentage coverage of 




































4 - Identification and validation of new MDM2 binding peptides derived from 
proteins affected by Nutlin treatment 
 
4.1 Introduction 
Quantitative shotgun proteomic mass spectrometry can yield a large amount of 
information, as shown in Chapter Two, which creates the problem of finding meaningful 
results in a substantial dataset. It could be argued that all proteins identified exhibiting 
an altered response to Nutlin in Chapter Two warrant further investigation. As this is not 
feasible here a subset of proteins were selected to be validated biologically. MDM2 has 
been shown to participate in networks extensively based on the ability to bind linear 
motifs80, and the MDM2-p53 interaction is a model example of this91. The large 
disordered region in the acidic domain of MDM2 also makes it a likely candidate for 
interacting via linear motif mechanisms. A screen was carried out on the MS leads 
acquired in this experiment for the presence of motifs homologous to p53, and peptides 
corresponding to these motifs were investigated for MDM2 binding. 
 
4.2 BOX-I like loose consensus motif 
The BOX-I region of p53 includes F19, W23 and L26 (Chapter One). It has previously 
been shown that the MDM2 binding protein IRF2 has a BOX-I like sequence and a 
BOX-V like sequence81, which is also found in the other IRF family member IRF1 
(Figure 4.1a). The core tryptophan residue which is mimicked by Nutlin in the case of 
BOX-I133 is replaced by a tyrosine in the IRF peptides and the leucine which is also 
mimicked by Nutlin is also present. The phenylalanine which is mimicked by Nutlin is 
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not found in either IRF1 or IRF2 sequence and is replaced by an alanine in these 
peptides. A hydrophobic residue to the N-terminus (Position 11) of the aromatic residue 
is found in all three peptides, as is a proline to the C-terminus of the core hydrophobic 
section. In the centre of the conserved hydrophobic residues in this motif is a positively 
charged residue; a lysine (BOX-I) or an arginine (IRF1, IRF2). The IRF1 and IRF2 
peptides also contain a charged region at the C-terminus of the sequence which is not 
present in the BOX-I sequence. Two very loose consensus motifs were constructed 
based on these hydrophobic and aromatic core residues found in both BOX-I and IRF 
peptides (Figure 4.1b). These low complexity motifs were chosen to select peptides with 
variation around this hydrophobic core.  
 
4.3 Comparison of BOX-I and IRF peptides binding to MDM2 
Relative binding of BOX-I and IRF peptides shown in Figure 4.1 to full-length 
recombinant MDM2 was measured by ELISA (Figure 4.2a). The BOX-I peptide bound 
MDM2, purified by cleavage from a GST tag, to a greater extent than both IRF peptides. 
However although SP column purified MDM2 still bound all three peptides, BOX-I 
bound this MDM2 to a lesser extent than the IRF peptides (Figure 4.2b, c). This 
indicates that the purification method affects MDM2 peptide binding, possibly due to the 
retention of cofactors by one method and not the other. Zinc competes BOX-I well, 
however it only has an effect on IRF peptides binding at higher concentrations (Figure 
4.2d) suggesting that zinc is a potential cofactor retained by SP column purification 
which affects BOX-I binding. These data taken together demonstrate that although the 
BOX-I and IRF peptides both bind MDM2 there are potentially differences in the 
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binding site or mechanism by which MDM2 binds these peptides. BOX-I has a Kd of 
440 nM for MDM2 compared with 90 nM for Nutlin131, 133, hence the efficacy of Nutlin 
as an MDM2-p53 protein-protein interaction inhibitor. Interestingly, the IRF1 and IRF2 
peptides do not exhibit this response to Nutlin or BOX-I (Figure 4.3b) and are competed 
effectively by the RB1 or BOX-V peptides (Figure 4.3d, e) which bind the MDM2 acid 
domain and mildly compete with BOX-I. IRF1 and IRF2 peptides may bind a different 
region of MDM2 than BOX-I or bind the hydrophobic domain in a site it is not possible 
for Nutlin to compete for.  
 
4.4 Screening of mass spectrometry hits using BOX-I like motif 
Using the loose consensus motif which links IRF and BOX-I peptides, the mass 
spectrometry results from the 2 hour time point of the PAcIFIC mass spectrometry 
screen were searched using prosite202 for the presence of BOX-I like motifs. Low 
confidence (ie/ single replicate) hits were also included. The stricter motif containing the 
charged residue in the centre of the motif was found in 38 proteins, and the looser motif 
was found in 145 proteins (Figure 4.4). A number of proteins contained multiple 
occurrences of this motif, notably DNA-PK which contains 28 instances of the motif.  
 
4.5 Investigation of peptides corresponding to the motif by ELISA 
Peptides corresponding to the core motif sequences found in these proteins, along with 
the 5 N-terminal and 10 C-terminal surrounding residues, were screened by ELISA for 
binding to full length MDM2. After removing peptides with very low complexity or 
located in the transmembrane region of membrane proteins, 94 peptides containing the 
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motif (Appendix 3) were tested by ELISA for binding to MDM2 and 20 peptides from 
the total tested showed some binding to MDM2. These binding peptides were 
categorized based on how stable the extent of this binding was relative to BOX-I (Figure 
4.5). A subset of peptides actually exhibited a higher level of binding by ELISA than 
BOX-I, others exhibited an intermediate amount of binding (Figure 4.5a, b), whereas 
some were weak or very weak binders (Fig 4.5c, d). The affinity of BOX-I for MDM2 is 
approximately 400 nM131, therefore it is important to note that those binders classed here 
as ‘weak’ exhibit in this assay around 10% of the BOX-I to MDM2 interaction intensity. 
These peptides are therefore weak in comparison to BOX-I, but still bind MDM2 higher 
than the background level. To further validate these motifs, peptides with the critical 
core aromatic residue mutated to an alanine were compared to the wild type peptides 
(Figure 4.6). In most cases the substitution of this residue resulted in a loss of binding to 
full length MDM2, highlighting the importance of this residue in the motif as previously 
reported131. Exceptions are the reptin peptide which is unaffected by the W to A 
mutation, and the UBF1, SERCA2 and IL25 peptides which show enhanced binding 
with the alanine mutation (Fig 4.6 a, b). This could be experimental error, or 
demonstrate that these peptides are non-specifically binding to MDM2. This confirms 
that the majority of the peptides selected depend on the core motif aromatic residue for 
binding to MDM2. 
 
Alignment of the peptides which bind to MDM2 (Figure 4.7) reveals two of the stronger 
binding peptides RPS7 and APIF-1 have a proline to the C-terminus of the core motif, 
correlating with the BOX-I and IRF peptides. 11 out of 20 new MDM2 binding peptides 
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have a positively charged residue in the centre of the hydrophobic motif, and none of 
these peptides are categorized as weak binders. 8 out of the 20 new peptides identified 
have a charged region at the far C-terminus of the motif similar to the IRF peptides, and 
for the weaker binders this frequently includes negatively charged residues alongside the 
positively charged residues. RPS23, calreticulin and RAB8A peptides have tyrosine or 
phenylalanine in position 3 which has previously been shown to be important for BOX-I 
binding into the hydrophobic pocket131. The ERp60 peptide has very low complexity 
around the motif, which may contribute to nonspecific binding to hydrophobic regions 
of MDM2. 
 
Overall the peptides which bind MDM2 compared to those which did not bind by 
ELISA have a higher representation of arginine residues in the core and N-terminal to 
the core motif, and are more likely to have a leucine/proline directly to the C-terminal of 
the core motif, and an aspartate at position 14. For an initial investigation this was 
calculated by noting the number of times a residue occurred in a peptide and counting it 
as ‘over-represented’ if it occurred in more than 20% of the peptides (Figure 4.8), a 
method which has previously been used to examine DAPK binding peptides203. Non-
binding peptides did not have any over-represented residues other than the core residues 
which were set in the prosite search, in particular there were no over-represented 
positively charged amino acids in the core of the motif. Leucine, valine, tyrosine and 
phenylalanine were more likely to appear than tryptophan, isoleucine and methionine, 
which may be due to the lower occurrence in general of the latter amino acids.  
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4.6 Competition assays with known MDM2 ligands 
Similarly to the IRF peptides, Nutlin does not compete with all of the newly identified 
MDM2 binding peptides (Figure 4.9b). The peptides from nTPR, SNF2L4, SERCA2, 
Mitofilin RAB8a, calreticulin and SFRS11 are competed by Nutlin. However the DBC1 
peptide is enhanced by Nutlin, an effect which has previously been observed for acid 
domain ligands. BOX-I has a less pronounced effect than Nutlin as a competitor, with 
very few peptides competed by BOX-I (Figure 4.9c). The RAB8A peptide which is 
competed well by Nutlin is also competed by BOX-I. Some peptides are enhanced for 
MDM2 binding by the addition of BOX-I. For example the peptides from DBC1, 
SNF2L4, calnexin and ERp60 all show increased binding with a higher concentration of 
BOX-I peptide. RB1 competes many of the peptides to a greater extent than it does 
BOX-I; including the IRF peptides as previously seen (Figure 4.9d). Unexpectedly, 
enhancement of MDM2 binding to some peptides is caused by RB1, the peptides 
derived from RPS23, SFRS11 and calnexin for example. The enhancement of the RPS23 
peptide is quite pronounced, as this is a very weak binder when no other ligand is 
present. We can therefore classify the newly identified MDM2 peptides based on which 
MDM2 ligands compete or enhance their binding (Fig 4.9e). 
 
4.7 Peptide binding to the N-terminal domain of MDM2 
BOX-I binds to the N-terminal domain, amino acids 1-126, of MDM2 with a higher 
intensity than any of the newly identified peptides (Figure 4.10). Many of the newly 
identified peptides do show some binding to this domain which is abrogated by the 
aromatic to alanine mutation in the core motif (Figure 4.10a). RPS23 and RAB8A do not 
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appear to bind the N-terminal domain in isolation. Nutlin is effective in competing many 
of the peptides from the N-terminal domain, however it should be noted that BOX-I is 
not competed as effectively from the N-terminal domain alone as it is from full-length 
MDM2 (Figure 4.10b, c). 
 
4.8 Thermal denaturation assay - full-length MDM2 
Thermal denaturation assays determine the melting point of a protein by measuring the 
amount of fluorescence of a probe, sypro orange, which is active when bound to 
hydrophobic regions of a protein. As the temperature is increased the protein unfolds 
revealing different hydrophobic sites, and the probe fluorescence is altered. The 
temperature at which the protein melts can be increased by stabilising ligands binding to 
a protein (Figure 4.11a)204. Full length MDM2 is somewhat resistant to thermal 
denaturation, with no clear melting temperature, but a broad melt-peak between 70-85°C 
(Figure 4.11b, c). This could be due to the high degree of disorder in the acidic domain, 
which might result in a large unstructured region of the protein resistant to thermal 
denaturation. MDM2 is also unusual in that it appears to bind sypro orange prior to 
denaturation which it is proposed is due to the dye binding into the hydrophobic pocket, 
resulting in high initial fluorescence137. Nutlin binding reduces this initial background 
presumably due to displacement of the dye bound in the hydrophobic pocket and this 
effect also contributes to the increase in visibility of the melt-peaks after addition of 
Nutlin. As previously observed for the N-terminal domain of MDM2137, in the presence 
of Nutlin it is possible to see a melting point with full-length MDM2, which in this case 
is 83°C, with a secondary melt-peak visible at 56°C (Figure 4.11d, e). Binding the BOX-
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I peptide results in a similar effect, with the main melt peak at 81°C. However in this 
case there is no secondary melt-peak (Figure 4.11f, g). This is in keeping with a model 
that Nutlin binds MDM2 with a higher affinity than BOX-I and therefore results in a 
more defined stabilization. The acidic domain binding peptide RB1 does not enhance the 
melting temperature of MDM2 and no clear melt-peak is visible (Figure 4.11h, i). As 
previously observed, Nutlin decreases the initial background reading of the assay 
(Figure 4.11b, d). RB1 actually increases this initial background, in contrast to the N-
terminal binding ligands (Figure 4.11h), and this is also observed with the N-terminal 
domain of MDM2 which does not contain the RB1 binding site (Figure 4.13h). This may 
be due to the relatively high background observed with RB1 peptide alone, indicating 
that dye can bind the RB1 peptide itself. Interestingly, BOX-I slightly increases the 
initial background also, opposite to the effect observed with Nutlin (Figure 4.11f). 
 
The IRF2 peptide does not have a similar effect to BOX-I and Nutlin on full-length 
MDM2. Two other newly identified peptides, one from RPS7, from a known MDM2 
binding protein, and the CypB peptide were investigated in this assay. The RPS7 peptide 
does not cause a similar increase in melting temperature to Nutlin and BOX-I, however 
it does shift the broad minimum seen with ligand free protein to a higher temperature 
(Figure 4.12a, b). The CypB peptide has a substantial background fluorescence, which is 
likely caused by sypro binding to the peptide therefore at this concentration it was not 
possible to determine whether or not this peptide binds full-length MDM2 (Fig 4.12c, d). 




4.9 Thermal Denaturation Assay – N-Terminal MDM2 construct 
Unlike full-length MDM2 the N-terminal domain of MDM2 in isolation does have a 
melt peak and this occurs at around 81°C. N-terminal MDM2 also has obvious melt 
peaks after the addition of Nutlin (Figure 4.13 a-d). Addition of Nutlin results in an 
increase in melting temperature for the N-terminal domain from 81°C to 85°C. This 
indicates that the N-terminal domain in isolation may be more stable than full-length 
MDM2 which has a melting temperature of 83°C after the addition of Nutlin (Figure 
4.11c). Another possiblility is that the N-terminal domain of MDM2 binds Nutlin more 
effectively than full length MDM2. This is supported by the earlier observation that 
Nutlin competes BOX-I less effectively from the N-terminal domain in isolation (Figure 
4.10). A secondary melt peak after the addition of Nutlin was also observed at 54°C. 
When BOX-I is added as a ligand the higher melting temperature is 81°C for full length 
MDM2 and 82°C for N-terminal MDM2, which fits with the model that BOX-I binds 
the same site as Nutlin with a lower affinity (Figure 4.13e, f). It is notable that MDM2 
with BOX-I peptide has a higher melting temperature than with Nutlin at the earlier 
melt-point observed, from 54°C with Nutlin to 57°C with BOX-I. There is also a more 
distinct peak at 75°C which appears as a shoulder on the melting transition at the higher 
temperature when Nutlin is present. This may be because Nutlin stabilizes both higher 
melting transitions so the shoulder is better resolved with a less effective ligand, such as 
BOX-I. IRF2 peptide does not exhibit the earlier peak which is stabilized by BOX-I 
(Figure 4.14a, b), however the higher melting temperature is stabilized to 82°C in the N-
terminal domain from 81°C in the protein without ligand. The S7 peptide and CypB 
 137 
peptides do not stabilise the higher melting temperature, and actually have a negative 
effect on this melting temperature (Figure 4.14 c-f), however they do stabilise the earlier 
melting temperature. A low concentration of the CypB peptide was used to overcome 
the effect of the high background observed for this ligand with full length protein.  With 
Nutlin the first melt-peak observed is 54°C, increasing to 57°C with the S7 peptide and 
60°C with the CypB peptide. Nutlin and BOX-I both decrease the initial background for 
the N-terminal construct, unlike for full-length MDM2 where BOX-I slightly increases 
the initial fluorescence background. All the other peptide ligands, particularly RB1, 
increase the background however as before this may be due to dye binding the peptide 
ligands. Thermal denaturation melting temperatures and background levels are 
summarized in Table 4.1. 
 
4.10 BOX-V-like sequences 
MDM2 has multiple known peptide binding partners, including the second p53 binding 
site BOX-V. BOX-V does not have a well defined consensus sequence as there is for 
BOX-I, therefore the BOX-V peptide was used in a protein BLAST (NCBI) search 
against the proteins which are altered 2 hours after Nutlin treatment. 18 proteins were 
returned from this search, and peptides corresponding to the BOX-V like region tested 
for binding to MDM2 (Figure 4.15). The peptides which bound to MDM2 were derived 
from the proteins TRIM33, PCNA, RPL11 and elongin. RPL11 was not a hit at 2 hours 
in the PAcIFIC screen but was included as a known MDM2 binding protein containing 




The strategy used in this study to filter the large amount of proteomic mass spectrometry 
data was to search for motifs which are known to bind to MDM2 in the proteins which 
are upregulated at an acute time. The acute time was chosen because at this early stage 
the changes in protein level observed are more likely to be due to stabilization or 
destabilization on a proteomic level rather than further downstream effects. Nutlin 
directly inhibits protein-protein interactions at the MDM2 N-terminus133, and 
allosterically regulates other MDM2 domains91, therefore proteins detected by the mass 
spectrometry screen which are altered by Nutlin treatment can potentially bind either the 
N-terminal or other domains of MDM2. Highlighting the importance of MDM2 allostery 
is the observed increase in binding of BOX-I to GST purified MDM2 compared to SP 
column purified MDM2. The most likely reason for this is the presence or absence of 
another co-factor which inhibits BOX-I binding, candidates include RNA80, zinc80, 
ATP61 or protein binders which may be retained by purification. The purification method 
does not affect the IRF peptides binding and the question this raises is whether these 
peptides bind the N-terminal domain of MDM2, a different domain, or indeed multiple 
domains. Addition or chelation of these cofactors in each MDM2 preparation may be a 
method to isolate how each of these ligands regulates MDM2. 
 
The disordered acidic domain of MDM2 could adopt a more defined conformation in the 
presence of ligands, also known as disorder-to-order transition205. This may be a crucial 
part of the allosteric mechanism mediating MDM2 interactions. It could also be 
significant on both sides of the interaction, as linear motifs are frequently associated 
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with disordered regions of proteins115 and highly disordered proteins such as p53 interact 
with MDM2 via linear motifs95. The allosteric mechanism of MDM2 coupled with 
speculation about the oligomeric status of MDM2 means many questions remain about 
MDM2 ability to bind peptide ligands, and how specific MDM2 consensus sequences 
are, so it was interesting to observe here the difference between IRF peptides and BOX-I 
binding and compare them to newly discovered MDM2 binding peptides. 
 
IRF2-MDM2 binding has been shown to depend on residues found in the core 
hydrophobic motif which is similar to BOX-I81. The consensus motif used to search this 
data, [Hyd]-[Aro]-x-x-[Hyd], was deliberately chosen to have a very low level of 
complexity and likely high rate of occurrence in many proteins due to the high 
variability allowed by this motif. With a secondary peptide binding screen, the large 
amount of proteins containing this motif could then be narrowed down to those peptides 
which can bind MDM2 and further similarity with the BOX-I and IRF peptides it is 
constructed from could be found. Indeed, it seemed that a positively charged residue at 
the centre of this core was beneficial, as was an aspartate at position 14. Previous studies 
with the BOX-I peptide and PMI inhibitor have confirmed the importance of the core 
residues mimicked by Nutlin131. The threonine adjacent to the phenylalanine in position 
three and the proline directly C-terminal of the core motif can actually enhance BOX-I-
MDM2 binding when converted to an alanine, highlighting the variability which may be 
permitted around core residues. Drawbacks with this approach include identification of 
so many peptides, however it could be argued that many consensus motifs have low 
complexity, and that residues around the core motif can influence binding such as in the 
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case of TPR binding HSP90206. With advances in peptide arrays testing thousands of 
peptides for binding to a protein is rapidly becoming more high-throughput207. There are 
numerous examples of proteins recognizing ‘non-canonical’ motifs which act in the 
same way as those fitting a consensus, for example the 14-3-3 proteins have an 
extremely large interactome based on linear motif binding208. 
 
The peptides obtained containing this BOX-I like motif exhibited a range of binding 
levels in comparison with BOX-I, this is interesting because transiently binding proteins 
may be vital in the MDM2 interaction whereas studies which normally focus on high 
affinity ligands may overlook transient interactions. Cell signaling pathways rely on 
transient binding to transmit information, and MDM2 is at the hub of a number of 
signaling pathways including ribosomal regulation96, 99, p53 regulation47, mRNA 
translation59 and transcriptional regulation106 where this type of interaction may be 
important. It is possible that part of the reason why the p53-MDM2 interaction is so 
widely characterized because it is an example of a very high affinity interaction, and 
these interactions are readily detected.  
 
The competition assays with known MDM2 ligands further reveals the high degree of 
complexity of MDM2 peptide binding. Peptides such as RAB8A, SNF2L4 are competed 
by Nutlin similarly to BOX-I. Many of the other peptides however do not respond in the 
expected manner, including the IRF peptides previously identified as important for 
MDM2 binding. Further increasing the complexity of MDM2 peptide binding models, 
RB1 is competitor of many of these peptides but enhances the binding of some other 
 141 
peptides. The extremely weak binder RPS23 is greatly enhanced in the presence of RB1, 
suggesting that the RB1 peptide opens a previously hidden binding site. This is possibly 
the hydrophobic pocket, or an as yet uncharacterized region in another domain of 
MDM2. Recent studies have shown the ‘open’ or ‘closed’ state of the hydrophobic 
pocket is extensively regulated by the MDM2 lid65, and possibly the C-terminus of 
p5338. These studies suggest that the regulation of this domain is extremely dynamic.  
 
Comparison of full length MDM2 to the N-terminal domain the thermal denaturation 
assay reveals that the melt-peaks are much clearer in the N-terminal domain construct. 
This is potentially because the melt-peaks observed for full-length MDM2 represent the 
N-terminal domain, as the acidic domain is disordered and may not exhibit a melt over 
this temperature range and the RING domain is very thermostable. The multiple melt-
peaks observed hint at a multi-stage unfolding mechanism, with part of the protein 
becoming denatured followed, at a higher temperature, by a more stable core analogous 
to what has been previously observed by limited trypsin proteolysis of full-length 
MDM291. Different ligands stabilization of different peaks suggests that these ligands 
bind different parts of the N-terminal domain than BOX-I, or bind by a different 
mechanism. The thermal denaturation assay on full-length MDM2 also intriguingly 
suggests a two way allosteric mechanism, with the RB1 peptide increasing sypro binding 
at the hydrophobic pocket. However the high background fluorescence of this peptide 
means further work is needed to determine if this effect is genuine. This agrees with 
computer modeling observations about the regulation of hydrophobic pocket binding 
being regulated by various MDM2 ligands and domains136. If acidic domain ligands can 
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change the confirmation of the N-terminal domain this could open or close the pocket, 
by regulating either the N-terminal domain itself or the lid139. The charged region on the 
IRF peptides and some of the new candidate peptides may be a factor in the binding of 
these peptides to MDM2. Since studies have shown the BOX-I binding interaction 
initially depends on docking via charge interactions outside the MDM2 pocket before 
intercalating into the same binding site that Nutlin occupies108. If these peptides are not 
very efficient at binding deep into the hydrophobic pocket Nutlin may not be able to 
compete these peptides effectively. Although the pattern of stabilization is not the same 
as for Nutlin, the newly identified MDM2 ligands S7 and CypB both have an effect on 
the N-terminal domain of MDM2, indicating that they can bind there. Further work to 
determine how these peptides bind MDM2 could include peptide arrays replacing each 
amino acid with every other amino acid, and more in depth kinetics assays such as 
fluorescence polarization, fluorescence resonance transfer methods or surface plasmon 
resonance. MS mapping or ion mobility MS to investigate MDM2 conformation would 
also clarify the MDM2 peptide binding mechanism. MDM2 can be described as a highly 
allosteric peptide binding protein, with extensive cross-talk between domains based on 
the results showing the effect of different ligands on different MDM2 binding peptides. 
 
The next obvious step after identifying MDM2 binding peptides derived from proteins 
altered by Nutlin treatment is to investigate whether the peptide binding translates to 
full-length protein binding, and whether the effects of Nutlin on MDM2 are limited to 
the inhibition of MDM2 functions previously described. Although Nutlin reactivates 
p53133, newly identified MDM2 proteins containing this motif, or validated for MDM2 
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binding in another way, may have a completely different response to Nutlin. The 
proteins identified in the MS screen, or containing a BOX-I like motif may behave like 
p53, E2F1 or an as yet unidentified class of MDM2 ligands and investigating these 
further will expand the known MDM2 interactome. Chapter 5 is an investigation of the 
effects of Nutlin on proteins in vivo characterization of full length candidate proteins 
































Figure 4.1 – A) Alignment of BOX-I region of p53 with the IRF1 and IRF2 
corresponding region. Residues essential for IRF binding MDM2 underlined in red, F 
residue important in BOX-I binding highlighted in blue, charged region only present in 
IRF peptides highlighted in green and proline highlighted in pink. B) Consensus motifs 
based on residues in position 6-10 constructed from this alignment, Hyd – Hydrophobic, 






























































Figure 4.2 – A) Schematic of ELISA peptide binding assay. B) Binding of FL-MDM2 
purified from cleavable GST tag to biotinylated BOX-I, IRF1 and IRF2 peptides 
(sequence as in Figure 4.1) and C) Binding of FL-MDM2 purified by SP column to 
peptides D) Zinc chloride competition ELISA of 2.5 µg/well MDM2 from BOX-I and IRF 










































Figure 4.3 - A) Schematic of ELISA competition assay. B-E) Competition ELISA with 
Nutlin or untagged BOXI, IRF1 and IRF2 peptides (sequence as in Figure 4.1) from 
various MDM2 ligands. Legend indicates immobilized peptide. B) Nutlin competition, C) 























Figure 4.4 - Summary of number of motifs (Defined in Figure. 4.1) found in proteins 
with altered levels 2 hours after Nutlin treatment in PAcIFIC proteomics screen. (Full 


















































Figure 4.5 - Validation of peptides containing consensus motif binding by ELISA (Full 
sequences shown in alignment in Figure 4.7, method as in Figure 4.2). Results indicated 
as the amount of peptide binding as a fraction of BOX-I maximum binding with 10µg 
MDM2. Results are categorized as follows:  A) Stronger than BOX-I, B) Intermediate, 




















































Figure 4.6 - A) ELISA binding of peptides to full length MDM2 (2.5 µg/well), sequences 
in Figure 4.7, compared to peptides with core W in the consensus motif defined in 
Figure 4.1 mutated to A.  B) Weaker binding peptides (strong binders removed from 















































Figure 4.7 - Alignment of peptides which bind to full-length MDM2, A) All peptides B) 
Top binders, C) Intermediate binders, D) Weak binders, E) Very weak binders as 
defined in Figure 4.5. Green – core motif hydrophobic residues, Dark Blue – core motif 
aromatic residue, Light Blue – Negatively charged residues, Light Pink – Positively 













































Figure 4.8 – Tally chart of residue frequency in motifs which bind MDM2 compared to 
those which do not bind. A) Peptides binding MDM2 B) All other peptides from screen 
of MS dataset which did not bind MDM2. Residues which are overrepresented in the 
MDM2 binding peptides are highlighted in bold in both tables, and incorporated into 










































Figure 4.9 - ELISA plates for competition assays for unbound vs. incubated with ligand 
(20 µM) MDM2 (2.5 µg/well); B) Nutlin C) BOX-I D) RB1, lower binding peptides are 
shown without strong binders below initial graph. E) Summary of MDM2 ligand effects 













































Figure 4.10 – ELISA of N-terminal MDM2 (residues 1-126) binding peptides identified 
as binding to full-length MDM2 (Sequences in figure 4.7). A) All peptides compared to 
core motif W to A mutant peptides, B) Strong binding peptides plus or minus Nutlin (40 








































Figure 4.11 - A) Schematic of thermal denaturation assay. Left column of graphs are 
raw data, right column are corresponding data transformed as –d(RFU)/dT, where RFU 
is relative fluorescence units. 1,2 and 3 represent three replicates of identical samples. 
B,C) FL-MDM2 with no ligand D,E) FL-MDM2 with Nutlin F, G) FL-MDM2 with BOX-
I peptide, H, I) FL-MDM2 with RB1 peptide. Ligand only measurements (background) 
are also shown in D,F, H and I. Ligand concentrations were all 20 µM and MDM2 














                                                                             
























Figure 4.12 - Thermal denaturation assay for full-length MDM2 with conditions and 
presentation as in Figure 4.11. A), B) IRF2 peptide C), D) S7 peptide E), F) CypB 
peptide. 1, 2 and 3 represent replicates of identical samples, and ligand only controls 















































Figure 4.13 - Thermal denaturation assay of N-terminal construct MDM2 (aa 1-126) 
with A),B) No ligand, C), D), Nutlin, E), F) BOX-I, G), H) RB1. A, B and C represent 
three identical replicates, ligand only controls are shown in C, E, G and H. Presentation 







































Figure 4.14 - Thermal denaturation assay of N-terminal construct MDM2 with A), B) 
IRF2 peptide, C), D) S7 peptide, E), F) CypB peptide. A, B and C represent identical 
replicates and ligand only controls are shown in A, C, E and F. Presentation and 































81 ± 1 3634 ± 152 
  Nutlin 56 ± 0 989 ± 66  Nutlin 54 ± 3 594 ± 16 
   83 ± 0     85 ± 1   
  BOX-I 
81 ± 
0.6 
2530 ± 109  BOX-I 57 ± 2 1791 ± 581 
         75 ± 1   
         82 ± 1   
  RB1  -  4523 ± 1443  RB1  - 
12568 ± 
1648 
  IRF2  - 3000 ± 264  IRF2 82 ± 1 5996 ± 1069 
  S7  90 ± 1 6366 ± 340  S7  57 ± 1 4539 ± 832 
         74 ± 1   
  CypB  - 
40220 ± 
5194 
 CypB 60 ± 2 4650 ± 330 
            76 ± 1   
 
 
Table 4.1 Summary of thermal denaturation assays figures 4.11-4.14. Melt temperature 
corresponds to peak minima in d(-RFU)/dT vs. Temperature graphs and initial 

























































Figure 4.15 - Peptides with similarity to BOX-V binding by ELISA to full-length MDM2 
B) Alignment of binding peptides containing BOX-V motif from early PAcIFIC hits 







5 - Validation of full-length MDM2 binding proteins and the effects of Nutlin in 
cells 
5.1 Introduction 
In Chapters Three and Four proteins which responded to Nutlin treatment were 
identified by proteomic MS, and motifs with similarity to the BOX-I sequence from p53 
derived from these proteins were shown to bind full-length or N-terminal domain 
MDM2. Further work is required to investigate the response of these proteins to Nutlin 
treatment, and establish whether these motifs have a role in full-length protein-protein 
interactions. Although some of these peptide motifs have been shown to bind MDM2 in 
vitro, this does not necessarily translate to mediating in vivo protein-protein interactions. 
The proteins with motifs which were investigated in Chapter Four by thermal 
denaturation, CypB and RPS7, were selected for further investigation by cell biology 
and biochemical assays.  
 
CypB is a peptidyl-prolyl isomerase which has been implicated in cancer progression209, 
210, but it is unclear by which mechanisms this occurs. RPS7 is a previously validated 
MDM2 binding ribosomal protein, which has been shown to be a substrate for MDM2 
ubiquitination and also plays a role in the regulation of the p53-MDM2-MDM4 axis96. 
The region of RPS7 which MDM2 binds has been mapped, and this includes the BOX-I 
like motif identified in Chapter Four. Of the proteins identified in the iTRAQ MS screen 
APE1, which has been shown to bind MDM297, and NPM, another previously validated 
MDM2 binding protein103, were detected at multiple times after Nutlin treatment. These 
proteins were further investigated to determine the effect Nutlin treatment has on these 
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proteins in particular. Pyruvate kinase was also tested for binding to MDM2, as a cancer 
target which was detected in the iTRAQ screen. Although fully validating each of these 
proteins would require more work, preliminary experiments here identify that they are 
related to MDM2 and represent leads which can be further investigated to expand the 
MDM2 interactome.  
 
5.2 Confirmation of Nutlin effects on cellular proteins by western blot 
Nutlin treatment of cells results in an increase in p53 protein levels as early as one hour 
after treatment, and subsequent increases in MDM2 and p21 (Chapter 3, Section 3.2). 
IRF2 protein levels after Nutlin treatment were also increased as early as two hours, and 
this persisted over the time course (Fig 5.1). Although IRF2 was not detected in either 
mass spectrometry screen, it is a known MDM2 binding partner and substrate81 and was 
used to design the BOX-I like motif used to screen the MS results (Chapter 4). Results 
obtained for the IRF2 response to Nutlin and relating to the IRF2 BOX-I like peptide 
therefore validate the results for new peptides derived from the MS results. Proteins 
which were detected in the PAcIFIC MS screen containing BOX-I like motifs were 
investigated for response to Nutlin treatment by western blot. The PAcIFIC hits RPS7, 
CypB and ERp60 were also detected in the iTRAQ screen, although none passed the 
1.33 threshold set for iTRAQ quantification ratio. CypB however was approaching the 
1.33 threshold by 12 hours after Nutlin treatment (Fig. 5.2). RPS7 was detected in both 
screens, although only detected as changed in level in the PAcIFIC screen at two and 
four hours after treatment. This was due to the absence of detection in the untreated 
cells, as RPS7 is a well-validated MDM2 binding protein however it warrants further 
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investigation (Fig. 5.2b). CypB levels were detected as increased at two hours after 
Nutlin treatment by western blot, with this increase maintained over the whole time 
course (Fig. 5.3). RPS7 was detected on a gel as higher molecular weight species as well 
as faintly detected at 20 kDa, and the level of these higher molecular weight species was 
slightly increased after Nutlin treatment (Fig. 5.3). Changes were not detectable by 
western blot for ERp60 which was detected at increased levels in the PAcIFIC screen. 
However this could be antibody dependent, an advantage of MS based protein detection 
methods is that they do not rely on the specificity and affinity of antibodies (Fig. 5.2d, 
5.3). The protein APE1 was detected at multiple time points in the iTRAQ screen, 
although it was not detected by PAcIFIC. It has previously been shown that this protein 
increases in level after Nutlin treatment, binds p53 and is ubiquitinated97. The western 
blot for APE1 after Nutlin treatment indicated that this protein was increased in level to 
a greater extent than any other protein tested in this study except for p53 (Fig. 5.4b). 
Over-exposure of this blot also revealed an increase in ubiquitination of APE1 after 
Nutlin treatment. In the PAcIFIC screen DNA-PK appeared decreased, whereas in the 
iTRAQ screen it was shown to increase over the time course (Fig. 5.4c,d). As the 
western blot shows there is an increased level of DNA-PK after Nutlin treatment (Fig. 
5.4e). The decrease detected in the PAcIFIC screen was possibly due to some 
relocalisation of DNA-PK  
 
5.3 Immunoprecipitation of MDM2 binding motif containing proteins 
CelluSpots™173 peptide arrays printed with peptides representing all of the motifs 
discovered in Chapter 4, and W to A mutant controls of these peptides, were probed with 
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full-length or N-terminal MDM2. The peptide derived from ERp60, which has high 
alanine content, bound both forms of MDM2 in this assay format (Fig. 5.5). Other 
peptides which bound MDM2 in this format included peptides derived from BAT3 and 
ribosomal protein L24, although the array binding detected was low for all peptides 
other than ERp60. Surprisingly the positive control peptide, BOX-I, did not bind by this 
peptide array assay. As the most intense binding peptide co-immunoprecipitation of 
ERp60 with MDM2 from MCF7 cell lysate was attempted. Although there was a low 
intensity band in the elution lane at approximately the correct molecular weight (Fig. 
5.6a) there was a high level of background, and it was not possible to co-
immunoprecipate MDM2 with ERp60 in the solid phase. CypB was also tested for 
MDM2 binding using co-immunoprecipiation, and was not co-immunoprecipitated with 
MDM2 (Fig. 5.6b). There was however, a smear present in the load lane for cells treated 
with Nutlin, which which could represent modified forms of CypB (Fig. 5.6b). 
 
5.4 CypB stabilization by drug treatment 
To further investigate the effects of Nutlin treatment on CypB, samples were treated 
with drugs and analysed on gradient SDS-PAGE gels. Treatment of MCF7 cells with the 
proteasome inhibitor MG-132 stabilised levels of CypB, Nutlin treatment resulted in a 
similar level of stabilization in the absence of the proteasome inhibitor (Fig. 5.7). In all 
samples a higher molecular weight band was observed at around 30 kDa, which could 
represent a CypB dimer or a modified form of CypB and has potential to be identified by 
MALDI, for example. Interestingly, after Nutlin and MG-132 treatment other high 
molecular weight bands were observed on the CypB blot with a polyclonal antibody. 
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These bands were stabilized to a greater extent with MG-132 than any other drug, 
therefore it is possible they are intermediates in the CypB degradation pathway.  
 
Cyclosporine is an immunosuppresant drug which binds members of the cyclophilin 
protein family. Nutlin induced increase in CypB was greater than for cyclosporine 
treatment alone, and also resulted in a greater stabilization of the higher molecular 
weight bands observed. MDM2 is stabilized by all drug treatments, particularly the 
combination of Nutlin and MG-132 or of cyclosporine and MG-132. These results 
indicate that CypB is also stabilized by Nutlin treatment, although they do not show 
whether or not this is due to a direct MDM2 effect or further downstream.  
 
5.5 Full-length CypB binds MDM2 in vitro 
Full length CypB protein contains three BOX-I like motifs (Fig. 5.8a), one of which has 
been shown to bind MDM2 (Chapter Four). Full-length CypB was purified to test for 
MDM2 binding in vitro. CypB coated on an ELISA plate bound both full-length MDM2 
and N-terminal domain MDM2 to a greater extent than to free GST which was used as a 
control (Fig. 5.8b). In a similar pattern to that observed for MDM2 binding to the CypB 
motif peptide this interaction was not affected by the addition of BOX-I peptide or 
Nutlin, and was competed by BOX-V peptide and enhanced by RB1 peptides (Fig. 
5.8c,d). Interestingly, all ligands competed with the CypB peptide for binding at the N-
terminal domain (Fig. 5.8e), suggesting that this domain has intrinsic or less specific 
peptide binding activity. This also confirms that the enhancement of CypB binding 
observed with the full-length protein is most likely due to RB1 peptide binding a domain 
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other than the N-terminal domain. CypB with the core Y47 residue in the BOX-I like 
motif shown to bind MDM2 in Chapter Four mutated to alanine unexpectedly caused a 
slight enhancement of CypB binding to MDM2 (Fig. 5.9a). This is contrary to the 
MDM2 binding CypB peptide, which loses MDM2 binding activity with this mutation 
(Chapter Four). Nutlin actually enhanced binding of the mutant protein to MDM2 and 
had no effect on the wild type protein, which again was unexpected (Fig. 5.9b). 
Mutation of this residue in PyMOL revealed a slight increase in the exposure of the 
residues surrounding the core of the motif, which may explain this effect (Fig. 5.9d,e). 
To map the interface where CypB binds MDM2, overlapping MDM2 peptides were 
coated onto an ELISA plate and incubated with full-length CypB. Peptides from the N-
terminal domain and RING domain bound to CypB, although no acidic domain peptides 
bound CypB outside experimental error (Fig. 5.10). Although these peptides bind CypB, 
this does not necessarily map the binding interface, as in the full-length protein these 
peptides may be occluded. However binding to overlapping peptides, such as with the 
RING peptides may indicate a binding site. 
 
5.5 In vivo ubiquitination assays 
In vivo ubiquitination assays detect ubiqutination by pull-down of transfected His-tagged 
ubiquitin, which may be conjugated to ubiquitination substrates. p53 transfected into 
H1299 cells, which do not have a detectable level of p53 transcription, exhibits a large 
increase in ubiquitination when cells are co-transfected with MDM2. p53 ubiquitination 
is not detected without MDM2 co-transfection (Fig 5.11a). IRF2 is ubiquitinated in the 
absence of MDM2 in H1299 cells, however there is a slight increase in the level of 
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polyubiquitination after the cotransfection of MDM2 indicating that MDM2 stimulates 
this process. CypB was not co-immunoprecipitated in this assay either with or without 
MDM2 transfection and Nutlin treatment (Fig. 5.11b), indicating MDM2 may not 
ubiquitinate CypB in vivo. APE1 has previously been shown to be ubiqitinated by 
MDM297 and here it was confirmed that there is an increased level of APE1 
ubiquitination after Nutlin treatment, compared to untreated cells (Fig. 5.11c). This is 
visualized as a single band, unlike polyubiquitinated p53 and IRF2. Interestingly the 
APE1 band in the elution lane was at the same molecular weight as the load lane, 
suggesting this protein is usually ubiquitinated or is sticking to the nickel column. 
 
5.4 In vitro ubiquitination assays of CypB 
To further investigate if MDM2 can ubiquitinate CypB, in vitro ubiquitination assays 
were carried out. Full-length MDM2 purified by GST cleavage was shown to be active 
towards p53 due to the presence of ubiqutination bands as well as full length p53, 
increasing with a titration of MDM2 (Fig. 5.12a,b). When CypB was used as a substrate 
in the assay there were no ubiquitination bands visible, and the initial level of CypB 
appeared to decrease (Fig. 5.12a). Addition of CypB to the p53 ubiquitination reaction 
did not inhibit MDM2 ubiquitination of p53 (Fig. 5.12b).The decrease in CypB was 
observed with polyclonal, monoclonal and anti-His antibodies therefore it is unlikely 
that this is because of epitope masking. There are very low intensity higher molecular 
weight bands visible with a longer exposure using the anti-his antibody (Fig. 5.12c) 
which are potentially modified forms of CypB. In some exposures a higher molecular 
weight band was detected at about 30 kDa, which was also observed after MG-132 
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treatment of cells (Fig.5.7). This band also decreased over the MDM2 titration. This 
could potentially be due to a high rate of ubiquitination occurring too fast to be captured 
by the assay in this format. Using K48A mutant ubiquitin, which is unable to form poly-
ubiquitin chains at this residue211, decreased the level of substrate reduction for CypB 
(Fig. 5.12d) compared to with wild type ubiquitin.  
 
5.6 Pyruvate kinase binds MDM2 
Pyruvate kinase (PK) was detected in the iTRAQ screen, and although it was not classed 
as upregulated by the ProteinPilot quantitation algorithm it was manually assigned as a 
potential hit based on presence of multiple peptides suitable for quantitation. PK may 
therefore be a potential candidate for Nutlin regulation (Fig. 5.13a). PK was selected to 
test for MDM2 binding due to the pivotal role of pyruvate kinase in many cancers212. 
The protein bound MDM2 by ELISA, and PK-MDM2 binding was observed both for 
MDM2 in the solid phase and pyruvate kinase in the solid phase by ELISA (Fig. 
5.13b,c). PK has multiple instances of a BOX-I like motif, although two of these motifs 
are buried structurally (Fig. 5.14a,b), the final two overlapping motifs are exposed at the 
PK surface (Fig. 5.14c). Together these data indicate that PK protein is an iTRAQ result 
which may warrant further investigation.  
 
5.7 MDM2 regulates nucleophosmin oligomerisation 
The nucleolar shuttle protein nucleophosmin (NPM) was detected at most time points in 
the iTRAQ MS screen as upregulated after Nutlin treatment. When testing whether this 
effect could also be detected by western blot SDS-PAGE resistant oligmers were visible 
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on a gradient gel (Fig. 5.15a). The amount of NPM oligomers, which run at the correct 
molecular weight to be pentamers as previously reported213, decreases as the amount of 
monomers increase. This demonstrates Nutlin treatment results in the deoligomerisation 
of NPM. To validate this, MCF7 cells were treated with siRNA to MDM2, and both the 
soluble and insoluble fraction analysed by SDS-PAGE (Fig. 5.15b). As the level of 
MDM2 was reduced, there was an increase in NPM oligomerisation, contrary to the 
effect observed with Nutlin treatment. Adding purified MDM2 exogenously to cell 
lysates also decreased the amount of NPM oligomers, indicating this effect is due to 
increased levels of MDM2 rather than an off target or downstream effect caused by 
Nutlin (Fig. 5.15c). Transfection of MDM2 into H1299 cells resulted in a 
deoligomerisation effect, similar to adding exogenous MDM2 or Nutlin treatment (Fig. 
5.15d). Together these data indicate that Nutlin activates the de-oligomerisation of 
NPM, and that this is a process which is mediated by MDM2.  
 
5.8 Discussion 
Validation of proteomic MS screens by biological methods is increasingly required, 
even if the data is confirmed using MS based proteomic methods. As the PAcIFIC 
screen discussed in Chapter Three represents pilot data it is imperative to support these 
results with cell biology and biochemical validation. The western blots carried out here 
for CypB and APE1 confirm the mass spectrometry results, and may clarify the 
ambiguity of the DNA-PK quantitation difference between label free and iTRAQ 
quantification. The peptide array format used here did not detect MDM2 binding of the 
BOX-I peptide, however it did detect MDM2 binding to a peptide derived from the 
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chaperone ERp60. The reason for this could be that the format of the array favours a 
conformation of BOX-I which does not bind MDM2. The negative result for the ERp60 
co-immunoprecipitation and the lack of corroboration for these MS results by western 
blot demonstrates that not all leads acquired by the methods used in this study are 
possible to validate by biological methods. The method could be refined by using motif 
search engines such as SLiMFinder which categorise motifs based on conservation and 
structural features as well as sequence features116. It may also be useful to use other 
protein-protein interaction assays, such as fluorescence resonance energy transfer 
(FRET) or bioluminescence resonance energy transfer (BRET) which could identify 
proximity of proteins in cells. 
 
Cyclophilin B (CypB) was more clearly linked to Nutlin inhibition of MDM2 than 
ERp60, due to the detection of a large increase in CypB after Nutlin treatment. In 
particular, the similarity of the Nutlin effect to MG-132 treatment on CypB levels shows 
Nutlin treatment is stabilizing this protein, potentially by inhibition of CypB 
ubiquitination. Another possiblility is that this is linked to the cyclophilins role in quality 
control of protein translation, if protein degradation is inhibited protein folding 
machinery may respond due to proteostatic mechanisms18. If this is the case then Nutlin 
and MDM2 are also implicated in the regulation of these pathways on a broader scale 
than the p53 pathway alone. Pin1 is a peptidyl prolyl isomerase which has been shown 
to demonstrate this kind of a response, in particular controlling the degree of p53 
ubiquitination214. Although it was not possible to detect ubiquitinated CypB in the in 
vivo assay, the depletion of substrate in the in vitro assay was interesting due to the fact 
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that this usually represents ubiquitination. It has been proposed that the Pin1 protein has 
E4 activity and pre-assembles ubiquitin chains214, it is possible that CypB could have a 
similar function. Although higher molecular weight species were not detected in the in 
vitro experiment, those stabilized in the MG-132 experiments are uncharacterized. If 
higher molecular weight species of CypB could be identified by further mass 
spectrometry, this could provide an answer to what is happening in these assays. 
 
Purified CypB full-length protein binds both full-length MDM2 and the N-terminal 
domain in isolation. This was detected by ELISA, which does not mimic cellular 
conditions. Another factor that could influence this result is that CypB is a peptidyl-
prolyl isomerase. If the MDM2 used in this assay has a PPI dependent folding step, it 
may actually be a CypB substrate. An interesting point about this interaction is that the 
full-length protein responds to competitors in a similar way to the CypB peptide, 
suggesting this peptide may indeed play a vital role in the CypB-MDM2 interaction. The 
lack of competition by Nutlin, and enhancement by the acid domain ligand RB1 is 
similar for peptide and protein, although thermal denaturation results (Chapter Four) 
suggest the CypB peptide is indeed binding the N-terminal domain. In particular, the 
RB1 stimulation of this binding interaction is interesting because this has not been 
observed for other MDM2 ligands, rather it is usually an inhibitory interaction91, and 
may indicate a different mechanism of MDM2 allostery between the N-terminal and 
acidic domains. Nutlin enhances the binding of Y47A mutant CypB to full length 
MDM2. Mutating this residue in the crystal structure shows an increase in the depth of 
the pocket containing the potential MDM2 binding motif, this possibly allows MDM2 to 
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access residues in the region around the core. The CypB site around the motif has been 
shown to be a docking site for the ER chaperones calnexin and calreticulin, which was 
not affected by cyclosporine215. This indicates CypB can bind via a secondary binding 
site which is not the cyclosporine binding pocket, therefore the region with the BOX-I 
like motif may be another CypB site which can form protein-protein interfaces. It has 
been shown in computational studies that the surrounding residues of the BOX-I motif 
contribute to the interaction with MDM2216, and if this CypB motif is binding the 
hydrophobic pocket it could be reliant on residues around the pocket which dock 
peptides108. The primary Nutlin binding site does not seem likely to be the CypB binding 
site as Nutlin cannot compete CypB. Although the protein was discovered due to the 
presence of a BOX-I motif a possibility is that this pattern of hydrophobic residues can 
interact in a different way with MDM2. Indeed in the previous chapter, thermal 
denaturation results show BOX-I has a slightly different profile than Nutlin which may 
indicate that peptides have subtle difference in binding than the drug. The initial 
structure of MDM2 with Nutlin has multiple drug molecules bound133, raising the 
possibility of multiple binding pockets in the N-terminal domain. As Nutlin enhances the 
binding of CypB Y47A mutant to MDM2, maybe the CypB motif binding site is 
regulated by the state of the hydrophobic pocket, and the intercalation of Nutlin, or the 
core residues of the BOX-I like motifs activates another binding site in the N-terminal 
domain. The regulation of the pocket by the lid domain may further complicate this 
allostery. Although PK was only shown to bind MDM2 by ELISA and not investigated 
in vitro, the presence of BOX-I like motifs on the surface of the protein suggest this 
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might be a good lead to investigate further. This may also shed more light on the 
contradictions highlighted by the experiments carried out here with CypB. 
 
Nucleophosmin (NPM) is a previously validated MDM2 binding protein103, which 
serves as an internal validation for the iTRAQ MS screen. Although MDM2 has been 
shown to bind NPM, and participate in a complex with NPM and ARF the Nutlin effect 
on this pathway has not been demonstrated. In cancer NPM can be present as a fusion 
protein with ALK which is a constitutively active tyrosine kinase promoting the survival 
of cancerous cells217. NPM mediated oligomerisation has been shown to be important for 
this function218. Nutlin has a striking effect on the oligomerisation of NPM, which is 
similar to the effect of increasing the level of MDM2 in the cell either by transfection of 
exogenous addition of purified protein. This demonstrates that Nutlin stabilization of 
MDM2 is a factor causing the NPM de-oligomerisation, and as this has previously been 
shown to be mediated by NPM binding the MDM2 N-terminal domain103. These 
findings raise the possiblility that Nutlin allosterically activates not only the acidic 
domain, but also areas of the N-terminal domain other than the hydrophobic pocket to 
interact with binding partners (Fig 5.16). This is especially interesting regarding the 
therapeutic potential of Nutlin as NPM targeting drugs have been designed which target 
this oligomerisation interface213. 
 
Although the peptide motifs identified in the last two chapters bind by ELISA, the 
environment in the cell has very different conditions than those in in vitro assays. Some 
of these motifs may be unable to bind in vivo, represent transient binding partners or 
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docking signals and it is possible in full length proteins these motifs are occluded. 
MDM2 has chaperone activity for p53 and part of the function of a chaperone protein is 
based on binding unfolded, disordered regions. If the peptide binding ability of MDM2 
is linked to chaperone activity, it does not necessarily follow that purified proteins 
containing these motifs will be able to bind MDM2. To validate further the protein-
protein interactions identified here it would be necessary to develop more robust co-
immunoprecipitation techniques, to complement the results obtained by ELISA. Further 
site directed mutagenesis of CypB motif and potential PK binding site would validate 
whether this motif is definitely linked to MDM2 binding or not. Whilst more work is 
required to fully identify the role MDM2 and Nutlin play in the regulation of each of the 
proteins discussed in this chapter, CypB and PK have been identified as new MDM2 
binding proteins and the Nutlin mode of action regarding NPM has been further 
elucidated. These leads were generated from the original proteomic MS screen, and the 
range of questions raised by the initial attempts to validate these proteins highlight the 
complexity of the MDM2 interactome and mechanism and the benefits and pitfalls of 
MS based screens. It has been shown that proteomic MS can be a valuable tool to 
investigate an interactome, however this is only the beginning of understanding how 

























Figure 5.1 – Protein levels visualized by western blot for MDM2 and IRF2 levels in total 


































Figure 5.2 – MS screen quantitation results (left spectral count result from PAcIFIC, 
right iTRAQ) and BOX-I like motifs corresponding to the motif discussed in Chapter 4 











                                   




















Figure 5.3 – Protein levels visualized by western blot for RPS7, ERp60 and CypB after 

















































Figure 5.4 –  APE1 levels after Nutlin treatment by A) iTRAQ MS and; B) detected by 
western blot C) DNA-PK PAcIFIC spectral counting quantitation results, D) iTRAQ 
quantiation results and E) DNA-PK levels visualized by western blot after Nutlin 
























Figure 5.5 – A) CelluSpots (Intavis) peptide array probed with N-terminal domain 
MDM2 (aa 1-126) (top) or full length MDM2 (bottom) (conc.). Peptides with a positive 


























Figure 5.6 – Western blot for co-immunoprecipitation of A) ERp60, elution bands 
highlighted with white box, and B) CypB, smear highlighted with white box, with 
MDM2. Polyclonal anti-MDM2 (2A10) was bound to protein G coated beads and 
proteins which bound eluted with low pH.  (L – Load (Cell lysate), W – Wash (Not 
































Figure 5.7 – Western blot to visualize protein levels of MDM2 and CypB after treatment 
with MG-132 (10 µM), Nutlin (40 µM) and cyclosporine (Cysp 10 µg/ml). β-actin blot 









































Figure 5.8 A) CypB primary amino acid sequence with BOX-I like motifs highlighted in 
yellow, and MDM2 binding peptide highlighted with asterisk. Cleaved leader sequence 
is underlined. B) Full-length CypB binding full-length and N-terminal domain MDM2 by 
ELISA illustrated in schematic. Competition assay with known MDM2 peptide ligands 
of; C) Full-length MDM2 from immobilized CypB peptide, D) Full-length MDM2 from 




























Figure 5.9 – Immobilized A) CypB wild type and B) CypB W to A mutant protein binding 
full-length MDM2 by ELISA. C) Structure of CypB bound to cyclosporine (gray) 
PDB:1CYN D) with BOX-I like MDM2 binding motif highlighted in red and E) with 
























Figure 5.10 – A) Overlapping MDM2 peptides and domain they are found in. B) Full-







































Figure 5.11 – A) In vivo ubiquitination assay (described in Chapter 2) for p53 and IRF2 
with and without co-transfection of MDM2 in H1299 cells. In vivo ubiquitination of B) 
CypB C) APE1. Load lanes (1-3) are cell lysate, Elution lanes are fraction eluted from 




































Figure 5.12 – In vitro ubiquitination assays with MDM2 (conc.) as the E3 ligase for A) 
CypB (detected with polyclonal anti-CypB), B) p53 with either BSA and CypB as 
potential competitors, Ub – ubiquitinated p53. C) CypB with a range of antibodies used 
















Figure 5.13 – A) iTRAQ MS result showing pyruvate kinase levels over Nutlin time 
course. B) Pyruvate kinase binding MDM2 by protein-protein ELISA with immobilized 
PK detected with anti-MDM2 antibody (2A10), C) with immobilized MDM2 detected 











































Figure 5.14 – A) PK primary amino acid sequence with BOX-I like motifs highlighted. 
B) PK structure with motifs highlighted in same colours as in A C) Position of BOX-I 






































Figure 5.15 – Nucleophosmin response to Nutlin treatment. A) In MCF7 cells after 
Nutlin treatment B) after siRNA to MDM2, C) after addition of exogenous MDM2 to 
lysates, D) after transfection of MDM2 into H1299 cells E) Summary of NPM response 































6 - Linear motifs as tools for investigating protein-protein interactions 
6.1 Introduction 
There are different methods which can be used to find linear motifs; one is through 
known binding partners and sequence similarity, and another is by optimization of 
known peptide ligands to discover the critical residues. For example if a protein has a 
known high affinity peptide ligand this can be used as a starting point to search for 
similar peptides which also bind, as with the MDM2 binding peptides 12.1 and PMI 
which are similar to BOX-I130. In either case the peptide ligand can be used as the base 
to design a peptidomimetic protein-protein interaction inhibitor, an example of this is 
Nutlin which mimics the BOX-I region of p53 and blocks binding to MDM2133. The 
protein AGR2 is a protein disulphide isomerase219 which has been shown to promote 
transformation in Barrett’s oesophagus and downregulates p53125. Little is known about 
the AGR2 interactome and the exact function of AGR2 in transformation and cancer 
pathways is yet to be elucidated. A 12-mer AGR2 binding peptide, HLPTTIYYGPPG 
was obtained by phage peptide display and optimized to the core hexapeptide 
PTTIYY124. This peptide aptamer was then validated as a modulator of p53 localisation 
and AGR2 localisation, although it is not yet clear by which pathway this is occurring128. 
To validate the potential of this peptide as a drug template, it was conjugated to the 
optimized version of the cell penetrating peptide penetratin (RRMKWKK) and used to 
treat MCF7 cells. 
 
6.2 A six-mer peptide which binds AGR2 
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The PTTIYY peptide binds to AGR2, shown by ELISA (Fig. 6.1) and previously by 
MS220. Previously identified peptides derived from proteins which are similar to 
PTTIYY were also tested by this method. These peptides exhibited an above background 
signal for AGR2 binding, although none were as effective in binding as the phage 
display derived peptide. The peptides derived from the protein SMG7 showed the largest 
amount of binding.    
 
6.3 Penetratin-PTTIYY causes stabilization of p21 and contributes to UV mediated 
stabilization of p53 
Variation in MCF7 cells used by different groups has previously been reported, and two 
types of MCF7 cell were identified each with different levels of AGR2, described here 
as high or low MCF7 cells (Fig. 6.2). It has previously been shown that transfected 
PTTIYY can alter the localization of AGR2 and p53, and affect the morphology of 
nuclei128. To investigate this further, Pen-PTTIYY was used to treat cells over a time 
course and overall levels of p53, p21 and AGR2 monitored by western blot. As a 
negative control the point mutated Pen-PTTIYA and the truncated peptide Pen-PTTI 
were used, as it has previously been shown the YY residues are important for AGR2 
binding124. Pen-PTTIYY aptamer treatment resulted in stabilization of p21 relative to the 
truncated control, as did treatment with Pen-PTTIYA (Fig.6.2a). There was no change in 
p53 levels, however the increase in p21 suggests p53 may be transcriptionally activated 
by the aptamers. When the aptamers were added to the cells in combination with a dose 
of UV radiation, the p53 level was increased dramatically only in those cells treated with 
Pen-PTTIYY, along with the level of p21 (Fig. 6.2b). A375 cells which do not have 
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detectable levels of AGR2 were not affected by the aptamer. It has been observed that 
UV treatment can induce p21 degradation221, and comparison of high AGR2 MCF7 cells 
to low AGR2 MCF7 cells after low UV treatment demonstrated that aptamer treatment 
rescues p21 from this degradation in the high AGR2 cells. In the low AGR2 cells both 
UV and aptamer treatment had little effect on any proteins, potentially there is a mild 
stabilization of p53 with UV treatment (Fig. 6.2c). Subcellular fractionation of MCF7 
cells was carried out, and treatment of high AGR2 MCF7 cells with the Pen-PTTIYY 
aptamer resulted in relocalisation of AGR2 and p53 both to the nucleus as early as 4 
hours after treatment with aptamer and UV or the proteasome inhibitor MG-132 (Fig. 
6.3).  
 
6.4 Transcriptional activation of p53 pathway in response to PTTIYY treatment 
A super array (SABiosciences) representing genes in the p53 pathway was used to 
analyse transcriptional activation in response to aptamer treatment (Fig. 6.4). This assay 
measures the levels of various mRNAs which are associated with the p53 pathway. 
There were differences in transcription detected between aptamer treated cells and cells 
which were untreated, and also differences between Pen-PTTIYY treated cells and those 
treated with the truncated control peptide (Fig. 6.4a). Activated genes included BAX, 
which is consistent with the hypothesis that PTTIYY activates p53 transcriptionally. 
MDM4 is also induced relative to control and untreated cells, which is a link between 
AGR2 and the p53-MDM2-MDM4 axis. There was a slight increase in RB1, which is 
another tumour suppressor closely linked to MDM2 and p53. Interestingly, titration of 
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The Pen-PTTIYY aptamer was discovered by phage peptide display, and it was shown 
here to bind AGR2 with high affinity. Sequences resembling this peptide which were 
discovered in proteins also bound AGR2 to a lesser extent, with peptides from SMG7 
and MEKK3 binding slightly to AGR2. These peptides may be weaker binders due to a 
more transient interaction, such those which can occur in cells and are important for cell 
signaling cascades. These results demonstrate that phage peptide display can be a useful 
method for beginning to investigate proteins with few known binding partners, and as a 
way to identify protein-protein interaction interfaces. Phage peptides with high affinity 
such as this are useful as tools for molecular biology, to co-immunoprecipitate proteins 
and in some cases act in a similar way to antibodies, although they are much quicker and 
cheaper to produce.  
 
The cellular effects of the AGR2 aptamer include relocalisation of AGR2 and p53. This 
may be one of the modes of negative regulation of the p53 pathway by AGR2, and 
targeting AGR2 may result in more nuclear p53 and therefore more active p53. p53 is a 
transcription factor controlling apoptosis related genes such as BAX, and this function 
takes place in nuclei. The activation of RB1 transcription by AGR2 transfection is also 
interesting, as this protein can bind MDM2 and act as a tumour suppressor, further 
linking AGR2 to p53 related cancer pathways. This is not observed in cells with low 
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AGR2, suggesting the aptamer is functioning in the high AGR2 cells because this is one 
of the dominant regulators of the p53 pathway when there are high levels of AGR2. 
Several drugs based on peptides are in development including a peptidomimetic which 
targets the Smac-XIAP interaction as a potential anti-tumour therapeutic222. Nutlin is 
similar to these drugs, because of the high similarity to BOX-I, however this was 
discovered by a high-throughput screen rather than rationally designed based on the 
peptide133. The results here show that this AGR2 derived peptide may be a viable 
template for further development as an AGR2 binding drug. 
 
This demonstration of cellular effects of the aptamer targeting AGR2 highlights the 
importance of linear motif interactions in regulation of interactomes. Using the phage 
display derived peptide as a protein-protein interaction inhibitor of unknown protein-
protein interactions is a slightly different approach than that of Nutlin to inhibit a known 
protein-protein interaction. The ability to target interfaces without knowing the binding 
partners of a protein makes peptide aptamers like this a useful approach to finding new 
binding partners for a protein, as well as investigating by which mechanisms and 
pathways they contribute to cancer cell survival.  
 
One approach to investigating linear motifs is to alter the interactome of a protein with a 
drug and look for similarity in sequence between which the proteins that are affected, 
and this is the route described in the previous chapters. The PTTIYY-AGR2 example 
described in this chapter uses phage display as the basis for discovering a peptide which 
may block a protein-protein interface. This can be optimized as a drug and also used to 
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search databases for similar sequences in potential AGR2 binding proteins, and is 
another approach to the problem of discovering new protein-protein interactions via 
linear motif mechanisms. The advantage of the method described here, is that little prior 
knowledge about a protein mechanism is required to follow the phage display route. 
Phage peptide display, and the aptamers which are derived from the technique are a 
complementary method to the studies described in Chapters Three and Four. For the 
MDM2 interactome Nutlin was used in combination with information about linear 
motifs which bind MDM2 to identify potential new binding proteins, whereas for AGR2 
there was little prior knowledge about which peptide sequences AGR2 is capable of 
binding. The phage peptide display provided both information about potential AGR2 
binding sequences, and may be developed further as a peptidomimetic. This 
demonstrates that it is possible to find out about the interactome of a relatively new 
target using similar methods that are applied to well characterized targets. Both of these 
methods contribute to our understanding of the interactome of a protein, by providing 
protein leads for further validation and are tools for finding out which pathways and 














































Figure 6.1 –A) Alignment of sequences with PTTIYY similarity from proteins in swisprot 
found by BLAST (NCBI). B) ELISA binding of AGR2 to immobilised PTTIYY and 










































Figure 6.2 – A) Levels of p53, p21 and AGR2 after aptamer treatment over time course 
detected by western blot. B) Effect of aptamers in combination with UV on MCF7 cells 
and on control A375 cells. C) Aptamer effect with low dose (1J/m2) UV on high and low 
AGR2 expressing MCF7 cells. YY – Pen-PTTIYY, YA – Pen-PTTIYA, TR – Pen-PTTI, No 
– No treatment 
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Figure 6.3 – A) Western blot showing subcellular localization of AGR2 and p53 after 
aptamer treatment and combination with UV or MG-132 treatment, and after subceullar 
fractionation. B) Change in p53 and AGR2 levels over time in the nuclear fraction. YY – 

















































Figure 6.4 – A) Super array quantitation of transcription levels of a subset of genes after 
treatment with AGR2 targeting aptamers PTTIYY or PTTI (control). B) Increase in RB1 








7 – Conclusions and Future Work 
 
The aim of this work was to use proteomic mass spectrometry to investigate the MDM2 
interactome, and investigate the utility of this method for discovering new protein-
protein interactions. A difficulty with quantitative proteomic studies on global protein 
levels can occur when filtering the large amount of information which may be obtained 
to highlight interesting leads and phenomena. Therefore to complement the analysis of 
the proteomic results obtained here, the results were screened for the presence of an 
MDM2 binding motif. This represents a new approach to filtering proteomic data, by 
using linear motifs derived from proteins already known interact with MDM2 to 
highlight potential members of the MDM2 interactome. Over a time course of treatment 
with the drug Nutlin, many known MDM2 binding proteins which have altered levels 
detected by both the less stringent label-free quantitation method and the iTRAQ screen, 
validating the proteomic mass spectrometry approach. There were also important 
differences between the two separate proteomic methods, and it may be useful to carry 
out several proteomic screens based on the problem being investigated. It has been 
shown here that even relatively small scale proteomics experiments can yield interesting 
information for biologists, and communication between mass spectrometrists and 
biologists is vital to understand this data and the significance of it. Considering the bias 
towards known proteins as drug targets, particularly those for which structural 
information is available this type of experiment could highlight new targets. In the future 
it would be interesting to compare more proteomic mass spectrometry experiments 
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targeting to MDM2, and further investigate the similarities and differences in the 
proteins identified by different proteomics methods. 
 
The method used in this project to investigate the proteomics data involved searching for 
sequences with similarity to known MDM2 binding proteins, p53 and IRF2. Although 
peptides from both of these proteins exhibit binding to MDM2, the consensus sequence 
differs slightly from the residues known to mimic BOX-I. The primary result of this 
approach was to identify new MDM2 binding peptides, which depend on a core 
aromatic residue. Interestingly, these peptides do not appear to behave exactly as the 
BOX-I peptide. This can be linked to computational and experimental observations 
about the conformational flexibility of the N-terminal domain of MDM2, and studies 
which show extensive allosteric communication between the domains of MDM2. It is 
suggested by this data that the MDM2 N-terminus may have multiple binding sites, 
regulated by the lid and acidic domain and the Nutlin/BOX-I pocket is only one aspect 
of the N-terminal domain binding capabilities. There is potential to continue this 
research by further defining the residues which are important for MDM2 binding at the 
N-terminal domain, and linking this to structural and computational studies to ascertain 
the effect these ligands have on MDM2 allosterically. The other interesting result 
regarding the function of the N-terminal domain obtained in this work was the regulation 
of nucleophosmin oligomerisation after Nutlin treatment. If MDM2 binds 
nucleophosmin and causes de-oligomerisation, Nutlin actually enhances this function. 
Therefore where previously Nutlin has been described as an MDM2 inhibitor, it is also 
an activator of MDM2.  
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Using consensus sequences to identify MDM2 binding peptides, and potentially binding 
proteins, is an approach which is linked to the AGR2 binding peptide aptamer examined 
in Chapter Six. The peptide is an optimized binder, as selection by phage display selects 
for high affinity peptides, however it can still be used to mine databases for similar 
sequences in potential AGR2 binding proteins and as a tool. These two approaches both 
use the model of linear motif interactions to find or inhibit protein-protein interactions 
and this is a promising approach both as a starting point for drug design and to 
investigate protein-protein interaction mechanisms. 
 
CypB and pyruvate kinase were both identified in vitro as novel MDM2 binding 
proteins, and this represents the beginning of work to fully validate these proteins in vivo 
and in vitro. Further experiments, such as co-immunoprecipitations and FRET could be 
used to further validate these interactions. As CypB and pyruvate kinase are 
identifications from label-free and iTRAQ screens respectively, this is a promising result 
for the role of proteomic mass spectrometry in target identification for cancer biology. 
CypB is involved in protein folding, and pyruvate kinase in metabolism which links 
MDM2 to proteostatic pathways. In particular, the identification of many proteins which 
are as yet unlinked to the p53 pathway highlights the fact that MDM2 is not solely 
involved in p53 regulation, although non-ubiquitin ligase functions of MDM2 may often 
be overlooked. Ubiquitin ligases are integral to the control of protein degradation, and a 
role in quality control of cellular proteins may be linked with this function. These 
proteomic studies have revealed that there are wide ranging effects after Nutlin 
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treatment, and this could be useful in identifying off-target effects as well as new 
proteins which can be targeted in combination with current drugs to reactivate tumour 
suppressor pathways. It is possible that many proteins have a large interactome, and the 
regulation of these networks depends on the balance of regulatory proteins and 
metabolites. Stimuli such as stress and drugs for example, can therefore cause wide 
ranging changes in the cell, some of which will be compensated for by feedback loops 
and some of which effect cellular responses. Although it is a common approach to 
examine one protein-protein interaction at a time, the situation in the cell is much more 
complicated in practice and proteomics experiments are one way of addressing this 
complexity. 
 
Most of the work to validate proteins from the mass spectrometry screens here was 
carried out on proteins which are affected at early time points after Nutlin treatment. It is 
striking that some of these proteins are affected throughout the time course, and others 
follow more transient patterns of stabilization and destabilization. This contrasts with 
genetic studies, which may be monitoring longer term changes. Changes in the proteome 
are the first cellular reaction to drugs and stimuli. The dynamic nature of the proteome 
can be investigated using experiments which monitor changes in global protein levels 
over time, and give a more complete picture of the events occurring in a cell. The 
experiments in this thesis work towards understanding the total interactome of MDM2 
starting with a global approach then becoming more focused, and further work can build 
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Acc.  Gene TC00 TC02 TC04 TC08 TC24 























































































P62857 RPS28 1.0 2.2 0 0 0 

















































5 P62906 RPL10A NEDD6 3.0 3.295663
6 
0 0 1.263476






























































        
Acc.  Gene TC00 TC02 TC04 TC08 TC24 
















P62917 RPL8 1.0 1.1 1.659827
9 
0 0 




































































































3 P50995 ANXA11 ANX11 0.0 3.295663
6 
0 0 0 















































5 P53396 ACLY 1.0 0 0 2.260477
7 
1.263476





1 P11586 MTHFD1 MTHFC 
MTHFD 
0.0 0 0 1.130238
8 
1.263476





2 Q14444 CAPRIN1 GPIAP1 
GPIP137 M11S1 
5.0 2.2 0 2.260477
7 
2.526952
1 P16152 CBR1 CBR CRN 0.0 1.1 0 2.260477
7 
0 



























































        
































































1 P28838 LAP3 LAPEP PEPS 0.0 0 0 2.260477
7 
0 











































1 P11387 TOP1 5.0 3.3 0 2.260477
7 
2.526952

















































































































P16422 EPCAM GA733-2 






















1 Q9GZV4 EIF5A2 1.0 1.098554
5 
0 0 0 















        
Acc.  Gene TC00 TC02 TC04 TC08 TC24 





































2 Q5SZK8 FREM2 0.0 0 0 2.260477
7 
0 



































3 Q08379 GOLGA2 4.0 0 0 0 0 
Q8TBA6 GOLGA5 RETII 
RFG5 PIG31 
2.0 0 0 0 0 
P01111 NRAS HRAS1 2.0 0 0 0 0 









































































































0 0 0 


































































1 P07910 HNRNPC HNRPC 1.0 1.1 3.319655
9 
0 0 
P19367 HK1 3.0 4.394218
1 
0 0 1.263476


















        






















3 Q04695 KRT17 2.0 0 1.659827
9 
0 0 














4 P35527 KRT9 4.0 0.0 0 0 0 












































P42704 LRPPRC LRP130 2.0 0.0 0 0 0 


























9 P43243 MATR3 KIAA0723 3.0 2.2 3.319655
9 
0 1.263476




































































1 O75439 PMPCB MPPB 0.0 2.197109
1 
0 0 0 





















3 P28331 NDUFS1 2.0 0 0 0 1.263476
1 Q09666 AHNAK PM227 25.0 12.1 11.61879
5 
10.17215 11.37128
























1 P17480 UBTF UBF UBF1 2.0 0 0 0 0 













        
Acc.  Gene TC00 TC02 TC04 TC08 TC24 























PSPC1 PSP1 2.0 0 0 0 0 





























































2 P18669 PGAM1 PGAMA 
CDABP0006 
3.0 0 0 0 0 














1 Q15366 PCBP2 5.0 5.5 0 0 5.053904

























































































1 P28066 PSMA5 1.0 0 0 0 1.263476


















































1 Q8N163 KIAA1967 DBC1 2.0 0 1.659827
9 
0 0 
P31949 S100A11 MLN70 
S100C 








        























































7 P43487 RANBP1 2.0 0 1.659827
9 
0 0 



















3 P62834 RAP1A KREV1 6.0 3.3 0 0 0 







1 P52565 ARHGDIA GDIA1 2.0 0 0 0 0 































































































3 Q9Y5M8 SRPRB PSEC0230 1.0 1.098554
5 
0 0 0 
























Q12874 SF3A3 SAP61 1.0 0 0 1.130238
8 
1.263476









0.0 0 0 2.260477
7 
0 























5 Q9UJZ1 STOML2 SLP2 
HSPC108 
2.0 0 0 0 0 
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 Acc. Gene TC00 TC02 TC04 TC08 TC24 
















Q969G3 SMARCE1 BAF57 1.0 0 0 1.130238
8 
0 









3 P48643 CCT5 CCTE 
KIAA0098 
2.0 0 0 1.130238
8 
0 

















































































1 P37802 TAGLN2 KIAA0120 
CDABP0035 
4.0 3.3 0 6.781433
1 
5.053904












































4 Q13641 TPBG 5T4 6.0 1.098554
5 
0 0 0 












Q9BQE3 TUBA1C TUBA6 4.0 0 0 0 0 






















































0 0 0 
Q00341 HDLBP HBP VGL 3.0 2.197109
1 
0 0 0 




















        














Replicate Two  
 




        
Acc. Gene TC00 TC02 TC04 TC08 TC24 
P61604 HSPE1 7.045928 8.954506 10.19414 11 11.28307 
P27348 YWHAQ 4.026245 0 0 3 3.223733 
Q16698 DECR1 DECR 1.006561 2.238627 1.699023 2 6.447466 
P62333 PSMC6 SUG2 3.019684 1.119313 1.699023 3 1.611867 
P17980 PSMC3 TBP1 11.07217 10.07382 5.097068 4 3.223733 
O00231 PSMD11 5.032806 2.238627 5.097068 4 9.671199 
Q9Y3D9 MRPS23 CGI-138 
HSPC329 
3.019684 1.119313 1.699023 2 1.611867 
P52815 MRPL12 RPML12 10.06561 7.835193 10.19414 9 8.059333 
Q8N983 MRPL43 1.006561 0 0 2 1.611867 
Q8N5N7 MRPL50 1.006561 0 0 0 3.223733 
Q99714 HSD17B10 ERAB 
HADH2 MRPP2 
11.07217 13.43176 20.38827 13 11.28307 
P46783 RPS10 4.026245 6.71588 5.097068 2 4.8356 
P25398 RPS12 3.019684 3.35794 0 1 0 
P62263 RPS14 PRO2640 2.013122 5.596567 5.097068 2 4.8356 
P08708 RPS17 3.019684 3.35794 6.796091 4 6.447466 
P39019 RPS19 12.07873 11.19313 11.89316 11 11.28307 
P15880 RPS2 RPS4 6.039367 6.71588 8.495114 4 3.223733 
P60866 RPS20 1.006561 4.477253 3.398046 2 4.8356 
P62847 RPS24 2.013122 0 1.699023 1 0 
P62857 RPS28 0 2.238627 1.699023 1 1.611867 
P23396 RPS3 OK/SW-cl.26 5.032806 8.954506 8.495114 6 6.447466 
P46782 RPS5 9.059051 15.67039 15.29121 12 12.89493 
P62753 RPS6 OK/SW-cl.2 1.006561 2.238627 0 0 0 
P62081 RPS7 1.006561 0 1.699023 1 1.611867 
P08865 RPSA LAMBR LAMR1 0 3.35794 5.097068 3 6.447466 
P08195 SLC3A2 MDU1 9.059051 6.71588 11.89316 8 8.059333 
Q96IR7 HPDL GLOXD1 5.032806 5.596567 6.796091 7 8.059333 
P10809 HSPD1 HSP60 71.46584 88.42575 95.14528 85 61.25093 
P05387 RPLP2 D11S2243E 
RPP2 
1.006561 4.477253 1.699023 2 1.611867 
 230 
P62913 RPL11 5.032806 10.07382 11.89316 7 6.447466 
P18621 RPL17 0 0 0 1 3.223733 
Q07020 RPL18 2.013122 3.35794 0 1 0 
P84098 RPL19 3.019684 4.477253 1.699023 3 3.223733 
P46778 RPL21 1.006561 4.477253 3.398046 2 4.8356 
P83731 RPL24 8.052489 16.7897 10.19414 9 8.059333 
P61254 RPL26 1.006561 1.119313 0 1 1.611867 
P46776 RPL27A 1.006561 1.119313 1.699023 1 1.611867 
Q02878 RPL6 TXREB1 0 2.238627 5.097068 1 1.611867 
P62424 RPL7A SURF-3 SURF3 7.045928 11.19313 8.495114 6 8.059333 
P11021 HSPA5 GRP78 24.15747 40.29528 32.28143 36 22.56613 
P24752 ACAT1 ACAT MAT 3.019684 3.35794 8.495114 5 4.8356 
Q99798 ACO2 5.032806 8.954506 1.699023 3 4.8356 
P60709 ACTB 27.17715 32.46009 49.27166 38 41.90853 
P63261 ACTG1 ACTB ACTG 4.026245 0 0 0 0 
P54819 AK2 ADK2 4.026245 5.596567 8.495114 6 8.059333 
Q9HDC9 APMAP C20orf3 
UNQ1869/PRO4305 
1.006561 0 0 2 1.611867 
P12235 SLC25A4 ANT1 6.039367 3.35794 3.398046 4 3.223733 
P05141 SLC25A5 ANT2 16.10498 7.835193 28.88339 22 19.3424 
P12236 SLC25A6 ANT3 
CDABP0051 
6.039367 8.954506 6.796091 10 9.671199 
O43707 ACTN4 29.19027 24.62489 30.58241 19 16.11867 
P06733 ENO1 ENO1L1 MBPB1 
MPB1 
12.07873 5.596567 11.89316 14 11.28307 
P07355 ANXA2 ANX2 ANX2L4 
CAL1H LPC2D 
15.09842 11.19313 16.99023 9 16.11867 
P08133 ANXA6 ANX6 4.026245 3.35794 0 0 1.611867 
Q07812 BAX BCL2L4 1.006561 0 0 0 3.223733 
O95831 AIFM1 AIF PDCD8 12.07873 5.596567 8.495114 5 8.059333 
P00505 GOT2 9.059051 3.35794 3.398046 5 3.223733 
P25705 ATP5A1 ATP5A 
ATP5AL2 ATPM 
28.18371 24.62489 20.38827 22 19.3424 
P06576 ATP5B ATPMB ATPSB 38.24932 34.69871 33.98046 34 33.8492 
O75947 ATP5H My032 2.013122 1.119313 0 2 0 
P56385 ATP5I ATP5K 4.026245 0 1.699023 4 6.447466 
P48047 ATP5O ATPO 14.09186 14.55107 6.796091 13 9.671199 
P53396 ACLY 3.019684 0 1.699023 1 1.611867 
O00571 DDX3X DBX DDX3 0 4.477253 3.398046 0 3.223733 
O15523 DDX3Y DBY 2.013122 0 0 1 0 
P13995 MTHFD2 NMDMC 0 1.119313 0 3 0 
Q6NUK1 SLC25A24 APC1 
MCSC1 SCAMC1 
3.019684 2.238627 0 2 1.611867 
P27824 CANX 9.059051 2.238627 3.398046 2 3.223733 
P27797 CALR CRTC 1.006561 7.835193 5.097068 7 6.447466 
P35221 CTNNA1 16.10498 7.835193 8.495114 15 8.059333 
P35222 CTNNB1 CTNNB 
OK/SW-cl.35 PRO2286 
1.006561 0 0 1 0 
O60716 CTNND1 KIAA0384 2.013122 0 0 0 0 
P07339 CTSD CPSD 0 10.07382 1.699023 7 4.8356 
 231 





        
Acc. Gene TC00 TC02 TC04 TC08 TC24 
Q13185 CBX3 14.09186 16.7897 11.89316 17 16.11867 
P45973 CBX5 HP1A 9.059051 6.71588 8.495114 6 6.447466 
O75390 CS 2.013122 2.238627 1.699023 1 1.611867 
Q00610 CLTC CLH17 CLTCL2 
KIAA0034 
4.026245 5.596567 1.699023 4 4.8356 
P09497 CLTB 1.006561 0 0 1 0 
P23528 CFL1 CFL 12.07873 16.7897 20.38827 15 8.059333 
Q9NX63 CHCHD3 6.039367 2.238627 1.699023 2 3.223733 
O75534 CSDE1 D1S155E 
KIAA0885 NRU UNR 
2.013122 1.119313 1.699023 2 0 
Q9BR76 CORO1B 1.006561 2.238627 1.699023 0 1.611867 
P12532 CKMT1A CKMT; 
CKMT1B CKMT 
2.013122 5.596567 1.699023 7 6.447466 
Q92879 CELF1 BRUNOL2 
CUGBP CUGBP1 
6.039367 5.596567 5.097068 3 6.447466 
P31930 UQCRC1 6.039367 7.835193 3.398046 6 6.447466 
P22695 UQCRC2 6.039367 0 6.796091 2 6.447466 
P07919 UQCRH 7.045928 3.35794 6.796091 6 12.89493 
P20674 COX5A 3.019684 0 0 0 0 
P10606 COX5B 6.039367 7.835193 3.398046 5 1.611867 
P14854 COX6B1 COX6B 8.052489 10.07382 6.796091 8 6.447466 
P15954 COX7C 3.019684 2.238627 5.097068 4 3.223733 
Q07065 CKAP4 6.039367 3.35794 0 2 0 
O43175 PHGDH PGDH3 1.006561 1.119313 3.398046 4 1.611867 
Q13011 ECH1 0 0 0 0 3.223733 
P30038 ALDH4A1 ALDH4 
P5CDH 
1.006561 2.238627 0 2 3.223733 
P54886 ALDH18A1 GSAS 
P5CS PYCS 
3.019684 2.238627 0 0 3.223733 
P15924 DSP 1.006561 1.119313 1.699023 1 1.611867 
P60981 DSTN ACTDP DSN 7.045928 3.35794 3.398046 5 1.611867 
Q9NR28 DIABLO SMAC 0 1.119313 1.699023 4 3.223733 
P09622 DLD GCSL LAD PHE3 4.026245 4.477253 6.796091 8 3.223733 
Q92878 RAD50 2.013122 2.238627 0 1 4.8356 
P49736 MCM2 BM28 CCNL1 
CDCL1 KIAA0030 
1.006561 1.119313 3.398046 5 1.611867 
P25205 MCM3 2.013122 0 3.398046 2 1.611867 
P33991 MCM4 CDC21 0 0 1.699023 2 3.223733 
P11387 TOP1 6.039367 2.238627 0 2 3.223733 
P78527 PRKDC HYRC HYRC1 7.045928 2.238627 1.699023 2 0 
P04843 RPN1 8.052489 7.835193 8.495114 8 8.059333 
Q9UPN9 TRIM33 KIAA1113 
RFG7 TIF1G 
8.052489 3.35794 1.699023 4 4.8356 
P13804 ETFA 4.026245 4.477253 3.398046 3 6.447466 
P38117 ETFB FP585 1.006561 5.596567 0 3 1.611867 
P68104 EEF1A1 EEF1A EF1A 
LENG7 
2.013122 4.477253 1.699023 4 3.223733 
P29692 EEF1D EF1D 7.045928 7.835193 5.097068 7 4.8356 
P26641 EEF1G EF1G 
PRO1608 
4.026245 3.35794 6.796091 5 3.223733 
 232 




        
Acc. Gene TC00 TC02 TC04 TC08 TC24 




3.019684 17.90901 8.495114 19 19.3424 
P30084 ECHS1 6.039367 15.67039 10.19414 16 12.89493 
P58107 EPPK1 EPIPL 10.06561 5.596567 1.699023 2 1.611867 
P16422 EPCAM GA733-2 
M1S2 M4S1 MIC18 
2.013122 3.35794 3.398046 4 4.8356 
P60842 EIF4A1 DDX2A EIF4A 1.006561 5.596567 5.097068 3 0 
Q99613 EIF3C EIF3S8; EIF3CL 0 0 1.699023 1 0 
Q04637 EIF4G1 EIF4F EIF4G 
EIF4GI 
2.013122 0 0 2 0 
Q9BSJ8 ESYT1 FAM62A 
KIAA0747 MBC2 
8.052489 5.596567 5.097068 9 9.671199 
P47756 CAPZB 2.013122 0 0 1 1.611867 
Q96AE4 FUBP1 12.07873 22.38627 16.99023 14 16.11867 
Q92945 KHSRP FUBP2 19.12466 13.43176 18.68925 20 12.89493 
Q96I24 FUBP3 FBP3 2.013122 1.119313 0 1 1.611867 
P49327 FASN FAS 18.1181 12.31245 6.796091 11 9.671199 
P22830 FECH 2.013122 0 0 0 0 
P21333 FLNA FLN FLN1 18.1181 15.67039 33.98046 29 16.11867 
O75369 FLNB FLN1L FLN3 
TABP TAP 
4.026245 4.477253 1.699023 7 6.447466 
P04075 ALDOA ALDA 14.09186 13.43176 8.495114 21 9.671199 
P07954 FH 5.032806 3.35794 5.097068 5 4.8356 
P11413 G6PD 0 0 0 3 1.611867 
P06744 GPI 2.013122 2.238627 3.398046 2 3.223733 
P14314 PRKCSH G19P1 7.045928 15.67039 15.29121 15 11.28307 
P04406 GAPDH GAPD 
CDABP0047 OK/SW-
14.09186 10.07382 3.398046 13 9.671199 
P43304 GPD2 6.039367 1.119313 0 4 4.8356 
Q08379 GOLGA2 6.039367 4.477253 5.097068 1 4.8356 
P01111 NRAS HRAS1 4.026245 0 0 4 6.447466 
P62826 RAN ARA24 OK/SW-
cl.81 
6.039367 10.07382 15.29121 11 9.671199 
P62879 GNB2 1.006561 1.119313 3.398046 3 4.8356 
Q14344 GNA13 3.019684 0 0 0 0 
P08107 HSPA1A HSPA1; 
HSPA1B 
21.13778 20.14764 11.89316 23 19.3424 
P11142 HSPA8 HSC70 HSP73 
HSPA10 
49.3215 39.17597 18.68925 21 51.57973 
Q92598 HSPH1 HSP105 
HSP110 KIAA0201 
2.013122 2.238627 1.699023 3 3.223733 
Q12931 TRAP1 HSP75 8.052489 7.835193 3.398046 7 4.8356 
P04792 HSPB1 HSP27 HSP28 11.07217 10.07382 8.495114 8 9.671199 
P07900 HSP90AA1 HSP90A 
HSPC1 HSPCA 
15.09842 16.7897 10.19414 20 17.73053 
P08238 HSP90AB1 HSP90B 
HSPC2 HSPCB 
20.13122 27.98283 18.68925 32 27.40173 
P30519 HMOX2 HO2 4.026245 1.119313 0 2 3.223733 
Q99729 HNRNPAB ABBP1 
HNRPAB 
6.039367 5.596567 6.796091 3 3.223733 
P09651 HNRNPA1 HNRPA1 22.14435 20.14764 22.0873 17 20.95426 
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P52597 HNRNPF HNRPF 7.045928 6.71588 6.796091 4 6.447466 
P31943 HNRNPH1 HNRPH 
HNRPH1 
10.06561 10.07382 11.89316 9 11.28307 
P55795 HNRNPH2 FTP3 
HNRPH2 
0 2.238627 0 1 0 
P61978 HNRNPK HNRPK 19.12466 25.74421 30.58241 22 12.89493 
P14866 HNRNPL HNRPL 
P/OKcl.14 
5.032806 4.477253 5.097068 4 4.8356 
P52272 HNRNPM HNRPM 
NAGR1 
24.15747 30.22146 10.19414 37 40.29666 
O60506 SYNCRIP HNRPQ 
NSAP1 
9.059051 5.596567 3.398046 8 9.671199 
O43390 HNRNPR HNRPR 2.013122 1.119313 0 0 1.611867 
Q00839 HNRNPU HNRPU 
SAFA U21.1 
9.059051 8.954506 5.097068 3 4.8356 
P22626 HNRNPA2B1 
HNRPA2B1 
8.052489 6.71588 3.398046 3 3.223733 
P07910 HNRNPC HNRPC 3.019684 3.35794 8.495114 2 1.611867 
P19367 HK1 3.019684 2.238627 0 3 4.8356 
P16403 HIST1H1C H1F2 5.032806 4.477253 5.097068 5 9.671199 
Q92522 H1FX 3.019684 3.35794 1.699023 3 3.223733 
Q09028 RBBP4 RBAP48 4.026245 5.596567 5.097068 5 4.8356 
Q16836 HADH HAD HADHSC 
SCHAD 
3.019684 3.35794 1.699023 4 6.447466 
Q9Y4L1 HYOU1 GRP170 
ORP150 
0 4.477253 3.398046 4 1.611867 
Q14974 KPNB1 NTF97 7.045928 11.19313 8.495114 5 4.8356 
Q8TEX9 IPO4 IMP4B RANBP4 0 3.35794 0 0 0 
Q12906 ILF3 DRBF 
MPHOSPH4 NF90 
3.019684 0 1.699023 1 0 
P50213 IDH3A 7.045928 8.954506 6.796091 9 8.059333 
P48735 IDH2 6.039367 6.71588 0 5 11.28307 
P14923 JUP CTNNG DP3 2.013122 0 0 0 0 
P05783 KRT18 CYK18 PIG46 38.24932 39.17597 81.55309 49 38.6848 
P08727 KRT19 61.40023 52.60773 79.85407 50 30.62546 
P04264 KRT1 KRTA 20.13122 7.835193 15.29121 13 14.5068 
P13647 KRT5 1.006561 0 0 1 0 
Q8N1N4 KRT78 K5B KB40 5.032806 5.596567 11.89316 6 6.447466 
P05787 KRT8 CYK8 124.8136 125.3631 208.9798 142 87.04079 
Q86UP2 KTN1 CG1 KIAA0004 6.039367 1.119313 3.398046 7 3.223733 
P42166 TMPO LAP2 0 2.238627 0 2 1.611867 
P42167 TMPO LAP2 7.045928 5.596567 5.097068 3 4.8356 
P20700 LMNB1 LMN2 LMNB 2.013122 2.238627 1.699023 0 0 
P46379 BAG6 BAT3 G3 0 1.119313 0 0 1.611867 
P42704 LRPPRC LRP130 4.026245 2.238627 0 1 1.611867 
Q96AG4 LRRC59 PRO1855 17.11154 10.07382 10.19414 11 9.671199 
P05455 SSB 4.026245 4.477253 6.796091 5 3.223733 
P40926 MDH2 45.29525 66.03948 62.86384 60 64.47466 
P43243 MATR3 KIAA0723 5.032806 1.119313 0 2 0 
P11310 ACADM 1.006561 2.238627 3.398046 1 3.223733 
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Acc. Gene TC00 TC02 TC04 TC08 TC24 




0 3.35794 3.398046 3 4.8356 
O60220 TIMM8A DDP DDP1 
TIM8A 
0 8.954506 6.796091 8 11.28307 
Q15388 TOMM20 KIAA0016 2.013122 0 0 0 0 
O94826 TOMM70A KIAA0719 
TOM70 
4.026245 4.477253 5.097068 5 3.223733 
Q16891 IMMT H P PIG4 
PIG52 
7.045928 2.238627 5.097068 2 3.223733 
P60660 MYL6 7.045928 11.19313 6.796091 9 3.223733 
P35579 MYH9 2.013122 2.238627 1.699023 2 1.611867 
O14745 SLC9A3R1 NHERF 
NHERF1 
5.032806 5.596567 6.796091 7 4.8356 
Q16718 NDUFA5 5.032806 2.238627 3.398046 3 4.8356 
O00217 NDUFS8 4.026245 4.477253 3.398046 2 1.611867 
P28331 NDUFS1 2.013122 0 0 0 0 
O15394 NCAM2 NCAM21 4.026245 2.238627 3.398046 2 4.8356 
Q09666 AHNAK PM227 11.07217 12.31245 3.398046 11 9.671199 
Q14697 GANAB G2AN 
KIAA0088 
3.019684 11.19313 11.89316 10 16.11867 
Q15233 NONO NRB54 19.12466 15.67039 3.398046 17 17.73053 
Q02818 NUCB1 NUC 4.026245 3.35794 3.398046 4 4.8356 
Q9NR30 DDX21 0 0 0 3 3.223733 
P19338 NCL 7.045928 8.954506 11.89316 8 4.8356 
P06748 NPM1 NPM 25.16403 24.62489 32.28143 24 27.40173 
O75607 NPM3 4.026245 2.238627 8.495114 7 6.447466 
Q5SRE5 NUP188 KIAA0169 1.006561 0 0 1 0 
P12270 TPR 8.052489 7.835193 10.19414 5 4.8356 
P15531 NME1 NDPKA NM23 3.019684 7.835193 5.097068 13 6.447466 
Q99733 NAP1L4 NAP2 1.006561 1.119313 0 2 3.223733 
P50897 PPT1 PPT 0 0 0 1 1.611867 
Q8WXF1 PSPC1 PSP1 2.013122 2.238627 1.699023 1 4.8356 
P62937 PPIA CYPA 23.15091 31.34077 28.88339 20 37.07293 
P23284 PPIB CYPB 0 5.596567 1.699023 7 6.447466 
P30405 PPIF CYP3 5.032806 8.954506 6.796091 9 8.059333 
Q02790 FKBP4 FKBP52 1.006561 2.238627 0 2 3.223733 
Q9Y3E5 PTRH2 BIT1 PTH2 
CGI-147 
1.006561 1.119313 0 0 1.611867 
Q06830 PRDX1 PAGA PAGB 
TDPX2 
7.045928 13.43176 11.89316 10 16.11867 
Q13162 PRDX4 2.013122 7.835193 10.19414 10 12.89493 
P30041 PRDX6 AOP2 
KIAA0106 
3.019684 1.119313 1.699023 1 1.611867 
P51659 HSD17B4 EDH17B4 3.019684 4.477253 1.699023 6 6.447466 
Q9Y285 FARSA FARS FARSL 
FARSLA 
0 3.35794 1.699023 1 1.611867 
P00558 PGK1 PGKA MIG10 
OK/SW-cl.110 
12.07873 5.596567 13.59218 10 9.671199 
Q15149 PLEC PLEC1 16.10498 8.954506 10.19414 8 6.447466 
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Acc. Gene TC00 TC02 TC04 TC08 TC24 
Q15366 PCBP2 4.026245 4.477253 3.398046 4 4.8356 
P11940 
PABPC1 PAB1 PABP1 
PABPC2 
3.019684 4.477253 1.699023 3 4.8356 
Q86U42 PABPN1 PAB2 PABP2 2.013122 2.238627 0 1 1.611867 
P26599 PTBP1 PTB 9.059051 8.954506 11.89316 11 8.059333 
P02545 LMNA LMN1 8.052489 10.07382 8.495114 5 8.059333 
Q92841 DDX17 8.052489 0 0 0 0 
P17844 DDX5 G17P1 HELR 
HLR1 
22.14435 13.43176 15.29121 14 12.89493 
P07737 PFN1 7.045928 7.835193 10.19414 7 12.89493 
P35232 PHB 20.13122 13.43176 15.29121 14 6.447466 
Q99623 PHB2 BAP REA 8.052489 8.954506 3.398046 8 9.671199 
P12004 PCNA 1.006561 2.238627 3.398046 3 3.223733 
Q9UQ80 PA2G4 EBP1 0 1.119313 0 3 1.611867 
P61289 PSME3 0 0 0 4 3.223733 
P25787 PSMA2 HC3 PSC3 3.019684 1.119313 0 3 1.611867 
P60900 PSMA6 PROS27 5.032806 5.596567 5.097068 6 11.28307 
O14818 PSMA7 HSPC 3.019684 0 0 2 1.611867 
P07237 P4HB ERBA2L PDI 
PDIA1 PO4DB 
9.059051 34.69871 42.47557 35 33.8492 
P30101 PDIA3 ERP57 ERP60 
GRP58 
10.06561 22.38627 22.0873 24 29.0136 
P13667 PDIA4 ERP70 ERP72 4.026245 15.67039 11.89316 21 16.11867 
Q15084 PDIA6 ERP5 P5 
TXNDC7 
7.045928 23.50558 22.0873 22 20.95426 
Q9C005 DPY30 2.013122 5.596567 1.699023 5 4.8356 
Q86UE4 MTDH AEG1 LYRIC 1.006561 0 0 3 1.611867 
Q9BPW8 NIPSNAP1 2.013122 2.238627 0 3 1.611867 
P31949 S100A11 MLN70 
S100C 
4.026245 2.238627 5.097068 2 4.8356 
Q96FQ6 S100A16 S100F 
AAG13 
4.026245 3.35794 5.097068 3 1.611867 
Q16740 CLPP 0 1.119313 0 3 1.611867 
B2RPK0 HMGB1P1 HMG1L1 
HMGB1L1 
4.026245 4.477253 8.495114 9 12.89493 
P0C6E5   2.013122 0 1.699023 2 3.223733 
P98179 RBM3 RNPL 10.06561 10.07382 6.796091 11 8.059333 
Q9Y383 LUC7L2 CGI-59 CGI-74 2.013122 4.477253 0 3 3.223733 
P32322 PYCR1 2.013122 4.477253 3.398046 3 11.28307 
Q96C36 PYCR2 3.019684 0 0 2 1.611867 
P11498 PC 4.026245 3.35794 1.699023 2 3.223733 
P11177 PDHB PHE1B 1.006561 2.238627 3.398046 3 3.223733 
P14618 PKM2 OIP3 PK2 PK3 
PKM 
13.0853 14.55107 13.59218 16 17.73053 
Q6IAA8 PDRO C11orf59 
PP7157 
2.013122 1.119313 0 2 1.611867 
Q13283 G3BP1 G3BP 3.019684 2.238627 1.699023 5 1.611867 
P62491 RAB11A RAB11 3.019684 4.477253 3.398046 2 4.8356 
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P62834 RAP1A KREV1 6.039367 0 0 3 0 
A6NIZ1   5.032806 6.71588 5.097068 5 3.223733 
P18754 RCC1 CHC1 3.019684 2.238627 3.398046 1 6.447466 
P62745 RHOB ARH6 ARHB 4.026245 1.119313 1.699023 1 1.611867 
Q9P2E9 RRBP1 KIAA1398 4.026245 3.35794 1.699023 4 6.447466 
Q8N7H5 PAF1 PD2 0 0 0 1 1.611867 
Q96PK6 RBM14 SIP 6.039367 2.238627 10.19414 4 3.223733 
Q14498 RBM39 HCC1 RNPC2 8.052489 2.238627 3.398046 2 4.8356 
P35637 FUS TLS 6.039367 7.835193 6.796091 6 4.8356 
Q9Y230 RUVBL2 INO80J TIP48 
TIP49B CGI-46 
7.045928 2.238627 3.398046 4 4.8356 
P31153 MAT2A AMS2 MATA2 0 0 0 1 3.223733 
P16615 ATP2A2 ATP2B 9.059051 4.477253 0 5 0 
P34897 SHMT2 13.0853 22.38627 16.99023 19 16.11867 
Q9UQ35 SRRM2 KIAA0324 
SRL300 SRM300 
8.052489 11.19313 6.796091 5 6.447466 
Q07955 SRSF1 ASF SF2 
SF2P33 SFRS1 
3.019684 2.238627 3.398046 2 3.223733 
Q05519 SRSF11 SFRS11 3.019684 0 0 1 1.611867 
P50454 SERPINH1 CBP1 
CBP2 HSP47 
4.026245 11.19313 13.59218 15 16.11867 
Q9H9B4 SFXN1 24.15747 17.90901 16.99023 14 9.671199 
Q9BWM7 SFXN3 5.032806 5.596567 5.097068 4 4.8356 
P37108 SRP14 3.019684 1.119313 1.699023 1 1.611867 
Q04837 SSBP1 SSBP 11.07217 12.31245 11.89316 9 16.11867 
P62318 SNRPD3 7.045928 4.477253 3.398046 2 8.059333 
P05023 ATP1A1 7.045928 2.238627 5.097068 3 8.059333 
P55011 SLC12A2 NKCC1 1.006561 0 0 1 0 
Q13813 SPTAN1 SPTA2 2.013122 1.119313 0 0 0 
Q13838 BAT1 UAP56 4.026245 0 0 0 0 
O75533 SF3B1 SAP155 5.032806 1.119313 0 1 0 
Q15393 SF3B3 KIAA0017 
SAP130 
0 1.119313 0 0 3.223733 
Q8WU68 U2AF1L4 U2AF1-RS3 
U2AF1L3 
3.019684 1.119313 0 0 0 
P23246 SFPQ PSF 24.15747 17.90901 18.68925 21 24.178 
P37268 FDFT1 3.019684 0 0 0 1.611867 
Q9GZT3 SLIRP C14orf156 DC23 
DC50 PD04872 
5.032806 3.35794 5.097068 4 4.8356 
Q7KZF4 SND1 TDRD11 9.059051 13.43176 10.19414 5 9.671199 
Q9UJZ1 STOML2 SLP2 
HSPC108 
7.045928 3.35794 1.699023 3 0 
P38646 HSPA9 GRP75 
HSPA9B 
40.26245 45.89185 44.17459 40 37.07293 
P31948 STIP1 5.032806 6.71588 5.097068 4 6.447466 
P31040 SDHA SDH2 SDHF 5.032806 5.596567 5.097068 6 8.059333 
Q96I99 SUCLG2 0 3.35794 1.699023 3 1.611867 
P55809 OXCT1 OXCT SCOT 2.013122 4.477253 1.699023 2 3.223733 
Q8TAQ2 SMARCC2 BAF170 3.019684 0 1.699023 1 1.611867 
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P50991 CCT4 CCTD SRB 1.006561 1.119313 0 1 0 
P48643 CCT5 CCTE KIAA0098 2.013122 1.119313 0 4 0 
Q99832 CCT7 CCTH NIP7-1 1.006561 0 0 2 0 
P49368 CCT3 CCTG TRIC5 8.052489 4.477253 3.398046 10 3.223733 
P50990 CCT8 C21orf112 CCTQ 
KIAA0002 
5.032806 1.119313 1.699023 2 1.611867 
Q8NBS9 TXNDC5 TLP46 
UNQ364/PRO700 
0 4.477253 5.097068 3 8.059333 
P30048 PRDX3 AOP1 7.045928 12.31245 6.796091 9 6.447466 
Q86V81 THOC4 ALY BEF 15.09842 8.954506 11.89316 11 9.671199 
Q5JTV8 TOR1AIP1 2.013122 2.238627 1.699023 3 1.611867 
P51532 SMARCA4 BAF190A 
BRG1 SNF2B SNF2L4 
1.006561 0 3.398046 1 0 
Q15369 TCEB1 1.006561 0 0 1 0 
Q13263 TRIM28 KAP1 RNF96 
TIF1B 
11.07217 7.835193 10.19414 8 12.89493 
P02786 TFRC 8.052489 2.238627 3.398046 3 4.8356 
P37802 TAGLN2 KIAA0120 
CDABP0035 
4.026245 4.477253 1.699023 6 8.059333 
P55072 VCP 20.13122 24.62489 16.99023 22 12.89493 
P29401 TKT 1.006561 5.596567 5.097068 4 4.8356 
Q9BSH4 TACO1 CCDC44 
PRO0477 
1.006561 2.238627 1.699023 4 4.8356 
Q9BVK6 TMED9 GP25L2 4.026245 2.238627 0 3 6.447466 
P40939 HADHA HADH 16.10498 8.954506 6.796091 16 17.73053 
P60174 TPI1 TPI 5.032806 10.07382 18.68925 9 17.73053 
Q13641 TPBG 5T4 3.019684 7.835193 5.097068 6 1.611867 
P09493 TPM1 C15orf13 TMSA 0 1.119313 1.699023 2 1.611867 
P06753 TPM3 5.032806 2.238627 3.398046 6 6.447466 
Q9BQE3 TUBA1C TUBA6 8.052489 7.835193 11.89316 8 4.8356 
Q13748 TUBA3C TUBA2; 
TUBA3D 
1.006561 1.119313 0 0 0 
P68366 TUBA4A TUBA1 0 3.35794 0 0 0 
P07437 TUBB TUBB5 OK/SW-
cl.56 
32.20996 13.43176 13.59218 18 11.28307 
P68371 TUBB2C 17.11154 15.67039 13.59218 15 11.28307 
O43290 SART1 3.019684 0 0 0 1.611867 
P62979 RPS27A UBA80 
UBCEP1 
3.019684 6.71588 3.398046 4 4.8356 
P22314 UBA1 A1S9T UBE1 1.006561 0 0 1 1.611867 
Q9Y3I0 C22orf28 HSPC117 2.013122 2.238627 1.699023 1 3.223733 
Q969H8 C19orf10 IL25 0 3.35794 5.097068 5 6.447466 
O75396 SEC22B SEC22L1 7.045928 1.119313 1.699023 2 3.223733 
Q00341 HDLBP HBP VGL 0 1.119313 0 2 1.611867 
P21796 VDAC1 VDAC 15.09842 8.954506 15.29121 8 6.447466 
P45880 VDAC2 8.052489 2.238627 1.699023 1 0 
P13010 XRCC5 G22P2 1.006561 3.35794 1.699023 4 8.059333 



















































Proteins altered two-fold after Nutlin treatment detected in PAcIFIC Screen in two 
replicates (FC – Fold Change) 
 










  FC 1 FC 2 
    0HR 2HR 0HR 2Hr     
Q9UJZ1 STOML2 2 0 7.045928 3.35794 Down 0.476579 
P53396 ACLY 1 0 3.019684 0 Down Down 
P28331 NDUFS1 2 0 2.013122 0 Down Down 
P60981 DSTN 4 1.098555 7.045928 3.35794 0.274639 0.476579 
O43290 SART1 4 1.098555 3.019684 0 0.274639 Down 
Q04637 EIF4G1 3 1.098555 2.013122 0 0.366185 Down 
P55011 SLC12A2  3 1.098555 1.006561 0 0.366185 Down 
P50990 CCT8 6 2.197109 5.032806 1.119313 0.366185 0.222403 
O95831 AIFM1  3 1.098555 12.07873 5.596567 0.366185 0.46334 
P04264 KRT1  16 6.591327 20.13122 7.835193 0.411958 0.389206 
Q96PK6 RBM14 10 4.394218 6.039367 2.238627 0.439422 0.370672 
P78527 PRKDC  7 3.295664 7.045928 2.238627 0.470809 0.317719 
P56385 ATP5I  7 3.295664 4.026245 0 0.470809 Down 
Q9Y383 LUC7L2  2 4.394218 2.013122 4.477253 2.197109 2.224034 
Q02878 RPL6  1 2.197109 0 2.238627 2.197109 Up 
P62857 RPS28 1 2.197109 0 2.238627 2.197109 Up 
P23284 PPIB 3 6.591327 0 5.596567 2.197109 Up 
P13010 XRCC5  2 4.394218 1.006561 3.35794 2.197109 3.336052 
P12004 PCNA 3 6.591327 1.006561 2.238627 2.197109 2.224034 
P14314 PRKCSH 6 15.37976 7.045928 15.67039 2.563294 2.224034 
Q9BSH4 TACO1 2 5.492773 1.006561 2.238627 2.746386 2.224034 
P07237 P4HB  13 39.54796 9.059051 34.69871 3.042151 3.830281 
O60220 TIMM8A  2 6.591327 0 8.954506 3.295664 Up 
Q13162 PRDX4 3 9.886991 2.013122 7.835193 3.295664 3.89206 





4 14.28121 3.019684 17.90901 3.570302 5.930758 
Q9UQ80 PA2G4 1 4.394218 0 1.119313 4.394218 Up 
Q14697 GANAB  3 14.28121 3.019684 11.19313 4.760403 3.706724 










  FC 1 FC 2 
    0HR 2HR 0HR 2Hr     
Q9Y6X8 ZHX2  0 1.098555 0 1.119313 Up Up 
Q9Y5L4 TIMM13  0 3.295664 0 3.35794 Up Up 
Q9Y4L1 HYOU1  0 2.197109 0 4.477253 Up Up 
P60842 EIF4A1  0 2.197109 1.006561 5.596567 Up 5.560086 
















































  FC 1 FC 2 
    0HR 4HR 0HR 4HR     
Q9Y383 LUC7L2  2 0 2.013122 0 Down Down 
Q9UJZ1 STOML2 2 0 7.045928 1.699023 Down 0.241135 
Q9NX63 CHCHD3 7 0 6.039367 1.699023 Down 0.281325 
Q9HDC9 APMAP  2 0 1.006561 0 Down Down 
Q99733 NAP1L4  3 0 1.006561 0 Down Down 
Q92878 RAD50 1 0 2.013122 0 Down Down 
Q86U42 PABPN1 4 0 2.013122 0 Down Down 
Q07065 CKAP4 5 0 6.039367 0 Down Down 
Q04637 EIF4G1 3 0 2.013122 0 Down Down 
Q02818 NUCB1  2 0 4.026245 3.398046 Down 0.843974 
P62834 RAP1A  6 0 6.039367 0 Down Down 
P56385 ATP5I  7 0 4.026245 1.699023 Down 0.421987 
P55011 SLC12A2  3 0 1.006561 0 Down Down 
P54886 ALDH18A1  7 0 3.019684 0 Down Down 
P53396 ACLY 1 0 3.019684 1.699023 Down 0.562649 
P51991 HNRNPA3 2 0 1.006561 0 Down Down 
P48735 IDH2 6 0 6.039367 0 Down Down 
P48643 CCT5  2 0 2.013122 0 Down Down 
P47756 CAPZB 2 0 2.013122 0 Down Down 
P42704 LRPPRC 2 0 4.026245 0 Down Down 
P37802 TAGLN2 4 0 4.026245 1.699023 Down 0.421987 
P30519 HMOX2 6 0 4.026245 0 Down Down 
P28331 NDUFS1 2 0 2.013122 0 Down Down 
P27824 CANX 7 0 9.059051 3.398046 Down 0.3751 
P19367 HK1 3 0 3.019684 0 Down Down 
P17980 PSMC3  4 0 11.07217 5.097068 Down 0.460349 
P11387 TOP1 5 0 6.039367 0 Down Down 
P09874 PARP1  4 0 6.039367 1.699023 Down 0.281325 
P01111 NRAS 2 0 4.026245 0 Down Down 
Q99623 PHB2  11 1.659828 8.052489 3.398046 0.150893 0.421987 
Q15233 NONO 20 3.319656 19.12466 3.398046 0.165983 0.177679 
Q92841 DDX17 9 1.659828 8.052489 0 0.184425 Down 
P43304 GPD2 7 1.659828 6.039367 0 0.237118 Down 
P00505 GOT2 6 1.659828 9.059051 3.398046 0.276638 0.3751 
P02786 TFRC 5 1.659828 8.052489 3.398046 0.331966 0.421987 
P58107 EPPK1  13 4.979484 10.06561 1.699023 0.383037 0.168795 
P60981 DSTN  4 1.659828 7.045928 3.398046 0.414957 0.482271 
P48047 ATP5O 15 6.639312 14.09186 6.796091 0.442621 0.482271 
Q09666 AHNAK 25 11.6188 11.07217 3.398046 0.464752 0.3069 










  FC 1 FC 2 
    0HR 4HR 0HR 4HR     
P16615 ATP2A2  7 3.319656 9.059051 0 0.474237 Down 
Q8N1N4 KRT78 6 13.27862 5.032806 11.89316 2.213104 2.363127 
P23284 PPIB 3 6.639312 0 1.699023 2.213104 Up 
P12004 PCNA 3 6.639312 1.006561 3.398046 2.213104 3.375896 
P29401 TKT 2 4.979484 1.006561 5.097068 2.489742 5.063844 
Q13162 PRDX4 3 8.29914 2.013122 10.19414 2.76638 5.063844 
P33991 MCM4 1 3.319656 0 1.699023 3.319656 Up 
P07910 HNRNPC 1 3.319656 3.019684 8.495114 3.319656 2.813246 
P07237 P4HB 13 43.15553 9.059051 42.47557 3.319656 4.688744 
P14625 HSP90B1  4 16.59828 3.019684 8.495114 4.14957 2.813246 
Q14697 GANAB  3 13.27862 3.019684 11.89316 4.426208 3.938545 
P50454 SERPINH1 3 13.27862 4.026245 13.59218 4.426208 3.375896 
Q15084 PDIA6 5 23.23759 7.045928 22.0873 4.647518 3.13476 
P13667 PDIA4 2 14.93845 4.026245 11.89316 7.469226 2.953909 
Q9Y5L4 TIMM13  0 1.659828 0 3.398046 Up Up 







































  FC 1 FC 2 
    0HR 8HR 0HR 8HR     
Q9UJZ1 STOML2  2 0 7.045928 3 Down 0.425778 
Q9BR76 CORO1B 1 0 1.006561 0 Down N/A 
Q8WXF1 PSPC1 2 0 2.013122 1 Down 0.496741 
Q08379 GOLGA2 4 0 6.039367 1 Down 0.16558 
P62834 RAP1A  6 0 6.039367 3 Down 0.496741 
P46783 RPS10 1 0 4.026245 2 Down 0.496741 
P43243 MATR3  3 0 5.032806 2 Down 0.397393 
P42704 LRPPRC  2 0 4.026245 1 Down 0.24837 
P30041 PRDX6  3 0 3.019684 1 Down 0.331161 
P28331 NDUFS1 2 0 2.013122 0 Down Down 
P20700 LMNB1 4 0 2.013122 0 Down Down 
O43290 SART1 4 0 3.019684 0 Down Down 
P58107 EPPK1  13 1.130239 10.06561 2 0.086941 0.198696 
Q16891 IMMT  8 1.130239 7.045928 2 0.14128 0.283852 
Q9NX63 CHCHD3 7 1.130239 6.039367 2 0.161463 0.331161 
P54886 ALDH18A1 7 1.130239 3.019684 0 0.161463 Down 
P30519 HMOX2  6 1.130239 4.026245 2 0.188373 0.496741 
Q15149 PLEC  20 4.520955 16.10498 8 0.226048 0.496741 
Q07065 CKAP4 5 1.130239 6.039367 2 0.226048 0.331161 
Q86U42 PABPN1  4 1.130239 2.013122 1 0.28256 0.496741 
Q05519 SRSF11 4 1.130239 3.019684 1 0.28256 0.331161 
P62318 SNRPD3 7 2.260478 7.045928 2 0.322925 0.283852 
P27824 CANX 7 2.260478 9.059051 2 0.322925 0.220774 
Q00839 HNRNPU 10 3.390717 9.059051 3 0.339072 0.331161 
P50990 CCT8 6 2.260478 5.032806 2 0.376746 0.397393 
P31949 S100A11 3 1.130239 4.026245 2 0.376746 0.496741 
O95831 AIFM1 3 1.130239 12.07873 5 0.376746 0.413951 
P05023 ATP1A1 13 5.651194 7.045928 3 0.434707 0.425778 
P11387 TOP1 5 2.260478 6.039367 2 0.452096 0.331161 
Q99729 HNRNPAB 7 3.390717 6.039367 3 0.484388 0.496741 
P61289 PSME3 1 2.260478 0 4 2.260478 Up 
P13010 XRCC5  2 4.520955 1.006561 4 2.260478 3.973926 
O60220 TIMM8A  2 4.520955 0 8 2.260478 Up 
P12004 PCNA 3 7.911672 1.006561 3 2.637224 2.980445 










  FC 1 FC 2 
    0HR 8HR 0HR 8HR     
P29401 TKT 2 6.781433 1.006561 4 3.390717 3.973926 
Q13162 PRDX4 3 11.30239 2.013122 10 3.767463 4.967408 
P50454 SERPINH1 3 12.43263 4.026245 15 4.144209 3.725556 
Q14697 GANAB  3 13.56287 3.019684 10 4.520955 3.311605 
P14625 HSP90B1  4 18.08382 3.019684 19 4.520955 6.29205 
P12532 CKMT1A  1 5.651194 2.013122 7 5.651194 3.477186 
P13667 PDIA4  2 15.82334 4.026245 21 7.911672 5.215778 
Q9Y5L4 TIMM13  0 1.130239 0 3 Up Up 
Q9Y4L1 HYOU1  0 1.130239 0 4 Up Up 
Q969H8 IL25 0 5.651194 0 5 Up Up 
Q8NBS9 TXNDC5  0 6.781433 0 3 Up Up 
P60842 EIF4A1 0 3.390717 1.006561 3 Up 2.980445 
P55145 MANF 0 3.390717 0 1 Up Up 







































  FC 1 FC 2 
    0HR 24HR 0HR 24HR     
Q9UJZ1 STOML2 2 0 7.045928 0 Down Down 
Q12906 ILF3 4 0 3.019684 0 Down Down 
P62834 RAP1A 6 0 6.039367 0 Down Down 
P58107 EPPK1 13 0 10.06561 1.611867 Down 0.160136 





2 0 1.006561 0 Down Down 
P48643 CCT5  2 0 2.013122 0 Down N/A 
P42704 LRPPRC  2 0 4.026245 1.611867 Down 0.40034 
P30041 PRDX6 3 0 3.019684 1.611867 Down 0.533787 
P20700 LMNB1  4 0 2.013122 0 Down Down 




8 1.263476 8.052489 3.223733 0.157935 0.40034 
P49368 CCT3  6 1.263476 8.052489 3.223733 0.210579 0.40034 
Q07065 CKAP4 5 1.263476 6.039367 0 0.252695 Down 
Q92841 DDX17 9 2.526952 8.052489 0 0.280772 Down 
Q16891 IMMT  8 2.526952 7.045928 3.223733 0.315869 0.457531 
P60981 DSTN 4 1.263476 7.045928 1.611867 0.315869 0.228766 
P78527 PRKDC 7 2.526952 7.045928 0 0.360993 Down 
Q07020 RPL18 3 1.263476 2.013122 0 0.421159 Down 
P50990 CCT8  6 2.526952 5.032806 1.611867 0.421159 0.320272 
P43243 MATR3  3 1.263476 5.032806 0 0.421159 Down 
O00264 PGRMC1 6 2.526952 8.052489 3.223733 0.421159 0.40034 
P30101 PDIA3  14 29.05995 10.06561 29.0136 2.075711 2.882447 
Q9BSH4 TACO1  2 5.053904 1.006561 4.8356 2.526952 4.804079 
Q16740 CLPP 1 2.526952 0 1.611867 2.526952 Up 
P30084 ECHS1 4 10.10781 6.039367 12.89493 2.526952 2.135146 
P23284 PPIB  3 10.10781 0 6.447466 3.36927 N/A 
Q15084 PDIA6 5 18.95214 7.045928 20.95426 3.790428 2.973954 
O60220 TIMM8A 2 7.580856 0 11.28307 3.790428 Up 
P07237 P4HB  13 50.53904 9.059051 33.8492 3.887619 3.736506 










  FC 1 FC 2 




4 24.00605 3.019684 19.3424 6.001511 6.405439 
P12532 CKMT1A 1 6.31738 2.013122 6.447466 6.31738 3.202719 
P13667 PDIA4  2 16.42519 4.026245 16.11867 8.212594 4.003399 
Q9Y6X8 ZHX2 0 1.263476 0 3.223733 Up Up 
Q9Y5L4 TIMM13  0 2.526952 0 4.8356 Up Up 
Q969H8 IL25 0 3.790428 0 6.447466 Up Up 
Q8NBS9 TXNDC5 0 8.844332 0 8.059333 Up Up 


































Detected as changed in a single replicate only 





    2HR     




regulator of chromatin subfamily E 
member 1  
SMARCE1 1 0 N/A 
Q8TBA6 Golgin subfamily A member 5  GOLGA5 2 0 N/A 
Q8N163 
Protein KIAA1967 (Deleted in 
breast cancer gene 1 protein)  
DBC1 2 0 N/A 
Q12874 
Splicing factor 3A subunit 3 
(SF3a60) 
SF3A3 1 0 N/A 
Q04695 Keratin, type I cytoskeletal 17  KRT17 2 0 N/A 




RANBP1 2 0 N/A 
P35527 Keratin, type I cytoskeletal 9  KRT9 4 0 N/A 
P28066 Proteasome subunit alpha type-5  PSMA5 1 0 N/A 
P18669 Phosphoglycerate mutase 1  PGAM1 3 0 N/A 
P17480 
Nucleolar transcription factor 1 
(UBF-1) 
UBF1 2 0 N/A 
O75347 
Tubulin-specific chaperone A 
(CFA) 
TBCA 2 0 N/A 
O75150 E3 ubiquitin-protein ligase BRE1B RNF40  2 0 N/A 
O95292 
Vesicle-associated membrane 
protein-associated protein B/C  
VAPB  7 1.098555 0.156936 
P14927 
Cytochrome b-c1 complex subunit 
7 (Complex III subunit 7) 
UQCRB  5 1.098555 0.219711 
Q14444 
Caprin-1 (Cell cycle-associated 
protein 1) 
CAPRIN1 5 2.197109 0.439422 
P40227 
T-complex protein 1 subunit zeta 
(TCP-1-zeta)  
CCT6A  5 2.197109 0.439422 
O00148 
ATP-dependent RNA helicase 
DDX39  
DDX39 5 2.197109 0.439422 
P04350 Tubulin beta-4 chain  TUBB4  17 7.689882 0.452346 
P12814 Alpha-actinin-1 ACTN1 7 14.28121 2.040173 
Q00059 
Transcription factor A, 
mitochondrial (mtTFA) 
TFAM  2 4.394218 2.197109 
P26373 
60S ribosomal protein L13 (Breast 
basic conserved protein 1) 
RPL13 1 2.197109 2.197109 





    2HR     
Accession Protein Gene 0Hr 2Hr FC 
P67936 Tropomyosin alpha-4 chain TPM4 0 1.098555 N/A 
P52907 
F-actin-capping protein subunit 
alpha-1  
CAPZA1 0 3.295664 N/A 
P51858 
Hepatoma-derived growth factor 
(HDGF) 
HDGF  0 1.098555 N/A 
P50995 Annexin A11 ANXA11  0 3.295664 N/A 
P37837 Transaldolase TALDO1 0 1.098555 N/A 
P16152 Carbonyl reductase [NADPH]  CBR1  0 1.098555 N/A 
O75439 
Mitochondrial-processing 
peptidase subunit beta 






    2HR     
Accession Protein Gene 0Hr 2Hr FC 
Q99832 
T-complex protein 1 subunit eta 
(TCP-1-eta) 
CCT7  1.006561 0 N/A 
Q96C36 
Pyrroline-5-carboxylate 
reductase 2  
PYCR2 3.019684 0 N/A 
Q8TAQ2 
SWI/SNF complex subunit 
SMARCC2  
SMARCC2  3.019684 0 N/A 
Q8N983 
39S ribosomal protein L43, 
mitochondrial 
MRPL43 1.006561 0 N/A 
Q8N5N7 
39S ribosomal protein L50, 
mitochondrial 
MRPL50 1.006561 0 N/A 
Q86UE4 Protein LYRIC (3D3/LYRIC) MTDH 1.006561 0 N/A 
Q5SRE5 Nucleoporin NUP188 homolog NUP188  1.006561 0 N/A 
Q15388 
Mitochondrial import receptor 
subunit TOM20 homolog  
TOMM20  2.013122 0 N/A 
Q15369 
Transcription elongation factor B 
polypeptide 1 (Elongin 15 kDa 
subunit)  
TCEB1 1.006561 0 N/A 
Q14344 
Guanine nucleotide-binding 
protein subunit alpha-13 
GNA13 3.019684 0 N/A 
Q13838 
Spliceosome RNA helicase 
BAT1 
BAT1 4.026245 0 N/A 
Q07812 Apoptosis regulator BAX  BAX 1.006561 0 N/A 
P63261 Actin, cytoplasmic 2 ACTG1 4.026245 0 N/A 
P62847 40S ribosomal protein S24 RPS24 2.013122 0 N/A 
P61006 
Ras-related protein Rab-8A 
(Oncogene c-mel) 
RAB8A  2.013122 0 N/A 






    2HR     
Accession Protein Gene 0Hr 2Hr FC 
P29373 
Cellular retinoic acid-binding 
protein 2  
CRABP2 2.013122 0 N/A 
P27348 14-3-3 protein theta  YWHAQ 4.026245 0 N/A 
P25205 
DNA replication licensing factor 
MCM3 
MCM3 2.013122 0 N/A 
P22830 Ferrochelatase, mitochondrial FECH 2.013122 0 N/A 
P22314 
Ubiquitin-like modifier-activating 
enzyme 1 (Protein A1S9)  
UBE1 1.006561 0 N/A 
P20674 
Cytochrome c oxidase subunit 
5A, mitochondrial  
COX5A 3.019684 0 N/A 
P14923 Junction plakoglobin JUP  2.013122 0 N/A 
P13647 Keratin, type II cytoskeletal 5  KRT5 1.006561 0 N/A 
P0C6E5 
Putative high mobility group 
protein B3-like protein 
  2.013122 0 N/A 
P09497 Clathrin light chain B  CLTB 1.006561 0 N/A 
O60716 Catenin delta-1 CTNND1 2.013122 0 N/A 
O15523 
ATP-dependent RNA helicase 
DDX3Y  




SEC22B 7.045928 1.119313 0.15886 
O75533 Splicing factor 3B subunit 1 SF3B1 5.032806 1.119313 0.222403 
Q14498 
RNA-binding protein 39 
(Hepatocellular carcinoma 
protein 1) 
RBM39  8.052489 2.238627 0.278004 
Q9Y3D9 
28S ribosomal protein S23, 
mitochondrial  
MRPS23 3.019684 1.119313 0.370672 
Q13148 
TAR DNA-binding protein 43 
(TDP-43) 
TARDBP  3.019684 1.119313 0.370672 
P37108 
Signal recognition particle 14 
kDa protein (SRP14)  
SRP14 3.019684 1.119313 0.370672 
P25787 
Proteasome subunit alpha type-2 
(EC 3.4.25.1) 
PSMA2  3.019684 1.119313 0.370672 
Q16718 
NADH dehydrogenase 
[ubiquinone] 1 alpha subcomplex 
subunit 5 








FKBP4  1.006561 2.238627 2.224034 
P62753 
40S ribosomal protein S6 
(Phosphoprotein NP33) 




ALDH4A1  1.006561 2.238627 2.224034 
Q9C005 
Protein dpy-30 homolog (Dpy-
30-like protein) 






    2HR     
Accession Protein Gene 0Hr 2Hr FC 
Q9Y285 
Phenylalanyl-tRNA synthetase 
alpha chain  
FARSA  0 3.35794 N/A 
Q9NR28 
Diablo homolog, mitochondrial 
(Smac) 
DIABLO  0 1.119313 N/A 
Q96I99 
Succinyl-CoA ligase [GDP-
forming] subunit beta, 
mitochondrial 
SUCLG2 0 3.35794 N/A 
Q8TEX9 Importin-4 (Imp4) IPO4  0 3.35794 N/A 
Q15393 Splicing factor 3B subunit 3  SF3B3  0 1.119313 N/A 
P68366 Tubulin alpha-4A chain  TUBA4A  0 3.35794 N/A 
P55795 
Heterogeneous nuclear 
ribonucleoprotein H2 (hnRNP 
H2)  
HNRNPH2  0 2.238627 N/A 
P46379 
Large proline-rich protein BAG6 
(BCL2-associated athanogene 6)  






MTHFD2  0 1.119313 N/A 
P09493 Tropomyosin alpha-1 chain TPM1 0 1.119313 N/A 
P07339 Cathepsin D  CTSD 0 10.07382 N/A 
O00571 
ATP-dependent RNA helicase 
DDX3X  






















After four hours Nutlin treatment 
Detected in Rep. One         
Accession Protein Gene 0Hr 4Hr FC 
Q9Y5M8 
Signal recognition particle 
receptor subunit beta  
SRPRB 1 0 N/A 
Q9GZV4 
Eukaryotic translation initiation 
factor 5A-2 (eIF-5A-2)  




regulator of chromatin 
subfamily E member 1 
SMARCE1 1 0 N/A 
Q8TBA6 Golgin subfamily A member 5  GOLGA5 2 0 N/A 
Q14444 
Caprin-1 (Cell cycle-
associated protein 1) 
CAPRIN1 5 0 N/A 
Q13435 Splicing factor 3B subunit 2  SF3B2 1 0 N/A 
Q12874 Splicing factor 3A subunit 3  SF3A3 1 0 N/A 
P63104 14-3-3 protein zeta/delta  YWHAZ 1 0 N/A 
P62906 60S ribosomal protein L10a  RPL10A 3 0 N/A 
P62888 60S ribosomal protein L30 RPL30 2 0 N/A 
P55036 
26S proteasome non-ATPase 
regulatory subunit 4  
PSMD4 1 0 N/A 
P52565 
Rho GDP-dissociation 
inhibitor 1 (Rho GDI 1)  
ARHGDIA 2 0 N/A 
P40227 
T-complex protein 1 subunit 
zeta (TCP-1-zeta)  
CCT6A 5 0 N/A 
P35527 Keratin, type I cytoskeletal 9  KRT9 4 0 N/A 
P30044 Peroxiredoxin-5, mitochondrial  PRDX5  4 0 N/A 
P28066 
Proteasome subunit alpha 
type-5  
PSMA5 1 0 N/A 
P18669 Phosphoglycerate mutase 1  PGAM1  3 0 N/A 
P18124 60S ribosomal protein L7 RPL7 3 0 N/A 
P17480 
Nucleolar transcription factor 
1 (UBF-1) 
UBF1 2 0 N/A 
P04350 Tubulin beta-4 chain  TUBB4 17 0 N/A 
O95292 
Vesicle-associated membrane 
protein-associated protein B/C 
VAPB  7 0 N/A 
O00148 
ATP-dependent RNA helicase 
DDX39 
DDX39 5 0 N/A 
Q92667 
A-kinase anchor protein 1, 
mitochondrial  
AKAP1 4 1.659828 0.414957 
P16401 Histone H1.5 HIST1H1B  2 4.979484 2.489742 
 252 
Detected in Rep. One         
Accession Protein                      Gene 0Hr 4Hr FC 
Q8NFV4 
Abhydrolase domain-
containing protein 11 




CAPZA1 0 1.659828 N/A 
P51858 
Hepatoma-derived growth 
factor (HDGF)  
HDGF 0 1.659828 N/A 
Q9Y3E5 
Peptidyl-tRNA hydrolase 2, 
mitochondrial  
PTRH2 1.006561 0 N/A 
Q9BVK6 
Transmembrane emp24 
domain-containing protein 9  
TMED9 4.026245 0 N/A 
Q9BPW8 Protein NipSnap homolog 1 NIPSNAP1 2.013122 0 N/A 
Q99832 
T-complex protein 1 subunit 
eta (TCP-1-eta)  
CCT7 1.006561 0 N/A 
Q96I24 
Far upstream element-binding 
protein 3 (FUSE-binding 
protein 3) 
FUBP3  2.013122 0 N/A 
Q96C36 
Pyrroline-5-carboxylate 
reductase 2  
PYCR2 3.019684 0 N/A 
Q8N983 
39S ribosomal protein L43, 
mitochondrial 
MRPL43 1.006561 0 N/A 
Q8N5N7 
39S ribosomal protein L50, 
mitochondrial  
MRPL50 1.006561 0 N/A 
Q86UE4 Protein LYRIC (3D3/LYRIC) MTDH  1.006561 0 N/A 
Q6NUK1 
Calcium-binding mitochondrial 
carrier protein SCaMC-1  
SLC25A24  3.019684 0 N/A 
Q6IAA8 
Ragulator complex protein 
PDRO 
PDRO  2.013122 0 N/A 
Q5SRE5 Nucleoporin NUP188 homolog  NUP188  1.006561 0 N/A 
Q15388 
Mitochondrial import receptor 
subunit TOM20 homolog  
TOMM20 2.013122 0 N/A 
Q15369 
Transcription elongation factor 
B polypeptide 1 
TCEB1 1.006561 0 N/A 
Q14344 
Guanine nucleotide-binding 
protein subunit alpha-13  
GNA13 3.019684 0 N/A 
Q13838 
Spliceosome RNA helicase 
BAT1 
BAT1 4.026245 0 N/A 
Q13813 Spectrin alpha chain, brain SPTAN1  2.013122 0 N/A 
Q13748 Tubulin alpha-3C/D chain TUBA3C  1.006561 0 N/A 
Q07812 Apoptosis regulator BAX  BAX  1.006561 0 N/A 
Q02790 
Peptidyl-prolyl cis-trans 
isomerase FKBP4  
FKBP4 1.006561 0 N/A 
P83916 Chromobox protein homolog 1 CBX1  2.013122 0 N/A 
P63261 Actin, cytoplasmic 2 ACTG1 4.026245 0 N/A 
P62753 
40S ribosomal protein S6 
(Phosphoprotein NP33) 
RPS6 1.006561 0 N/A 
 
 
         
 253 
Detected in Rep. One 
Accession Protein Gene 0Hr 4Hr FC 
P61006 
Ras-related protein Rab-8A 
(Oncogene c-mel) 
RAB8A 2.013122 0 N/A 
P50991 
T-complex protein 1 subunit 
delta (TCP-1-delta)  
CCT4  1.006561 0 N/A 
P37268 Squalene synthase (SQS)  FDFT1 3.019684 0 N/A 





ALDH4A1  1.006561 0 N/A 
P29373 
Cellular retinoic acid-binding 
protein 2  
CRABP2 2.013122 0 N/A 
P27348 14-3-3 protein theta  YWHAQ 4.026245 0 N/A 
P25787 
Proteasome subunit alpha 
type-2  
PSMA2 3.019684 0 N/A 
P25398 40S ribosomal protein S12 RPS12 3.019684 0 N/A 
P22830 Ferrochelatase, mitochondrial FECH 2.013122 0 N/A 
P22314 
Ubiquitin-like modifier-
activating enzyme 1 
(Ubiquitin-activating enzyme 
E1) 
UBA1  1.006561 0 N/A 
P20674 
Cytochrome c oxidase subunit 
5A, mitochondrial 
COX5A 3.019684 0 N/A 
P14923 Junction plakoglobin JUP  2.013122 0 N/A 
P13647 Keratin, type II cytoskeletal 5 KRT5 1.006561 0 N/A 
P09497 Clathrin light chain B  CLTB 1.006561 0 N/A 
P08133 Annexin A6  ANXA6  4.026245 0 N/A 
O75947 
ATP synthase subunit d, 
mitochondrial  
ATP5H  2.013122 0 N/A 
O75533 Splicing factor 3B subunit 1 SF3B1  5.032806 0 N/A 
O60716 Catenin delta-1 CTNND1 2.013122 0 N/A 
O43390 
Heterogeneous nuclear 
ribonucleoprotein R (hnRNP 
R) 
HNRNPR 2.013122 0 N/A 
O15523 
ATP-dependent RNA helicase 
DDX3Y 




SEC22B  7.045928 1.699023 0.241135 
Q14498 
RNA-binding protein 39 
(Hepatocellular carcinoma 
protein 1) 
RBM39  8.052489 3.398046 0.421987 
P51532 Transcription activator BRG1  SMARCA4 1.006561 3.398046 3.375896 
P49736 
DNA replication licensing 
factor MCM2  




CALR 1.006561 5.097068 5.063844 
Q9Y285 
Phenylalanyl-tRNA synthetase 
alpha chain  
FARSA  0 1.699023 N/A 
Q9NR28 Diablo homolog, mitochondrial  DIABLO  0 1.699023 N/A 
 254 
Detected in Rep. One         
Accession Protein Gene 0Hr 4Hr FC 
Q99613 
Eukaryotic translation initiation 
factor 3 subunit C (eIF3c)  
EIF3C  0 1.699023 N/A 
P09493 Tropomyosin alpha-1 chain  TPM1  0 1.699023 N/A 
P07339 Cathepsin D  CTSD 0 1.699023 N/A 
O00571 
ATP-dependent RNA helicase 
DDX3X 






































After eight hours Nutlin treatment 
Detected in 
Rep. One         
Accession Protein Gene 0Hr 8Hr FC 
Q9Y5M8 
Signal recognition particle receptor 
subunit beta 
SRPRB  1 0 N/A 
Q9GZV4 
Eukaryotic translation initiation factor 
5A-2 (eIF-5A-2) 
EIF5A2 1 0 N/A 
Q8TBA6 Golgin subfamily A member 5 GOLGA5  2 0 N/A 
Q8N163 
Protein KIAA1967 (Deleted in breast 
cancer gene 1 protein) 
DBC1 2 0 N/A 
Q14011 
Cold-inducible RNA-binding protein 
(A18 hnRNP) 
CIRBP 1 0 N/A 
Q13247 Serine/arginine-rich splicing factor 6  SRSF6 4 0 N/A 
Q04695 Keratin, type I cytoskeletal 17  KRT17 2 0 N/A 
P62917 60S ribosomal protein L8 RPL8 1 0 N/A 
P62906 60S ribosomal protein L10a  RPL10A  3 0 N/A 
P52565 
Rho GDP-dissociation inhibitor 1 (Rho 
GDI 1)  




RANBP1 2 0 N/A 
P35527 Keratin, type I cytoskeletal 9  KRT9 4 0 N/A 
P28066 Proteasome subunit alpha type-5  PSMA5 1 0 N/A 
P26373 
60S ribosomal protein L13 (Breast 
basic conserved protein 1) 
RPL13 1 0 N/A 
P18669 Phosphoglycerate mutase 1 PGAM1 3 0 N/A 
P18124 60S ribosomal protein L7 RPL7 3 0 N/A 
P17480 
Nucleolar transcription factor 1 (UBF-
1) 
UBF1 2 0 N/A 
O95292 
Vesicle-associated membrane 
protein-associated protein B/C 
VAPB  7 0 N/A 
P62266 40S ribosomal protein S23 RPS23 4 1.130239 0.28256 
Q14444 
Caprin-1 (Cell cycle-associated 
protein 1) 
CAPRIN1 5 2.260478 0.452096 
P40227 
T-complex protein 1 subunit zeta 
(TCP-1-zeta) 
CCT6A  5 2.260478 0.452096 
P14927 Cytochrome b-c1 complex subunit 7  UQCRB  5 2.260478 0.452096 
O00148 ATP-dependent RNA helicase DDX39  DDX39 5 2.260478 0.452096 




ABHD11 0 3.390717 N/A 
Q5SZK8 
FRAS1-related extracellular matrix 
protein 2 (ECM3 homolog) 
FREM2 0 2.260478 N/A 





Rep. One         
Accession Protein Gene 0Hr 8Hr FC 
P67936 Tropomyosin alpha-4 chain TPM4 0 3.390717 N/A 
P51858 
Hepatoma-derived growth factor 
(HDGF)  
HDGF  0 1.130239 N/A 
P37837 Transaldolase  TALDO1 0 3.390717 N/A 
P28838 Cytosol aminopeptidase LAP3 0 2.260478 N/A 









          
Accession Protein Gene 0Hr 8Hr FC 














































































          
Accession Protein Gene 0Hr 8Hr FC 
Q14498 
RNA-binding protein 39 (Hepatocellular 





































































Far upstream element-binding protein 3 























































NADH dehydrogenase [ubiquinone] iron-





































          
Accession Protein Gene 0Hr 8Hr FC 
Q99613 
Eukaryotic translation initiation factor 3 
subunit C (eIF3c)  
EIF3C 0 1 N/A 
Q96I99 
Succinyl-CoA ligase [GDP-forming] 
subunit beta, mitochondrial  
SUCLG
2 
0 3 N/A 
Q8N7H5 
RNA polymerase II-associated factor 1 
homolog (hPAF1)  
PAF1 0 1 N/A 
P55795 
Heterogeneous nuclear ribonucleoprotein 
H2 (hnRNP H2)  
HNRNP
H2 
0 1 N/A 
P50897 Palmitoyl-protein thioesterase 1 (PPT-1)  PPT1  0 1 N/A 
P31153 
S-adenosylmethionine synthase isoform 
type-2  







0 3 N/A 
P09493 Tropomyosin alpha-1 chain  TPM1  0 2 N/A 




























After 24 hours Nutlin treatment 
Detected in  
Rep. One         
Accession Protein Gene 0Hr 24Hr FC 
Q9Y5M8 
Signal recognition particle 
receptor subunit beta 
SRPRB 1 0 N/A 
Q9GZV4 
Eukaryotic translation initiation 
factor 5A-2 (eIF-5A-2)  




regulator of chromatin subfamily 
E member 1  
SMARCE1 1 0 N/A 
Q8TBA6 Golgin subfamily A member 5  GOLGA5 2 0 N/A 
Q8N163 
Protein KIAA1967 (Deleted in 
breast cancer gene 1 protein)  
DBC1 2 0 N/A 
Q14011 
Cold-inducible RNA-binding 
protein (A18 hnRNP) 
CIRBP 1 0 N/A 
Q13435 Splicing factor 3B subunit 2 SF3B2 1 0 N/A 
Q13247 
Serine/arginine-rich splicing 
factor 6  
SRSF6 4 0 N/A 
Q04695 Keratin, type I cytoskeletal 17  KRT17 2 0 N/A 
Q00059 
Transcription factor A, 
mitochondrial  
TFAM 2 0 N/A 
P62917 60S ribosomal protein L8 RPL8 1 0 N/A 
P62910 60S ribosomal protein L32 RPL32 4 0 N/A 
P62888 60S ribosomal protein L30 RPL30 2 0 N/A 
P62266 40S ribosomal protein S23 RPS23 4 0 N/A 
P52565 
Rho GDP-dissociation inhibitor 
1 (Rho GDI 1)  




RANBP1 2 0 N/A 
P35527 Keratin, type I cytoskeletal 9 KRT9 4 0 N/A 
P26373 
60S ribosomal protein L13 
(Breast basic conserved protein 
1) 
RPL13  1 0 N/A 
P18669 Phosphoglycerate mutase 1 PGAM1  3 0 N/A 
P17480 
Nucleolar transcription factor 1 
(UBF-1) 




TPT1 2 0 N/A 
O95292 
Vesicle-associated membrane 
protein-associated protein B/C  
VAPB 7 0 N/A 
O75347 
Tubulin-specific chaperone A 
(TCP1-chaperonin cofactor A) 
TBCA 2 0 N/A 
P40227 
T-complex protein 1 subunit 
zeta (TCP-1-zeta) 
CCT6A 5 1.263476 0.252695 
P14927 
Cytochrome b-c1 complex 
subunit 7 (Complex III subunit 
7) 
UQCRB 5 1.263476 0.252695 
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Detected in  
Rep. One         
 
Accession Protein Gene 0Hr 24Hr FC 
P62906 
60S ribosomal protein L10a 
(CSA-19)  
RPL10A 3 1.263476 0.421159 
P18124 60S ribosomal protein L7 RPL7 3 1.263476 0.421159 
O94906 
Pre-mRNA-processing factor 6 
(PRP6 homolog)  
PRPF6  3 1.263476 0.421159 




ABHD11  0 2.526952 N/A 
Q01105 Protein SET  SET 0 1.263476 N/A 
P52907 
F-actin-capping protein subunit 
alpha-1 
CAPZA1 0 1.263476 N/A 








          
Accession Protein Gene 0Hr 24Hr FC 
Q99832 
T-complex protein 1 subunit 
eta (TCP-1-eta)  
CCT7 1.006561 0 N/A 
Q5SRE5 Nucleoporin NUP188 homolog NUP188 1.006561 0 N/A 
Q15388 
Mitochondrial import receptor 
subunit TOM20 homolog  
TOMM20  2.013122 0 N/A 
Q15369 
Transcription elongation factor 
B polypeptide 1 
TCEB1 1.006561 0 N/A 
Q14344 
Guanine nucleotide-binding 
protein subunit alpha-13  
GNA13 3.019684 0 N/A 
Q13838 
Spliceosome RNA helicase 
BAT1  
BAT1  4.026245 0 N/A 
Q13813 Spectrin alpha chain, brain SPTAN1  2.013122 0 N/A 
Q13748 Tubulin alpha-3C/D chain  TUBA3C 1.006561 0 N/A 
P83916 Chromobox protein homolog 1 CBX1 2.013122 0 N/A 
P63261 Actin, cytoplasmic 2  ACTG1 4.026245 0 N/A 
P62847 40S ribosomal protein S24 RPS24 2.013122 0 N/A 
P62753 
40S ribosomal protein S6 
(Phosphoprotein NP33) 
RPS6  1.006561 0 N/A 
P51532 Transcription activator BRG1 SMARCA4  1.006561 0 N/A 
P50991 
T-complex protein 1 subunit 
delta (TCP-1-delta)  
CCT4 1.006561 0 N/A 
P35222 Catenin beta-1 CTNNB1  1.006561 0 N/A 
Detected in 
Rep.Two 
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Accession Protein Gene 0Hr 24Hr FC 
P20674 
Cytochrome c oxidase subunit 
5A, mitochondrial  
COX5A 3.019684 0 N/A 
P14923 Junction plakoglobin  JUP  2.013122 0 N/A 
P13647 Keratin, type II cytoskeletal 5 KRT5 1.006561 0 N/A 
P09497 Clathrin light chain B  CLTB 1.006561 0 N/A 
O75947 
ATP synthase subunit d, 
mitochondrial  
ATP5H 2.013122 0 N/A 
O75533 Splicing factor 3B subunit 1  SF3B1 5.032806 0 N/A 
O60716 Catenin delta-1 CTNND1 2.013122 0 N/A 
O15523 
ATP-dependent RNA helicase 
DDX3Y 
DDX3Y 2.013122 0 N/A 
Q96FQ6 Protein S100-A16  S100A16  4.026245 1.611867 0.40034 
P08133 Annexin A6  ANXA6 4.026245 1.611867 0.40034 
O00217 
NADH dehydrogenase 
[ubiquinone] iron-sulfur protein 
8, mitochondrial 









HADH 3.019684 6.447466 2.135146 
P18754 
Regulator of chromosome 
condensation  
RCC1 3.019684 6.447466 2.135146 
Q9C005 Protein dpy-30 homolog  DPY30 2.013122 4.8356 2.40204 
Q8N5N7 
39S ribosomal protein L50, 
mitochondrial 
MRPL50 1.006561 3.223733 3.202719 
Q07812 Apoptosis regulator BAX  BAX  1.006561 3.223733 3.202719 
Q02790 
Peptidyl-prolyl cis-trans 
isomerase FKBP4 (PPIase 
FKBP4)  
FKBP4 1.006561 3.223733 3.202719 
P30038 
Delta-1-pyrroline-5-carboxylate 
dehydrogenase, mitochondrial  








CALR 1.006561 6.447466 6.405439 
Q9Y285 
Phenylalanyl-tRNA synthetase 
alpha chain  
FARSA  0 1.611867 N/A 
Q9NR30 Nucleolar RNA helicase 2 DDX21 0 3.223733 N/A 
Q9NR28 
Diablo homolog, mitochondrial 
(Smac) 
DIABLO 0 3.223733 N/A 
Q96I99 
Succinyl-CoA ligase [GDP-
forming] subunit beta, 
mitochondrial  
SUCLG2 0 1.611867 N/A 
 
 




Accession Protein Gene 0Hr 24Hr FC 
Q13011 
Delta(3,5)-Delta(2,4)-dienoyl-
CoA isomerase, mitochondrial  




PPT1 0 1.611867 N/A 
P46379 
Large proline-rich protein 
BAG6 
BAG6 0 1.611867 N/A 
P31153 
S-adenosylmethionine 
synthase isoform type-2 
MAT2A 0 3.223733 N/A 
P09493 Tropomyosin alpha-1 chain TPM1 0 1.611867 N/A 
P07339 Cathepsin D  CTSD 0 4.8356 N/A 
O00571 
ATP-dependent RNA helicase 
DDX3X  

































Appendix 3  
 
  Sequence Protein 
1 ETFSDLWKLLPENNVLSPL BOX-I 
2 SSAVRVYRMLPPLTKNQRK IRF-1 
3 NNAFRVYRMLPLSERPSKK IRF-2 
4 NNVLPVFDNLMQQKLVDQNI CathepsinD 
5 DEFTHLYTLIVRPDNTYEVK  Calreticulin 
6 RPLVVVYYSVDFSFDYRAAT Erp72-1 
7 KQLEPVYNSLAKKYKGQKGL Erp72-2 
8 FLDEYIFLAVGRVGSTSENI DDX3X 
9 KNRIAIYELLFKEGVMVAKK Ribosomal S10 
10 LIAGSVFFLLLPGPSAADEK CyclophilinB-1 
11 KVTVKVYFDLRIGDEDVGRV CyclophilinB-2 
12 DGKHVVFGKVLEGMEVVRKV CyclophilinB-3  
13 GTPGRVFDMLNRRYLSPKYI eIF4A-1 
14 DQIYDIFQKLNSNTQVVLLS eIF4A-2 
15 DTLCDLYETLTITQAVIFIN eIF4A-3 
16 GLAFSLYQAMAKDQAVENIL Serpin H1 
18 KYKKKMWGWLWTEAGAQSEL PDIA6 
20 VERSRIFSKLCLNIRLAVKE CCD44-1 
21 EERNVFKFICDASSLHQVR CCD44-2 
22 VNLDKLWTLVSEQTRVNAAK Ribosomal L27 
23 AREKKLYANMFERLAEEENK Rotamase-1 
24 KLYANMFERLAEEENKAKAE Rotatmase-2 
25 AFLRSMWGVLSALGRSGAEL TFAM 
26 LRRLALFPGVALLLAAARL eRP60 
27 RTDGKVFQFLNAKCESAFLS Ribosomal L24 
28 LCNQGLFECLALNLHCLGGQ BAT3 
29 EEEDEVWQVIIGARAEMTSK Smac 
30 PDDAEVYRLIEVTGLARSEI AFP Regulator Two 
31 ERAYDIYSRLLRERIVCVMG CLPP-1 
32 TAGLAIYDTMQYILNPICTW CLPP-2 
33 KCGDLVFAKMKGYPHWPARI HDGF 
34 RKAIIIFVPVPQLKSFQKIQ Ribosomal S7 
 
35 ETFSGVYKKLTGKDVNFEFP Ribosomal S7-2 
 264 
  
 Sequence Protein 
37 VRQRDMYRILLSQTTGVAIP Nucleoprotein TPR 
39 VNSVLLFTILNPIYSITTDV hnRNPL 
40 SVLKPLWKGIRQHRGKGLAA SAP155 
41 EKNRKLFDLLDVLEFNQVVI BAT1 
42 NVNEIFYDLVRQINRKTPVE Rap1A 
43 VADGMVFGALLPCEECSGQL PARP1 
44 PQGTVIFEDISIEHFEGTVT NrasUpstream-1 
45 GDSKKLFFHVKEVQDGIELQ NrasUpstream-2 
46 DRNVEMFMTIEKSLVQNNCL SMARCC22 
47 DEVCRIFYDMKVRKCSTPEE Destrin 
48 GLEEAVYRNIQACKELAQTT TCP Theta 
49 LKEKPLWFDVYDAFPPLREP Ribosomal S23 
50 LTNPELFQRVGIIPPKGCLL Proteasome S23 
51 DKKTHLYTLILNPDNSFEIL Calnexin-1 
53 KSRTTLFRKIGDFRSLEKIS Apoptosis inducing factor 1 
54 IVLWNIFNRMPIARKIIKDG  Apoptosis inducing factor 1-2 
55 EQMRTLFGFLGKIDELRLFP  SRFS11 
56 PYSDKLFEMVLGPAAYNVPL Mitofilin 
57 RKAHQLWLSVEALKYSMKTS Mitofilin-2 
58 HASIHLWDLLEGKEKPVCGT Caprin1 
59 LTNPELFQRVGIIPPKGCLL Proteasome S10B 
60 RSLLDLFLDMEAATGQEVEL Proteasome regulatory S9 
61 THLAKLYDNLLEQNLIRVIE Proteasome regulatory S9-2 
62 PVEKRVFKNLQLFMENKQPE Topoisomerase1 
63 NKQPEDDLFDRLNTGILNKH Topoisomerase1-2 
64 KTKKTMFGKMYFPDVEAHGP Desmoyokin 
65 FLDEYIFLAVGRVGSTSENI DDX3Y 
66 DHSHLLYSTIPRMQEPGQIV Catenin d 1-1 
67 PEVVRIYISLLKESKTPAIL Catenin d 1-2 
68 KKLGEMWKNLNDSEKQPYIT HMG3M 
69 TRSKDIFDQLAKSLAPSIHG MCM3-1 
70 SRFDLLFIMLDQMDPEQDRE MCM3-2 
71 KTYDYLFKLLLIGDSGVGKT RAB8A 
72 TGFGMIYDSLDYAKKNEPKH Ribosomal S24  
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 Sequence Protein 
74 RLLARMWNDLSEKKKAKYKA UBF-1-2 
75 DFGYRVYKMLLSLPEKVVSP DBC1 
78 NEAKGVYEKVGEATETALTC SERCA2-1 
79 EEGRAIYNNMKQFIRYLISS SERCA2-2 
80 IPVQLLWVNLVTDGLPATAL SERCA2-3 
81 ADMADVYKLLVQLKVVEDGI Catenin a1-1 
84 SFFEEVFTELQEKYGEIEEM Splicing factor U2AF 
85 I TLRILFRPVASQLPRIFTS Prohibitin-2 
86 ALQRVLYRHMQAKGVLLTDG SNF2L4 
87 EGPDAMYVKLISSDGHEFIV Elongin15 
88 WSDRSIFSGIGSTAEPVSQS LYRIC 
89 DSPREVFFRVAADMFSDGNF BAX 
90 FNMPNLYQKLESDPRTRTLL STIP1 
91 RYSRKVWDQVKASNPDLKLW SMARCE1-1 
92 KIIGGMWRDLTDEEKQEYLN SMARCE1-2 
93 FGVALLFGGVDEKGPQLFHM PSA5 
94 VAKECADLWPRIASNAGSIA Ribosomal L23 

































P13667 VYysV PDIA4   Q15149 LWevM PLEC1 
P13667 VYnsL PDIA4   Q15149 IYqaL PLEC1 
P12532 VYarL KCRU   Q15149 LFqaM PLEC1 
P12532 VFadL KCRU   Q15149 VYqaM PLEC1 
P12532 LFdpV KCRU   Q15149 LFqaM PLEC1 
P60842 VFdmL IF4A1   P54886 LYeaM P5CS 
P60842 IFqkL IF4A1   P54886 LFdqI P5CS 
P60842 LYetL IF4A1   O75534 IFedI CSDE1 
Q14697 LYnpM GANAB   O75534 LFfhV CSDE1 
Q14697 LYgsV GANAB   P09874 VFgaL PARP1 
Q14697 LFgkM GANAB   P14866 LFtiL HNRPL 
Q14697 VFllL GANAB   P14866 LYgnV HNRPL 
Q14697 IWldI GANAB   O95292 LFfiV VAPB 
Q14697 VWndM GANAB   P07355 VYkeM ANXA2 
Q14697 LYvhM GANAB   P07355 LYdsM ANXA2 
Q14697 VWydI GANAB   P07355 LYyyI ANXA2 
Q14697 LYlpV GANAB   O75439 VFdyL MPPB 
Q14697 LFvaL GANAB   P16152 VYlaL CBR1 
P50454 LYqaM SERPH   P50995 LYhdI ANX11 
P07237 LFifI PDIA1   P51858 VFakM HDGF 
P07237 IWdkL PDIA1   P52907 VFndV CAZA1 
Q15084 MWgwL PDIA6   P12270 MYriL TPR 
P13010 IFtdL XRCC5   P12270 VFgtV TPR 
P13010 VFkkI XRCC5   P17480 VYlkV UBF1 
P13010 VYvqL XRCC5   P17480 MWndL UBF1 
P13010 MFssL XRCC5   P18669 LWtvL PGAM1 
P13010 LFqcL XRCC5   P18669 MWlpV PGAM1 
P13010 IWnmL XRCC5   P28066 LFggV PSA5 
P13010 LFplI XRCC5   P31948 LYqkL STIP1 
Q9BSH4 IFskL TACO1   P42704 IWdtL LPPRC 
Q9BSH4 VFkfI TACO1   P42704 VFsaL LPPRC 
Q9BSH4 VYdnI TACO1   P42704 LWseI LPPRC 
P14314 VWaaI GLU2B   P42704 LYnlI LPPRC 









P23284 VFgkV PPIB   P42704 VWnkI LPPRC 
Q13641 VFlgI TPBG   P42704 LFrkV LPPRC 
Q13641 IFllV TPBG   P42704 IYkpV LPPRC 
P11310 VFedV ACADM   P42704 LYehL LPPRC 
P30519 LYfpM HMOX2   P62879 IWdaM GBB2 
P30519 LFenV HMOX2   Q12874 IFdqL SF3A3 
P30519 IFneL HMOX2   Q12874 LFgkI SF3A3 
O00231 LFldM PSD11   Q12874 IYeyV SF3A3 
O00231 LYdnL PSD11   Q12874 LWakL SF3A3 
P62333 LFqrV PRS10   Q8N163 VFtgI K1967 
O95831 LFrkI AIFM1   Q8N163 VFfqL K1967 
O95831 IFnrM AIFM1   Q8N163 VWtiM K1967 
P05023 LYlgV AT1A1   Q8N163 LFleM K1967 
P05023 VFlgV AT1A1   Q8N163 VYkmL K1967 
P05023 IFdnL AT1A1   Q8N163 LFgnL K1967 
P05023 VYdeV AT1A1   Q8TBA6 LFdfL GOGA5 
P78527 VYelL PRKDC   Q8TBA6 MYgkV GOGA5 
P78527 IFnfV PRKDC   Q8TBA6 VFviI GOGA5 
P78527 LFevL PRKDC   Q8TBA6 IYmaL GOGA5 
P78527 MYveL PRKDC   Q8TBA6 LWvmI GOGA5 
P78527 VYtpV PRKDC   Q969G3 VWdqV SMCE1 
P78527 VFlaL PRKDC   Q969G3 MWrdL SMCE1 
P78527 LFrhL PRKDC   Q9BQE3 VFvdL TBA1C 
P78527 IFldV PRKDC   P27797 LYtlI CALR 
P78527 LYepL PRKDC   P29401 VYclL TKT 
P78527 LFkrL PRKDC   P29401 VWeaM TKT 
P78527 VFeaL PRKDC   P29401 IYsqI TKT 
P78527 VYkgI PRKDC   P29401 MFrsV TKT 
P78527 MYsrL PRKDC   P15531 VWegL NDKA 
P78527 VFneL PRKDC   P30038 VYrgL AL4A1 
P78527 IFenL PRKDC   P30038 VYriL AL4A1 
P78527 VFflL PRKDC   P30038 LWkqV AL4A1 
P78527 LYfqL PRKDC   P30038 LWpqI AL4A1 
P78527 IYkmM PRKDC   P30038 IFgpV AL4A1 
P78527 MYniL PRKDC   P30101 LFpgV PDIA3 
P78527 LFssL PRKDC   P32322 LFlaV P5CR1 









P78527 LYrsI PRKDC   P55809 LWegL SCOT1 
P78527 IWddI PRKDC   Q02790 LYanM FKBP4 
P78527 VYpfI PRKDC   Q02790 MFerL FKBP4 
P78527 MYerM PRKDC   Q16698 VFftL DECR 
P78527 MYaaL PRKDC   P83731 VFqfL RL24 
P78527 LFqvM PRKDC   O75396 LFrkL SC22B 
P78527 MYsiM PRKDC   O75396 VFfiM SC22B 
P60981 IFydM DEST   P40939 VYkkV ECHA 
P50990 VYrnI TCPQ   P40939 VFkgL ECHA 
Q9UJZ1 LYlrI STML2   P40939 IFsnL ECHA 
Q9UJZ1 VYgaL STML2   P40939 VFedL ECHA 
P56385 LFlgV ATP5I   P16615 VYekV AT2A2 
P55011 IWgvM S12A2   P16615 IYnnM AT2A2 
P55011 LFirL S12A2   P16615 LWvnL AT2A2 
P55011 VYvgI S12A2   P05141 LYdeI ADT2 
P55011 IFqaL S12A2   P35221 VYklL CTNA1 
P55011 MWisL S12A2   P35221 IYkqL CTNA1 
P55011 LYiyV S12A2   P35221 VYdgI CTNA1 
P55011 MYinL S12A2   P07919 LFdfL QCR6 
Q04637 IFasM IF4G1   P07919 LFnnL QCR6 
Q04637 LFrrV IF4G1   P06733 IYeaL ENOA 
Q04637 MFqqL IF4G1   P06733 LYrhI ENOA 
Q04637 LFifV IF4G1   P06733 VYhnL ENOA 
Q04637 LYeiL IF4G1   Q16718 LYtkI NDUA5 
Q04637 VWlyL IF4G1   Q16718 LWepL NDUA5 
Q04637 LFreI IF4G1   P07437 LFkrI TBB5 
Q04637 VFdwI IF4G1   Q9UPN9 VFcpV TRI33 
P53396 LYkfI ACLY   Q9UPN9 IFtlI TRI33 
P53396 IWtmV ACLY   P11387 VFknL TOP1 
P53396 VFknM ACLY   P11387 LFdrL TOP1 
P53396 VYegV ACLY   P25787 VYsgM PSA2 
P53396 VYedL ACLY   P37108 VYitL SRP14 
P53396 IYagM ACLY   Q8WU68 VFteL U2AF4 
Q9Y4L1 MFydM HYOU1   Q9Y3D9 LWfdV RT23 
Q9Y4L1 LFerV HYOU1   Q16891 LFemV IMMT 
Q9Y4L1 VYpiL HYOU1   Q16891 LWlsV IMMT 
Q9Y4L1 LFsrM HYOU1   Q9Y230 LFneL RUVB2 
Q9Y4L1 VFetL HYOU1   P02786 VFflI TFR1 
Q9Y4L1 LFfrV HYOU1   P02786 LYtpV TFR1 
Q9Y4L1 IFteV HYOU1   P02786 LFgnM TFR1 
Q9Y6X8 VYrlI ZHX2   P02786 IFgvI TFR1 
Q969H8 LWaaL CS010   P02786 MFsdM TFR1 
Q99798 VYghL ACON   P02786 LYtlI TFR1 









P46783 IYelL RS10   P27824 VFlvI CALX 
P51659 LYkpL DHB4   O75533 LFnqI SF3B1 
P51659 VFeeI DHB4   O75533 LWkgI SF3B1 
P35579 LFcvV MYH9   O75533 LYeyL SF3B1 
P35579 IFyyL MYH9   O75533 LFeyI SF3B1 
P35579 MFrwL MYH9   O75533 VWpnV SF3B1 
P35579 LWkdV MYH9   O75533 VYwkI SF3B1 
P35579 MFrtV MYH9   O75533 IYnsI SF3B1 
P35579 LFtkV MYH9   P43304 LYdlV GPDM 
P45880 IYqkV VDAC2   P43304 LYirL GPDM 
P46776 LWtlV RL27A   P43304 LYyeM GPDM 
P68371 LFkrI TBB2C   Q86UP2 LFfwL KTN1 
P11021 VFevV GRP78   Q86UP2 LYdeV KTN1 
P30040 VYlgM ERP29   Q86UP2 LWneL KTN1 
P30040 VYdaL ERP29   Q86UP2 LFpkV KTN1 
Q00059 MWgvL TFAM   O00571 IFlaV DDX3X 
P12814 IWtiI ACTN1   P07339 VFdnL CATD 
Q00839 LFphV HNRPU   P08865 MWwmL RSSA 
P13693 IYrdL TCTP   P13995 VWeiI MTDC 
P13693 MFsdI TCTP   P42166 VYvqL LAP2A 
Q96IR7 LWqsV HPDL   P46379 LFecL BAT3 
Q99623 MYqrL PHB2   P68366 VFvdL TBA4A 
P13639 LFyeL EF2   Q15393 VFgvI SF3B3 
P13639 VFdaI EF2   Q15393 MFekI SF3B3 
P13639 VFsgL EF2   Q15393 VYhvV SF3B3 
P13639 LYasV EF2   Q15393 MFacL SF3B3 
P13639 IYgvL EF2   Q15393 MFffL SF3B3 
Q09666 MFgkM AHNK   Q15393 LFcqI SF3B3 
P04350 LFkrI TBB4   Q15393 VYfeM SF3B3 
A6NIZ1 IFydL RP1BL   Q15393 LYlnI SF3B3 
O00148 LFdlL DDX39   Q15393 VFnqV SF3B3 
Q07065 IFteV CKAP4   Q15393 VYttL SF3B3 
Q07065 IYteV CKAP4   Q16740 MWpgI CLPP 
Q07065 LYgdV CKAP4   Q16740 IYsrL CLPP 
Q07065 LFvkV CKAP4   Q16740 IYdtM CLPP 
Q14444 LWdlL CAPR1   Q8TEX9 LFysL IPO4 
Q5JTV8 LWsrI TOIP1   Q8TEX9 LFpiV IPO4 
P58107 VYaaM EPIPL   Q8TEX9 LFaaL IPO4 
P58107 LFqaI EPIPL   Q8TEX9 VFeeV IPO4 
P58107 LFqaM EPIPL   Q8TEX9 VFklL IPO4 
P58107 LWelL EPIPL   Q8TEX9 LFplL IPO4 
P58107 LYerL EPIPL   Q8TEX9 LFsfL IPO4 
P58107 VFakL EPIPL   Q96I99 IFegI SUCB2 
P58107 LFqaM EPIPL   Q96I99 LFlkI SUCB2 
P58107 LYqaM EPIPL   Q96I99 IFggI SUCB2 









P58107 VFqaM EPIPL   Q9Y285 VFrsI SYFA 
P58107 LWdlL EPIPL   Q9Y285 VFrvV SYFA 
P58107 LWqaM EPIPL   Q9Y285 IFleM SYFA 
P58107 LWdlL EPIPL   O15523 IFlaV DDX3Y 
P58107 LFqaM EPIPL   O60716 LYstI CTND1 
P58107 LFqaM EPIPL   O60716 IYisL CTND1 
P58107 IYalI EPIPL   P0C6E5 MWknL HMG3M 
P58107 LWalL EPIPL   P14923 LFyaI PLAK 
P58107 IYqaM EPIPL   P14923 LFvqL PLAK 
P58107 MWkgV EPIPL   P14923 LYssV PLAK 
P58107 LFqaM EPIPL   P20674 IYpyV COX5A 
P58107 VWelL EPIPL   P22314 LFgqL UBA1 
P58107 VWdvL EPIPL   P22314 LYkvV UBA1 
P58107 VWdvL EPIPL   P25205 IFdqL MCM3 
P58107 IYqaM EPIPL   P25205 LFimL MCM3 
P58107 MWkgV EPIPL   P35222 LFyaI CTNB1 
P58107 LFqaM EPIPL   P35222 LFvqL CTNB1 
P58107 VWelL EPIPL   P35222 LYspI CTNB1 
P58107 VWdvL EPIPL   P37268 IFylV FDFT 
P58107 VWdvL EPIPL   P37268 IYqyM FDFT 
P58107 IYqaM EPIPL   P37268 IYhrI FDFT 
P58107 MWkgV EPIPL   P51532 LWalL SMCA4 
P58107 LFqaM EPIPL   P51532 LYrhM SMCA4 
P58107 VWelL EPIPL   P51532 MFqhI SMCA4 
P58107 VWdvL EPIPL   P51532 LFcqM SMCA4 
P58107 VWdvL EPIPL   P51532 LFmrM SMCA4 
P58107 IYqaM EPIPL   P51532 VFiqL SMCA4 
P58107 MWkgV EPIPL   P51532 VFtsV SMCA4 
P58107 LFqaM EPIPL   P61006 LFklL RAB8A 
P58107 VWelL EPIPL   P62834 IFydL RAP1A 
P58107 VWdvL EPIPL   P62847 IYdsL RS24 
P58107 VWdvL EPIPL   P63261 VFpsI ACTG 
P58107 IYqaM EPIPL   P63261 MYvaI ACTG 
P58107 MWkgV EPIPL   P63261 MYpgI ACTG 
P58107 LFqaM EPIPL   Q05519 LFgfL SFR11 
P58107 VWelL EPIPL   Q07812 VFfrV BAX 
P58107 VWdvL EPIPL   Q07812 IWkkM BAX 
P58107 VWdvL EPIPL   Q13838 LFdlL UAP56 
P58107 IYqaM EPIPL   Q14344 IYsnV GNA13 
P58107 MWkgV EPIPL   Q14344 IFetI GNA13 
P58107 LFqaM EPIPL   Q14344 VFsnV GNA13 
P58107 LFlsL EPIPL   Q14344 VFrdV GNA13 
Q15149 IYevL PLEC1   Q15369 MYvkL ELOC 
Q15149 LYedL PLEC1   Q15388 VFqmL TOM20 
Q15149 IWtiI PLEC1   Q5SRE5 LWtiL NU188 









Q15149 LYdaM PLEC1   Q5SRE5 VYglL NU188 
Q15149 IYqsL PLEC1   Q5SRE5 MFphL NU188 
Q15149 LFndV PLEC1   Q5SRE5 VYsfL NU188 
Q15149 MYrrV PLEC1   Q5SRE5 IYmlL NU188 
Q15149 LWhqL PLEC1   Q5SRE5 VWtdL NU188 
Q15149 VYaaL PLEC1   Q5SRE5 VYacL NU188 
Q15149 LFqaM PLEC1   Q5SRE5 LFlnL NU188 
Q15149 IWeiI PLEC1   Q5SRE5 MWscL NU188 
Q15149 LYqqL PLEC1   Q5SRE5 LFgtL NU188 
Q15149 IYnaL PLEC1   Q5SRE5 IYyvV NU188 
Q15149 LFqaL PLEC1   Q5SRE5 LFldV NU188 
Q15149 LYseL PLEC1   Q86UE4 IFsgI LYRIC 
Q15149 VWelI PLEC1   Q8TAQ2 MFmtI SMRC2 
Q15149 IYeaM PLEC1   Q96C36 LFlaV P5CR2 
Q15149 LFqaM PLEC1   Q99832 LYdkL TCPH 
 
